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In head and neck squamous cell carcinoma (HNSCC), the evidence that human 
papillomavirus (HPV) is associated with a subgroup of tumours has increased over the 
last thirty years. Prospective randomised controlled clinical trials have now 
established that detection of HPV in oropharyngeal tumours (~60-70% of cases in 
North America and Europe) may confer a survival advantage to the patient. 
 
Within the oropharynx, HPV16 constitutes ~90-95% of HPV subtypes associated with 
malignancy. This contrasts with uterine cervix mucosa, where approximately 15 high-
risk subtypes cause >99% of disease. Other factors such as differences in genetic 
background, host immune response, hormonal and environmental influences (e.g. 
tobacco smoke, alcohol) all play a part in the pathway and susceptibility to 
oncogenesis. 
 
Analogous to uterine cervix disease, HPV-associated cancers involve wild-type TP53 
whilst HPV negative tumours often have mutations in this gene.  
 
As most patients with HPV associated OPSCC present at an advanced stage, the 
detection and genetic analysis of a pre-malignant state would be important as it infers 
the potential for a screening test (similar to the uterine cervix model). To investigate 
this, whole transcriptome analysis with verification of results by reverse 
transcription–quantitative polymerase chain reaction (PCR), was performed on 
OPSCC fresh tissue biopsy samples. Predictable fold changes of RNA expression in 
HPV-associated disease included multiple transcripts within the p53 oncogenic 
pathway (e.g. CDKN2A / CCND1). In addition to this, a testis-specific gene not 
normally expressed in somatic cells, SYCP2, showed a consistently elevated fold 
change from baseline in pre-malignant and malignant tissue.  
 
A subtle immune defect has long been thought to trigger the susceptibility of some 
individuals to persistent HPV infection with either low or high risk HPV types. 
Following on from this, we investigated if clinical outcomes in HPV-related head and 
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neck cancer may be affected by host immune response. Peripheral blood from patients 
with OPSCC treated by chemoradiotherapy underwent IFN-γ enzyme-linked 
immunosorbent spot assay (ELISPOT) to examine cell-mediated immune responses to 
HPV16 E2, E6 and E7. T cell responses against E6 or E7 peptides correlated with 
HPV DNA/RNA status. Within the HPV16+ OPSCC cohort, enhanced 
immunoreactivity to antigen E7 was linked to improved survival. In addition, an 
observed increase in regulatory T cell frequencies after treatment would suggest that 
immunosuppression may contribute to a reduced HPV specific cell mediated 
response.  
 
A further aspect of this study was to determine the role of HPV and Epstein Barr 
Virus (EBV) in the pathogenesis of squamous cell carcinoma within the temporal 
bone region. This is an uncommon tumour which is normally preceded by a history of 
inflammation within the external auditory canal (EAC) or middle ear / mastoid cavity. 
Although HPV has been implicated in many head and neck malignancies, its role in 
SCC of the temporal bone has not been established. Treatment strategies could change 
if a viral aetiology can be found. HPV16 DNA was detected in ~20% of the cases 
studied, however, no significant difference in disease specific survival was noted for 
the papillomavirus positive group. Epstein-Barr virus was not detected. 
 
The data presented highlight the functional and biological influence of high risk HPV 
infection on HNSCC. Further studies are likely to focus on developing non-invasive 
screening tools, therapeutic strategies based on vaccination or immune modulation or 
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1.1 Squamous cell carcinoma of the oropharynx 
 
1.1.1 Anatomy 
The oropharynx is one the most important functional sites within the head and neck 
region as it is located at the bifurcation of the respiratory and digestive tract. Tumours 
at this site will affect speech, swallowing and ultimately the airway. Decisions about 
treatment are influenced not only by the optimal method of tumour ablation, but also 
by important functional considerations.  
 
The oropharynx is divided into four anatomical subsites and extends from the level of 
the soft palate above to the dorsal surface of the epiglottis below (Figure 1, Table 1). 
Tumours may arise in the oropharynx from different epithelial elements and three 
main histological types are recognised: 
 
1.  Squamous cell carcinoma – tumour arising from squamous epithelium 
2.  Lymphoma – arising from lymphoid follicles in the tonsils or base of the tongue  
3. Salivary gland tumours – derived from minor salivary glands sited mainly at the 
soft palate or capsule of the tonsil  
 
As noted in other sites within the head and neck region, the most common cancer 
encountered in the oropharynx is squamous cell carcinoma which accounts for >90% 
of cases (Mehanna, 2011). Non-Hodgkin lymphomas tend to occur more frequently in 
the oropharynx compared to other sites in the head and neck because of the higher 
concentration of lymphoid tissue. Salivary gland tumours and other rare tumours 














Table 1 Oropharyngeal subsites  
    
Subsite Anatomical regions included 
Anterior wall 
(oropharynx) 
• Vallecula (dorsal surface of the epiglottis) 



















An estimated 600,000 cases of Head & Neck Squamous Cell Carcinoma (HNSCC) 
occur each year, making it the sixth most common cancer worldwide. In developed 
countries, since the 1980s, the incidence of oropharyngeal carcinoma (one of the 
largest subgroups of HNSCC) has dramatically increased, and there has been a change 
in the disease demographic towards younger aged males with less tobacco 
consumption (de Martel et al., 2012). 
 
Risk factors traditionally associated with development of Oropharyngeal Squamous 
Cell Carcinoma (OPSCC) include tobacco and excess alcohol consumption, which 
have a synergistic effect and are responsible for most global disease. 
 
The worldwide incident rate of OPSCC is 3.8 per 100,000 population. In Europe, 
some countries have a higher rate than the global average e.g. Hungary (16.9 per 
100,000). The highest number of oropharyngeal cancer cases emanate from South 
East Asia (especially India which has an incident rate of 12.5 per 100,000) (Price et 
al., 2010, Soerjomataram et al., 2012). 
 
Human papillomavirus has a causal role in almost all uterine cervix cancers, and in 
the last 20-30 years this same virus has become increasingly important in SCC 
affecting the tonsil or tongue base regions. Within the head and neck region, the role 
of HPV in non-oropharyngeal cancer is less well defined. A review by Mehanna et al. 
(2012) found HPV DNA was detected in 20% of SCCs affecting the larynx, oral 
cavity, nasopharynx and hypopharynx. However, the clinical significance of these 
findings is reduced when it is noted that the same detection rate has remained static in 
comparison to OPSCC.  
 
There are >20 HPV types identified to have an aetiological role in invasive cancer of 
the uterine cervix. HPV16 and HPV18 are responsible for ~70% of uterine cervix 
cancer cases (Winer et al., 2006), while the most predominant type associated with 
OPSCC is HPV16 (~95%) (Ang et al., 2010). Infection with a non-HPV16 type is less 
likely to lead to OPSCC in contrast to cancers of the uterine cervix (Isayeva et al., 
2012). This would suggest that the natural history of HPV life cycle is different 
 23 
according to the site (e.g. oropharyngeal crypt mucosa) and cell (e.g. keratinocyte) of 
infection. Other factors such as susceptibility of the site to hormonal control 
mechanisms, access to the site by other carcinogens found in tobacco smoke, alcohol 
and betel leaf chewing might also play some role. 
 
A recent study from the National Institute of Health (USA) found an increase in the 
prevalence of OPSCC that are HPV-associated from 16.3% in the 1980s to 72.2% 
during the 2000s (Chaturvedi et al., 2011).  A systematic review published after this 
study suggests that the proportion of HPV-associated OPSCC in trials recruiting 
before the year 2000 (40.5%) was almost half the rate for trials recruiting after 2005 
(72.2%) (Mehanna et al., 2012). Schache et al. (2011) performed the only large 
retrospective UK study which suggested a similar rise in prevalence rates (14% in 
1998 increasing to 57% in 2009) (Schache et al., 2011). 
 
In the United States, it is predicted that if published trends continue for HPV-
associated OPSCC, this will overtake the annual incidence of cervical cancers by the 
year 2020 (Figure 2). This data may be influenced by the substantial decline in 
cervical cancer rates due to screening (Chaturvedi et al., 2011). The observed rise in 
HPV-associated OPSCC has now been confirmed in other developed countries with 
similar cervical cancer screening protocols (Garnaes et al., 2015). 
 
Human papillomavirus is now a significant cause of oropharyngeal cancer (especially 
in developed countries); however, the exact prevalence will vary according to the 
level of tobacco-associated disease. In Europe, the proportion of HPV-positive 
tumours varies from ~90% in Sweden to less than 20% in communities with the 










Figure 2A: The annual number of HPV-associated oropharyngeal cancers (in the 
USA) is projected to exceed that of uterine cervix cancers by the year 2020. Figure 
2B: This dramatic change appears to be driven by a rapid rise in male cases 


















Figure 3 Swedish national cancer registry data showing an exponential rise in the 


























Smokers have a six-fold increase in cancers compared to non-smokers. Stopping 
smoking may reduce the risk of OPSCC but this will take >10-20 years to reduce to 
the level of a non-smoker (Parkin, 2011). 
 
Tobacco is still the prime aetiologic agent responsible for SCC of the upper 
aerodigestive tract. The average cigarette contains more than 4000 chemicals, many 
of which have been identified as toxic or carcinogenic. Burning of tobacco releases 
benzopyrine, methylchloranthrene and other aromatic hydrocarbons which reach the 
surface of the epithelium dissolved in saliva. Further breakdown of these carcinogens 
produces carcinogenic epoxides, which bind to DNA molecules, damaging them and 
initiating the process of cancer formation (Patel et al., 2009).  
 
A higher frequency of p53 mutations is observed in tobacco users, which is a key 
determinant of oncogenesis (Gandini et al., 2008). The carcinogenic process depends 
on multiple factors: type of tobacco, the duration and intensity of carcinogen 
exposure, genetic factors, type of delivery method, epithelial mucous production, 





Alcohol and tobacco have a synergistic effect and can increase the risk of developing 
HNSCC by 20-120 times that of a non-alcoholic/non-smoker (Pelucchi et al., 2008). 
Alcohol dehydrates the cell wall and promotes the ability of tobacco carcinogens to 
permeate local tissues, in addition it depletes antioxidants, which have a protective 
role in cancers (Seitz and Becker, 2007). The solubility of carcinogens in tobacco is 
increased when saliva is mixed with alcohol, and this in turn promotes absorption into 
the surface epithelium (Seitz and Becker, 2007, Pelucchi et al., 2008). The quantity, 





There is strong evidence for the causal association of HPV infection in OPSCC 
(Gillison et al., 2000). HPV infection is strongly associated with young, sexually 
active, non-smoker males and may be accountable for the changing demographic 
profile of OPSCC towards a younger, non-smoking population (Chaturvedi et al., 
2011).  
 
Risk factors for HPV infection include oral sex practices, a large number of sexual 
partners and first intercourse at a younger age. Changing sexual practices associated 
with modern society may increase the cumulative effect of HPV infection in OPSCC 
(Chung and Gillison, 2009).  
 
HPV-associated OPSCC behaves differently from the other, more common HPV-
negative variety which affects an older age group and is normally associated with 
smoking and alcohol. These former patients often present with a neck node, respond 
well to radiation and have a better prognosis than the HPV-negative cohort (Fakhry et 
al., 2008). As a result, many academic centres are investigating the potential to de-
escalate existing treatments that are often associated with severe side effects (Trotti 
and Gillison, 2011, Masterson et al., 2014). It is now known that smokers with HPV-
associated OPSCC have a higher risk profile compared to non-smokers with HPV-





Tobacco-associated susceptibility to oropharyngeal carcinoma can also be determined 
by genetic factors. It is estimated that the risk of developing OPSCC, in patients with 
a first-degree relative, can increase 2- to 14-fold above baseline. Patients with Fanconi 
anaemia (a rare inherited condition linked to leukaemia or aplastic anaemia) are also 
at significantly increased risk for OPSCC in comparison to the general population 
(Kumar et al., 2013). At this stage, it is unclear if a similar genetic susceptibility to 





A non-balanced diet may be associated with ~10-15% of oropharyngeal cancers. 
Foods derived from high calorie sources have been reported to present a higher risk 
e.g. starch rich pulses, processed / salted meats and eggs (Sapkota et al., 2008).  
 
Reactive oxygen species can initiate carcinogenic pathways while antioxidants enable 
some protection against the molecular damage. Vegetables and fruits contain naturally 
occurring antioxidants; other antioxidants include those derived from vitamins A and 
C. Dietary deficiencies, particularly of iron, selenium, folate, vitamin E, and other 
trace elements have been linked to increased risk of cancer of the upper aerodigestive 
tract (Gonzalez, 2006).  
 
 




It is a regrettable fact that oropharyngeal carcinoma normally presents at an advanced 
stage, with >75% patients allocated to the stage III/IV category (Tables 2, 3). The 
underlying reason for this delayed presentation is attributed to the vagueness of 
symptoms such as persistent sore throat, otalgia or discomfort on swallowing. The 
majority of patients with HPV-associated OPSCC present with a new onset neck mass 
[57-79%] (Gillison et al., 2011). This finding suggests that, in comparison with HPV-
negative disease, these tumours metastasize to local lymph nodes when the primary 
tumour is relatively small 
 
A distorted voice often described as akin to having a “hot potato” in the mouth has 
also been described. Tumours that are large at presentation (>T3) are often associated 








A thorough examination of the neck and upper aerodigestive tract is essential to 
determine potential malignant disease. Flexible endoscopy under local anaesthetic has 
greatly facilitated the ease of examination of the pharynx and larynx. Smaller tumours 
of the tongue base or tonsil arising in lymphatic crypts may not be detectable unless 
palpated under general anaesthetic. Ulcerative tumour types invade deeply, whereas, 
exophytic tumours spread superficially. A hypoglossal nerve paresis may cause 
wasting (+/- fasciculation) of the tongue with deviation to the ipsilateral side on 
protrusion.  
 
Systematic palpation of the neck must be performed to detect nodal spread from 
OPSCC. Malignant disease is typically fixed, irregular and firm but can masquerade 
as inflammatory lymph node enlargement if examined at an early stage (Mendenhall 
et al., 2006). Neck palpation can be difficult to perform in patients with a large neck 
or muscular spasm with a 30% inaccuracy rate reported by many studies (Dayanand et 
al., 2010). Tonsil SCC drains primarily to jugulodigastric, submandibular and upper 
posterior triangle nodes. Further spread to the deep cervical chain (levels II, III and 
IV) is also characteristic with occasional involvement of the carotid sheath or 
retropharyngeal region. Bilateral lymphatic spread (levels II-IV) occurs in 





Any suspicious node in the neck should undergo Fine Needle Aspiration Cytology 
(FNAC) or core biopsy provided no contra-indications exist. This may allow rapid 
differentiation between an SCC, lymphoma or a branchial cyst. 
 
Detection of metastatic nodal disease is more sensitive with ultrasound than palpation 
alone and has a specificity of ~75%. This improves to >90% if combined with FNAC 
/ core biopsy (van den Brekel and Castelijns, 2005). 
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Lesions, which are confirmed or highly suspicious for malignancy, will need further 
investigation in the form of a neck + chest computed tomography (CT) scan +/- 
Magnetic Resonance Imaging (MRI). This is mandatory to assess the size of the 
primary tumour and accurately evaluate the neck to determine presence, size, site and 
invasive potential of malignant lymph nodes. MRI has an advantage for assessing 
small lesions due to enhanced soft tissue definition whereas CT is better for assessing 
bony invasion to the mandible (Weber et al., 2003).  
 
Fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) is a useful 
imaging technique that can demonstrate an increased concentration of radio-
nucleotide tracer in malignant tissue. This works on the basis that malignant cells are 
metabolically more active than the cells within normal adjacent tissue. Accumulation 
of the FDG tracer can also occur in areas of inflammation or infection leading to 
possible confounding results (Al-Ibraheem et al., 2009). 
 
FDG-PET now has an established role in the detection of a second primary or distant 
metastasis in locally advanced OPSCC. The integrated use of FDG-PET and CT is 
also deemed more accurate than either alone for detection and anatomic localisation 
of head and neck malignancy (Jwa et al., 2012). Meta-analysis data (Xu et al., 2012) 
indicate PET/CT to have a specificity of 96% and sensitivity of 83% for detection of 
distant malignant disease, whereas for conventional imaging, the values are 96% and 
44% respectively. 
 
Accurate response assessment after chemo-radiotherapy (CRT) is essential treatment 
in patients with advanced disease. PET/CT is optimally timed after 12 weeks of 
completion of treatment, but can be done sooner if there is clinical suspicion of 
recurrence. In a meta-analysis of 51 studies, the reported negative predictive value 










The American Joint Committee on Cancer (AJCC)  / Union for International Cancer 
Control (UICC) criteria are now the most accepted classification for OPSCC (Edge et 
al., 2010). Distant metastases are unusual at presentation but may eventually occur in 
~10% of patients, which is second only to hypopharynx subsite. The lungs are the 
commonest region to be involved followed by spread to bones or the liver (Yao et al., 
2012). HPV-associated OPSCC can also rarely present with brain metastases 
(Ruzevick et al., 2013). In 2017, the AJCC / UICC released the 8th Edition of the 
staging manual for head and neck malignant disease (Amin et al., 2017). This created 
a separate algorithm for HPV-associated cancer of the oropharynx to give a more 
accurate prediction of survival for newly diagnosed patients (Table 2; see also section 
1.1.6). At the time of writing this thesis, the British Association of Head & Neck 
Oncologists still recommend the widespread adoption of the 7th TNM classification 




















Table 2: Changes to TNM classification of primary oropharyngeal squamous cell 
carcinoma (Amin et al., 2017).  




T1 Tumour 2 cm or smaller in greatest 
dimension 
T1 Unchanged 
T2 Tumour larger than 2 cm but 4 cm or 
smaller in greatest dimension  
 
T2 Unchanged 




T4a Tumour invades the larynx, 
deep/extrinsic muscle of tongue, medial 
pterygoid, hard palate or mandible 
 
T4 Moderately advanced tumour 
invading larynx, extrinsic tongue 
muscles, medial pterygoid, hard 
palate or mandible or beyond 
T4b Tumour invades lateral pterygoid 
muscle, pterygoid plates, lateral 





N1 Metastasis in a single ipsilateral lymph 
node, 3 cm or smaller in greatest 
dimension 
 
N1 Metastasis in a single ipsilateral 
lymph node, 6 cm or smaller in 
greatest dimension 
 
N2a Metastasis in a single ipsilateral lymph 
node larger than 3 cm but 6 cm or 
smaller in greatest dimension 
 
N2 Metastasis to contralateral or 
bilateral lymph nodes, 6 cm or 




Metastasis in multiple ipsilateral lymph 
nodes, 6 cm or smaller in greatest 
dimension 
 
N2c Metastasis in bilateral or contralateral 
lymph nodes, 6 cm or smaller in greatest 
dimension 
 
N3 Metastasis in a lymph node larger than 6 
cm in greatest dimension 
 
N3 Metastasis in any cervical lymph 




M0 No distant metastasis  M0 No distant metastasis 
M1 Distant metastasis  M1 Distant metastasis 
 
TNM version 7: Stage I: Describes a small tumour (T1) with no spread to lymph nodes (N0) and no 
distant metastasis (M0). Stage II: Describes a tumour that is smaller than 4 cm (T2) and has not spread 
to lymph nodes (N0) or to distant parts of the body (M0). Stage III: Describes a larger tumour (T3) 
with no spread to lymph nodes (N0) or metastasis (M0), as well as smaller tumours (T1, T2) that have 
spread to regional lymph nodes (N1) but have no sign of metastasis (M0). Stage IVA: Describes any 
invasive tumour (T4a) with either no lymph node involvement (N0) or spread to only a single, same-
sided lymph node (N1) but no metastasis (M0). It is also used for any tumour (any T) with more 
significant nodal involvement (N2) but no metastasis (M0). Stage IVB: Describes any tumour (any T) 
with extensive nodal involvement (N3) but no metastasis (M0). Stage IVC: Indicates there is evidence 
of distant spread (any T, any N, M1). 
TNM version 8: Stage I: T1 or T2 + N0 or N1 + M0. Stage II: T1 or T2 + N2 + M0 / T3 or T4 + N0 
or N1 + M0. Stage III: T3 or T4 + N2 + M0. Stage IV: Any T or N + M1. 
 33 
1.1.6 Treatment  
 
The current treatment of OPSCC depends on clinician/patient preference and stage of 
the disease (Table 3). Radiotherapy or surgery are modalities usually employed for 
early disease (T1 N0 / T2 N0). For more advanced lesions, treatment usually involves 
primary chemoradiation (+/- neck dissection) or surgical excision (+/- free flap 
reconstruction +/- adjuvant chemoradiotherapy if adverse histological features) 
(Mehanna, 2011). 
 
Table 3: Oropharyngeal squamous cell carcinoma stage at presentation. The data 
indicate most patients are diagnosed at an advanced stage (III/IV), which may be 
attributed to the vagueness of symptoms such as persistent sore throat, otalgia or 
discomfort on swallowing. In addition, HPV-associated disease is more likely to 
present with cystic nodal disease. 
 










(Masterson and Tanweer, 2013) 4.4 7.4 19.3 68.9 
(Bhide et al., 2008) 0.8 1.6 37.2 60.5 
(Preuss et al., 2007) 8.6 14.8 22.5 49.2 




HPV-associated OPSCC patients are usually younger, non-smokers, with improved 
physiological reserve compared to HPV-negative counterparts (Posner et al., 2011). 
In addition, Ang et al. (2010) found their HPV-positive OPSCC group to be 
associated with a Caucasian ethnicity and small (<T2) primary tumour size.  
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With these observations in mind, how can the response to treatment in patients with 
HPV-associated OPSCC be explained? One possibility is that HPV-associated disease 
is less aggressive than tobacco- or alcohol-induced carcinoma. Most clinical studies 
assessing outcome in OPSCC observe that HPV status is an independent variable 
predicting tumour response; this is regardless of treatment modality if it is delivered 
per the standard of care (Licitra et al., 2006). 
 
The improved clinical outcome observed in HPV-associated OPSCC is generally 
ascribed to a distinct biological pathway. Treatment of HPV-associated cells with 
cisplatin and fluorouracil chemotherapy will repress HPV E6 and E7 viral oncogene 
expression and re-instate the p53/pRb tumour suppressor pathways (Leemans et al., 
2011). This contrasts with tobacco- or alcohol-induced cancers that incorporate 
mutations conferring a more resistant phenotype.  
 
At present, HPV-associated OPSCC is treated in a similar manner to HPV-negative 
disease, and one may argue that complications of treatment are more burdensome in 
this former group (long term side effects in a younger cohort could exert a higher 
socio-economic cost to society).  
There are now several large trials currently ongoing which investigate the different 
options for de-escalation of treatment in HPV-positive OPSCC. The various 
approaches include the use of cetuximab (an epidermal growth factor receptor 
(EGFR) inhibitor) in place of conventional chemotherapy or reduction in 
chemoradiation dosing schedules (Trotti and Gillison, 2011). As HPV-associated 
disease is a distinct biological entity, future strategies are underway to reduce 
expression of the E6/E7 oncoprotein or develop vaccines that specifically target 
HPV16 (Jones, 2012). 
 
Although there is an enhanced interest in HPV-associated OPSCC, it must not be 
overlooked that, on a global scale, most patients are still classified as HPV-negative. 
This latter cohort has inferior clinical outcomes, which have not changed over the past 
20-30 years. One study, designed for adjuvant therapy in HPV-negative disease, 
utilises a modified adenovirus (ONYX-015) to target and destroy mutated p53 cancer 
cells (Yoo et al., 2009). More recently, the SPECTRUM trial demonstrated a trend 
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towards improved clinical outcomes in HPV-negative OPSCC using panitumumab 
(EGFR inhibitor) combined with cisplatin radiotherapy (Vermorken et al., 2013). 
 
 
1.1.7 Clinical outcomes 
 
The development of a second primary tumour is noted to be more likely in HPV-
negative in comparison to HPV-positive OPSCC (Licitra et al., 2006). As the follow-
up in this study amounted to only ~40-50 months, it may be difficult to draw 
conclusions. However, a more recent trial with a longer observation period (median = 
7 years), confirmed this observation by demonstrating that loco-regional failure rate in 
HPV-associated OPSCC was significantly lower than HPV-negative OPSCC [27% 
versus 71%; P<0.0001] (Posner et al., 2011). Such information may be encouraging, 
although it is important to be aware that a diagnosis of one HPV-related cancer may 
increase the risk of developing a second HPV-related malignancy (Edgren and 
Sparen, 2007).  When present, distant metastatic spread from HPV-associated OPSCC 
occurs mainly in the lungs, liver, bones or more rarely to the brain. 
 
A comprehensive review by Genden (2013), which looked at retrospective studies in 
OPSCC, revealed a significantly improved survival (~25% relative risk) in HPV-
associated OPSCC in comparison to HPV-negative disease. 
 
In a study of 323 patients enrolled to a prospective clinical trial, Ang et al. (2010), 
reported a three-year survival of 57% vs. 82% for HPV-negative OPSCC against 
HPV-associated disease by analysing pre-treatment biopsy samples. A prospective 
study by Fakhry et al. (2008) observed that HPV-associated OPSCC had an improved 
overall survival, with 95% of patients alive after two years, compared to 62% of those 
with HPV-negative disease. 
 
Although, short-term outcomes for HPV-associated patients may be explained by the 
molecular biology of the tumour, other factors may also influence the survival quoted 
above, i.e. patients with HPV-associated disease often tend to have an improved 
physiological reserve due to their younger age, and this, in turn, may increase the 
probability of undergoing full course treatment. Also, relatively less tobacco 
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consumption in the HPV-associated group may reduce the risk of field cancerisation 
(Gillison et al., 2011). However, Ang et al. (2010) conclude that the survival benefit 




1.1.8 HPV infection in the oral cavity 
 
Kreimer et al. (2013) recently studied the natural history of oral cavity HPV infection 
for 1626 healthy male volunteers. In this study, the median follow-up of 12 months 
revealed that newly acquired oncogenic HPV infections were rare and most were 
cleared within this period.  
 
The relationship between the practice of oral sex and oral HPV infection is a subject 
of increased interest. Further research has also been directed towards the practice of 
oral sex and the development of OPSCC. In 2012, an epidemiological study detailed 
an association between sexual behaviour and HPV infection within the oral cavity 
(Gillison et al., 2012). They observed that the relative risk of HPV infection 
correlated with an increased number of sexual partners. There was also a significant 
difference in relative risk compared to those with no history of sexual contact. 
 
A further cross-sectional study investigated the sexual practice of 1000 adults. This 
demonstrated a positive correlation with the number of oral sex partners, with a 
significantly greater risk for the subset with 5-10 oral sex partners (Pickard, 2012). 
However, Termine (2011) observed that the best predictor of oral HPV infection was 
a younger age of sexual debut and that orogenital sexual practice did not influence 
this outcome.  
 
Gillison et al. (2012) commented that the correlation of oral sex with HPV-positive 
OPSCC is difficult to prove due to the co-linearity of sexual behaviours i.e. oral sex 
practice is frequently accompanied by other practices / factors that may increase the 
chance of HPV transmission. In addition, the perceived embarrassing nature of 
orogenital sexual behaviour may result in artificially low reporting by subjects. To 
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reduce this form of bias, studies now frequently utilize computers to allow 
“automated interviews”, which guarantee anonymity (D'Souza et al., 2009).  
 
Herrero et al. (2003) performed a multi-site study and found that subjects reporting a 
history of oral sex were more likely to develop HPV-associated oropharyngeal SCC 
disease (OR = 3.2, 95% CI = 1.5 to 6.4).  In addition, HPV DNA positive tumours 
were increased two-fold in subjects with >1 oral sex partner, and in subjects with >6 
partners this increased to five-fold (Termine, 2011).  Marur et al. (2010) observed that 
a significant minority of HPV-associated OPSCC patients reported no history of oral 
sex practice which suggests that this is not the only aetiological factor. 
 
Although some observational studies have reported opposing results, a meta-analysis 
in 2009 concluded that OPSCC was associated with >4 lifetime orogenital sex 
partners and/or >6 lifetime sexual partners (Heck, 2009).  
 
There are no studies which have investigated the natural history of oral cavity HPV 
infection preceding OPSCC; however, uterine cervix cancer studies demonstrate that 
the average length of infection is 5-15 years before progression to malignancy 
(Beachler, 2012). 
 
1.1.9 HPV detection methods in OPSCC  
 
The most accepted approach for HPV analysis is based on detection of DNA or RNA 
by signal or target amplification methods. HPV L1 capsid antigen and E6 / E7 
oncoproteins can be detected by immunohistochemical techniques, but these are not 
frequently used due to lack of sensitivity (Robinson et al., 2010).  
 
Signal amplification incorporates the hybridisation of a target probe with viral nucleic 
acids. The resulting complex can be visualised in situ with either chromogenic or 
fluorescent in situ hybridisation (ISH) assays (Singhi and Westra, 2010).  
 
The amplification of a specific nucleic acid sequence by “target” methods involves 
the use of primers, nucleic acid polymerases and nucleotides. The resulting 
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polymerase chain reaction (PCR) is now the most accepted target amplification 
method for HPV detection (Schache et al., 2011). 
 
At present, no standardised protocol exists for HPV detection in OPSCC (Robinson et 
al., 2012). The gold standard test is recognised to be RNA quantitative PCR (E6 / E7) 
but this is difficult to achieve outside the confines of a research laboratory due to the 
requirement for fresh frozen rather than FFPE tissue. One observational trial 
recommended the use of p16INK4A immunohistochemistry as a surrogate screening 
marker for high risk HPV followed by DNA in situ hybridisation to increase assay 
specificity (Singhi and Westra, 2010). 
 
A study from the Netherlands found that when HPV16 DNA ISH is combined with 
p16INK4A this will improve the overall sensitivity and specificity rate to 96% (Smeets 
et al., 2007). A study from the UK also compared the DNA ISH method with 
p16INK4A IHC for detecting HPV in head and neck cancers. Although they found that 
the DNA ISH assay was less sensitive compared with qPCR detection of viral E6/E7, 
combined DNA ISH and p16INK4A gave an overall improved performance (Schache et 
al., 2011).  
 
1.1.10 Dysplastic changes preceding invasive SCC in HPV associated OPSCC 
 
HPV-positive oropharyngeal squamous cell carcinomas have characteristic histologic 
features such as a basaloid morphology or lobular growth pattern. The tumours 
frequently show a high mitotic activity as demonstrated by cell cycle markers e.g. 
MCM7 or Ki-67 (Ghittoni et al., 2010). HPV-associated OPSCC relates to a non-
keratinizing histological appearance, which can result in the wrong allocation to a 
poorly differentiated SCC category. It is now accepted that HPV-associated malignant 
epithelium (within the oropharynx) emanates from the reticulated lining of tonsil 
crypts rather than squamous epithelium, and, therefore, a non-keratinized appearance 
supports the interpretation of a well-differentiated tumour process (Begum S et al., 
2005). As yet, few studies in the literature have described the association of HPV16-
positive OPSCC and presence of pre-malignant lesions (Mooren et al., 2014, Kreimer 
et al., 2013). 
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OPSCC carcinogenesis may involve progressive transformation from normal 
epithelium to pre-malignant tissue (dysplasia / carcinoma in situ) to invasive cancer 
(Miller and Johnstone, 2001, Jayaprakash et al., 2011, Leemans et al., 2011, van 
Zeeburg et al., 2012, Mooren et al., 2014). Classification of dysplastic (pre-
malignant) epithelium within the oropharynx is a subject of continued debate. The 
intra- and inter-observer variation are relatively high in comparison to uterine cervix 
cancer due to lack of a single validated morphological criterion and the biological 
differences found within tonsil and tongue base epithelium (Fleskens and Slootweg, 
2009). 
 
While the presence of HPV subtypes within invasive oropharyngeal SCC has been 
evaluated in large epidemiological studies (Mehanna et al., 2012, Nasman et al., 
2015) there is limited data on this subject in regions of confirmed dysplasia / 
carcinoma in situ (Mooren et al., 2014).  
 
Prior studies in areas of confirmed dysplasia / carcinoma in situ have reported 
markedly variable HPV prevalence rates due to limitations of size and variable assay 
techniques (Miller and Johnstone, 2001, Chaudhary et al., 2009). Jayaprakash et al. 
(2011) published a meta-analysis of 22 relevant articles, suggesting HPV16 to be 
present in ~25% of all dysplastic lesions within the oropharyngeal subsite – the same 
author concluded this to be a conservative estimate due to the inclusion of oral cavity 
SCC lesions in some of the studies (traditionally a subsite with low HPV16 
prevalence). 
 
As the majority (~75%) of patients with HPV-positive OPSCC present at an advanced 
stage with cystic nodal disease (Licitra et al., 2006, Ang et al., 2010), investigation of 
pre-malignant molecular pathways represents an important research priority, with the 
ultimate aim to produce a non-invasive screening tool (Psyrri et al., 2012). 
 
At present, there is a relative paucity of data regarding factors that influence 
progression of disease from normal epithelium to in situ carcinoma to invasive 
malignancy.  In normal individuals, mucosal HPV carriage in the head and neck 
varies between 2% - 8% (Duray et al., 2011, Gillison et al., 2012). HPV16 prevalence 
in the oral cavity is ~1% in the US population (Gillison et al., 2012). Age (peak 
 40 
prevalence 30-34 and 60-64 years), sex (males >females), smoking, and multiple 
sexual partners were independently associated with oral HPV infection in 
multivariable models. The duration / persistence of oral HPV16 is most likely 
influenced by local and systemic immune status of an individual (discussed further in 
chapter 4). Initial studies suggest that most oral HPV infections are likely to be 
cleared within a year (Chung et al., 2014). In OPSCC, Thavaraj et al. (2014) indicate 
that virus-induced field cancerisation and/or multifocal oncogenic HPV infection is 
uncommon outside of the palatine or lingual tonsil region. 
 
Despite the limitations mentioned above, histopathological evaluation based on light 
microscopic examination remains the best option for assessing malignant potential of 
pre-invasive oropharyngeal lesions. The WHO (Gale et al., 2005) and Ljubljana (Gale 
et al., 2000) classification systems are the most accepted in HNSCC and both follow 
parameters similar to those in frequent use for the grading of squamous lesions of the 
uterine cervix (Figure 4) (Baldwin et al., 2003). It is a matter of debate as to whether 
this is appropriate, as uterine cervix epithelium will display a more obvious difference 
between abnormal and normal epithelial layers and consequently the level of 
dysplasia. 
 
1.1.11 Biomarker screening 
 
Within the invasive epithelium of HPV-associated OPSCC, the major pathways 
targeted by HPV oncoproteins E6 / E7 may include p53, p16INK4A, cyclin D1, hTERT 
and pRb [comprising RB1 / RBL1 / RBL2 and involved in cell cycle regulation 
(Leemans et al., 2011)]; EGFR and TGF-β [intracellular growth factor signaling 
(Bornstein et al., 2009, Sheu et al., 2009)]; tyrosine kinase receptors [evasion of 
apoptosis by PIK3CA amplification, HRAS mutation and PTEN loss (Chiosea SI et al., 
2013)]; Wnt / β-catenin [cadherin-catenin adhesion system  (Rampias et al., 2010)]; 
and hypoxia-inducible factor [neo-angiogenesis (Aderhold et al., 2013)]. HPV 
involvement with the above pathways can result in progressive mutations and 
ultimately genomic instability. As yet, limited data exists as to whether these or other 
similar pathways extend to dysplastic tissue surrounding viral associated OPSCC. 
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To date, data from three large genome-wide sequencing studies of HNSCCs are 
available (Stransky, 2011, Agrawal, 2011, Network., 2015). The results from 
sequencing data have been disappointing from a therapeutic target standpoint because 
of the relative paucity of oncogene mutations in comparison to the more-frequent 
tumour suppressor gene (TSG) mutations.  
 
TSGs are poor therapeutic targets because restoring loss-of-function in these genes is 
more difficult than inhibiting increased activity resulting from gain-of-function in 
oncogenes. Of the 15 most-frequent mutations in HNSCC, only two are known 
oncogenes, PIK3CA and HRAS, and only PIK3CA is currently considered to be 
therapeutically targetable (Kang, 2015). 
 
HPV-positive tumours have a lower average number of mutations per tumour, and 
rarely have TP53 mutation and loss of p16INK4A function compared with HPV-
negative tumours, reflecting the biological differences in these tumours (Stransky, 
2011, Agrawal, 2011). 
 
HNSCC has an immunosuppressive influence with patients demonstrating low 
absolute lymphocyte counts, decreased antigen-presenting function and elevated T-
regulatory cells (Masterson et al., 2016a). HNSCC achieves immune evasion by down 
regulating expression of the antigen-processing molecules, TAP1/2 and MHC1. In 
addition, co-inhibitory receptors, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and 
programmed death ligand-1 (PD-L1) which induce immune tolerance to HNSCC, are 
frequently expressed on tumours (Ferris, 2015). The cytokine microenvironment 
promotes tumorigenesis with excessive immunosuppressive cytokines such as VEGF, 
IL-6, TGF-β, and IL-10. 18 The success of immune-checkpoint inhibitors in solid 
tumours, along with the increases in HPV-positive HNSCC incidence, has raised 
enthusiasm for novel immunotherapeutic approaches and development of 







Figure 4: The uterine cervical intraepithelial neoplasia (CIN) classification system is 
based on the proportion of dysplasia observed without invasion of the basement 
membrane (⅓, ⅔ and full thickness representing CIN I, II & III respectively). 
(Baldwin et al., 2003). 
 
 
1.1.12 Squamous Cell Carcinoma of the temporal bone 
 
Squamous cell carcinoma (SCC) is the most prevalent tumour type within the 
temporal bone region. The reported incidence is <6 cases per million per year, which 
accounts for 0.3% of all cancers within the head and neck. There is a slight 
predisposition to the male sex, and the median age at presentation is within the 
seventh decade (Gidley et al., 2010). 
Modern skull base and reconstructive surgery techniques have improved the treatment 
of SCC of the temporal bone. Surgery, in the form of a lateral or extended temporal 
bone resection, is now more effective due to a greater understanding of skull base 
anatomy. Imaging techniques such as magnetic resonance (MR) and computed 
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tomography (CT) help produce accurate assessment of the disease extent regarding 
soft tissue involvement and / or bone erosion. With this approach, recent case series 
have demonstrated improved control of local advanced (T4) disease with five-year 




Established risk factors for SCC within the epithelium of the temporal bone are 
chronic suppurative otitis media (CSOM) and previous radiotherapy (Masterson et al., 
2014). Exposure to ultraviolet light may be a risk factor for SCC that originates in the 
external auditory canal (Lobo et al., 2008).  
 
One theory, which may provide a connection for the various predisposing factors, is 
the establishment of metaplastic or neoplastic change from a chronic inflammatory 
disease process. Chronic otitis media and cholesteatoma are common in patients with 
SCC affecting the temporal bone (Gidley et al., 2010). In recent years, several studies 
have suggested an aetiological role for high risk human papillomavirus, however, they 
are limited to archival samples with disparate methods of collection (Jin et al., 1997, 
Wang et al., 2009). As yet, no study has been conducted on a prospective basis with 
fresh tissue due to the infrequent nature of this condition. It is also not clear if this 
viral subgroup demonstrates an improved survival after treatment.  
 
A past medical history of radiotherapy is relevant and may serve as a red flag at 
presentation. Goh et al. (1999) reported seven patients with temporal bone 
malignancy all of whom were initially treated by radiotherapy for other head and neck 
disease. The latency period before symptoms ranged from 5-30 years (Goh et al., 
1999). This potential risk should be considered when deciding upon the most 
appropriate treatment for individuals with tumours of the head and neck - especially if 
the patient is young and/or the condition is benign i.e. acoustic neuroma or vascular 
malformation. 
Long term ultra-violet light exposure to the pinna or lateral concha can lead to 
carcinogenic change that migrates medially (Lobo et al., 2008). This is more likely in 
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Caucasians (versus other ethnic groups) who are prone to non-melanoma skin cancers 
in sun exposed areas. A genetic susceptibility to skin cancer may also exist, 
manifesting as the development of skin cancers in sites not exposed to sunlight (in 




The modified Pittsburg staging system predicts disease outcome by tumour size, local 
/ distant metastatic spread and/or facial nerve involvement. A revised University of 
Pittsburgh staging system in 2000 suggested that temporal bone SCC with evidence of 
a facial nerve palsy should be categorized as T4 (Moody et al., 2000). Multiple 




At present, there is no consensus strategy for operative management of a temporal 
bone tumour. The main surgical approaches are en-bloc resection versus piecemeal 
resection or radical mastoidectomy (all with adjuvant radiotherapy). A proportion of 
oncological procedures require piecemeal tumour removal as the main segment of 
tissue is weakened or fragmented by the carcinoma. In patients treated outside tertiary 
centres, the diagnosis is often made during a mastoid exploration for a presumed 
cholesteatoma or other middle ear disease. In this latter scenario, a pragmatic 
approach (influenced by patient choice) entails postoperative radiotherapy alone, 
which may adversely affect patient survival.  
 
 
In recent studies, the best survival outcomes are achieved with en-bloc extended 
temporal bone resection followed by radiotherapy (Gidley et al., 2010, Bacciu et al., 
2013, Masterson et al., 2014). All demonstrate improved survival figures despite 





Tumours with a well-differentiated histology have a favourable outcome, with most 
series reporting an ~80% survival rate. Advanced stage tumours have reduced 
survival rates even after adequate surgery and adjuvant radiation treatment. Other 
adverse factors include node positive status, facial nerve palsy, positive surgical 
margins and carotid artery involvement (Higgins and Antonio, 2010, Masterson et al., 
2014). 
 
Prior surgical intervention is often a pre-requisite towards making the diagnosis of 
malignancy, but this can complicate pre-operative staging, disrupt margins and 
require the surgeon to operate in an inflammatory region. The literature is divided as 
to whether persistent / residual disease will result in significantly reduced survival 

















1.2 Human papillomavirus  
 
 
1.2.1 The virus 
 
Human Papillomavirus is a major carcinogen, with an estimated link to 4.8% of total 
worldwide cancers in 2008 (de Martel et al., 2012). The overwhelming majority of 
uterine cervix cancers (99.7%) are causally associated with HPV, but the situation is 
not so clearly defined for other sites within the body. The virus consists of double 
stranded circular DNA and is strictly epitheliotropic. There are >150 types of HPV, 
some of which are involved in carcinogenesis and are designated as high-risk 
(Leemans et al., 2011). 
 
HPV16 is associated with the significant majority of viral associated cancers within 
the head and neck and in particular the oropharynx subsite. In addition, strong 
evidence exists to suggest an oncogenic role for HPV E6 and E7 with inhibition of 
p53 and pRb (retinoblastoma) tumour suppressor proteins, respectively (Rautava and 
Syrjanen, 2012).  
 
Expression of the E6 protein will cause inhibition of p53, leading to loss of cell cycle 
arrest and apoptosis when DNA damage is detected within the cell. Expression of the 
E7 protein will abrogate  the interaction of pRb with E2F1, leading to unopposed 
progression through the cell cycle (Leemans et al., 2011). Persistent HPV infection is 
pre-requisite for the establishment of this oncogenic change, and thus, the virus must 
evade both innate and adaptive immune defences.  
 
 
1.2.2 HPV subtypes 
 
HPV types, subtypes and variants are categorised by variations in the L1 nucleotide 
sequence and will display a tropism towards either mucosal or skin surfaces. Low risk 
HPV types (2, 4, 6, 11, 13, 32, 42, 43, and 44) form benign papillary growths, while 
high risk HPV types (16, 18, 31, 33, 34, 35, 39, 45, 51, 56, 58 and 59) are correlated 
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with a number of pre-malignant and malignant lesions found in the anogenital and 
upper aerodigestive tract regions (Rautava and Syrjanen, 2012).  
 
The papillomaviruses were designated as a distinct family of viruses in 2004.  The 
taxonomy levels include Family e.g. papillomavirus; Genus e.g. alpha or beta; Type 
e.g. HPV16 (>10% difference in sequence of L1 from other HPV types such as 
HPV18); Subtype i.e. 2-10% dissimilarity in L1 sequence; Variant e.g. <2% 
dissimilarity in L1 sequence. Mucosal HPV types mainly belong to the alpha genus 
while the skin cancer types are primarily restricted to the beta genus (Figure 5) (de 
Villiers et al., 2004). 
 
Figure 5: The papillomavirus phylogenetic tree is classified by L1 gene sequence 
variation. Oncogenic (high risk) HPV subtypes are restricted to the alpha genus (de 






1.1.3 Genomic organisation and structure 
 
The HPV viral genome is circular, non-encapsulated and has an approximate size of 
8000 base pair units (Figure 6). The solitary DNA strand consists of 8 open reading 
frames (ORFs). The genome is further divided into three components, which are 
respectively, the early region, the late region and a non-coding upstream regulatory 
region (URR) (Stanley, 2012a). 
 
The viral proteins E1-E7 are transcribed from the early (E) region and control the 
transcription of viral DNA. Viral proteins L1 and L2 are transcribed from the late (L) 
region and control construction of the virion and egress from the host cell (Leemans et 
al., 2011). 
 
The replication factors E1 and E2 function at the level of viral DNA replication and 
transcription.  E4 is considered to be involved in the regulation of late viral functions 
(e.g. viral particle release), however, this exact role remains unclear (Stanley, 2012a). 
E5 protein affects the early stage of viral integration by influencing tyrosine kinase 
growth factor receptor signaling pathways. E6 and E7 genes have a role in the normal 
viral life cycle by targeting the host proteins pRb and p53, which in turn preserves the 
replicative potential of infected cells (Moody and Laimins, 2010). 
 
Benign HPV types are associated with low risk HPV DNA in episomal form while 
high risk HPV DNA in malignant lesions is often, but not always, integrated within 
the cellular genome (Feller et al., 2009). Integration of the viral genome may act to 
disrupt the inhibitory function of E2 leading to increased expression of E6 and E7 
(Moody and Laimins, 2010). This may in turn provide a selective growth advantage to 
affected cells, as integrant-derived transcripts have better stability than those derived 
from episomal viral DNA (Rautava and Syrjanen, 2012).  
 
However, many studies suggest that co-existence of both episomal and integrated 
forms can be important in HPV mediated carcinogenesis. Mixed forms of HPV16 




























1.2.4 HPV life cycle 
 
HPVs show selective affinity for undifferentiated keratinocytes, infecting the basal 
cell layer of squamous epithelium (Moody and Laimins, 2010). The virus obtains 
access to the basal cell region via microscopic breaks in the skin or mucosa and is 
maintained at this site at a low copy number (~1-10 copies per cell). Viral entry into 
tonsil crypt epithelium is of specific interest as this is the most prevalent HPV-
associated carcinoma outside the anogenital site. The reticulated (sponge-like) lining 
of the crypts is important as a first line in immune defence and facilitates transport of 
antigens to provide a reservoir of immunoglobulins (Kim et al., 2007). A propensity 
for defects in this epithelial lining may explain the predisposition for high risk HPV 
infection. 
 
The life cycle of HPV is closely aligned with the differentiation of epithelial cells. In 
the productive stage of viral DNA replication, the HPV genome can be amplified 
significantly (~1000 copies per cell). When keratinocyte cells divide, one daughter 
cell begins to terminally differentiate while the other remains in the basal layer. As 
the differentiated keratinocyte has no ability to replicate, the virus is required to 
express E2 as an initiating factor. The target sequences for E2 are the E2 binding sites 
(E2BSs), which are in the regulatory region of most HPVs. If the viral genome has 
integrated, this stimulates the host cell to move from G1 to S phase, by removing the 
inhibitory function of E2 and increasing expression of E6 and E7 (Moody and 
Laimins, 2010). 
 
The manufacture of new virus-like particles within the superficial layer of the 
epithelium follows late gene transcription and translation, and the affected host cells 
are eventually desquamated (Doorbar, 2006). This process requires expression of E1-
E4, in addition to the late genes (L1 and L2), to facilitate viral DNA encapsulation 













1.2.5 Virus oncogenic activity  
 
Amplification of the papillomavirus to levels above 1,000 copies is normally reserved 
for differentiated keratinocytes that are restricted from further cell division. 
Oncogenic (high risk) viruses have developed strategies to uncouple this cellular 
proliferation and differentiation primarily by expression of viral proteins E6 and E7 
(Doorbar, 2006). 
 
The exact mechanism in which high and low risk E6 and E7 proteins differ has not 
been fully determined, although it has been suggested that the former group has a 






High risk E6 protein can inhibit the action of p53 by binding to cellular ubiquitin 
ligase E6AP. It also blocks the action of p21, which has a regulatory function within 
the cell in response to DNA damage. This dual action ameliorates the ability of the 
host cell to undergo apoptotic response. E6 can also lead to increased expression of 
hTERT (telomerase reverse transcriptase), which negates loss of telomerase and in 
turn facilitates cell immortalization / genomic instability. 
 
The hypo-phosphorylated form of pRb associates with E2F1 molecules that in turn 
can regulate the normal cell cycle. High risk E7 can bind to hypophosphorylated pRb, 
abrogating its interaction with E2F1, resulting in an effect similar to that of pRb in a 
phosphorylated state, in which the cell is led into cell cycle (S phase). Cyclins D1-3 
are activated by the resultant mitogenic signals and in turn act to promote cell cycle 
progression. E7 will also act to block p21 and in addition increase expression of 
cyclin-dependent kinase inhibitor-2A (P16INK4A). This in turn binds to CDK4, 
inhibiting subsequent interaction with cyclin D and stimulating passage through the 
G1 phase of the cell cycle (Figure 8) (Ghittoni et al., 2010). 
 
As the infection continues, the E2 protein will normally induce E6 and E7 down-
regulation and subsequently restore p53 induced apoptosis. Where this is not the case, 
both E6 and E7 will contribute to cell transformation and maintenance of a malignant 
phenotype. Persistent viral infection is required to achieve this, and immune evasion 













Figure 8: Schematic presentation of progression toward malignancy caused by HPV 
oncoproteins E6 and E7. The diagram is restricted to oncological pathways only - E6 

























1.2.6  Immune response in HPV-associated malignancy 
 
The role of both innate and adaptive immunity in the development of HPV-associated 
HNSCC is poorly understood. Evidence gained from uterine cervix cancer trials 
would suggest an impeded immune response to HPV is a requirement before 
malignant change can arise (Woodman et al., 2007). Further evidence to support this 
comes from studies on immunocompromised patients (HIV positive) who demonstrate an 
increased frequency, duration and pattern of HPV infection in comparison to normal 
controls (Schiffman et al., 2007). 
 
It is estimated that <1% of high risk HPV infections within the uterine cervix progress to 
carcinoma in situ (Tindle, 2002). Within the oral cavity, the exact mechanism behind 
persistence of HPV infection and subsequent risk of oncogenic transformation are likely 
to involve multiple factors e.g. local tissue environment (Waldeyers ring), virus clearance 
rate and exposure to tobacco / alcohol (Gillison et al., 2012). 
 55 
HPV can avoid detection by the host immune system by restricting antigen presentation – 
a process aided significantly by the absence of a haematological phase within the viral life 
cycle (Stanley, 2012a). Immunogenic peptides from both E6 and E7 oncoproteins are 
not efficiently processed or presented by the host cell during replication, and, this 
correlates with reduced expression of human leukocyte antigen (Moody and Laimins, 
2010). This may be due to a variety of mechanisms including the restriction of E6 and 
E7 to the cell nucleus or by limiting transcription of the virus before host cell 
integration (Tindle, 2002). 
 
Regarding the L1 capsid protein, a study investigating the epitope-specific response by 
Langerhans cells found an ameliorated response to human papillomavirus virus like 
particles. This leads to the inference that the virus limits expression (and thus detection) 
of capsid protein within superficial differentiated epithelial cells (Fausch et al., 2002). 
 
Innate immune response to a viral infection involves the activation of type 1 
interferons which have anti-proliferative, anti-angiogenic and immune-stimulatory 
activities (Kanodia et al., 2007). HPV E6 and E7 have demonstrated ability to impede 
the function of type 1 interferon-alpha and -beta, which further prevents response by 
dendritic cells (Stanley, 2012a). E6 down-regulates Signal Transducer and Activator 
of Transcription 1 (STAT-1) and binds to Interferon Regulatory Transcription Factor 
(IRF-3) which prevents transcription of interferon-beta mRNA. E7 reduces induction 
of interferon-alpha via loss of Interferon-Stimulated Gene (ISG) factor-3 transcription 
complex (Kanodia et al., 2007). 
 
Immune tolerance is a further evasive tactic employed by HPVs. First, E7 shares 
antigenic motifs with several human proteins and this molecular mimicry can lead to a 
reduced immune response (Vu et al., 2010). Second, a relative lack of inflammatory 
cytokines induced by high risk HPVs may lead to dendritic cells transmitting a 
“tolerance” signal to T lymphocyte cells, and subsequent loss of an adaptive response 
(Tindle, 2002). 
 
In summary, the mechanisms described above all work to reduce the detection and 
presentation of human papillomavirus antigens, which in turn ameliorate host 
immunogenic response. It is perhaps surprising to note that the overwhelming majority 
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of HPV infections resolve naturally after activation of a cell mediated immune response. 
Therefore, we may speculate that modification of immune responses to HPV-




1.2.7  Vaccination 
 
Prevention strategies can involve either reducing the risk of exposure to the various 
infective agents or the development of a screening tool. Regarding the former 
strategy, a prophylactic vaccine, based on the synthesis of recombinant L1 proteins into 
virus-like particles (the capsid with no genetic material), is now widely available. 
Antibodies targeting the major viral capsid protein L1 have demonstrated high levels of 
efficiency in patients who have no established HPV infection (Riemer et al., 2010). 
Indeed, several studies demonstrate that L1 vaccine antibody levels and the overall rate of 
seroconversion are significantly higher when compared to natural HPV exposure 
(Stanley, 2008). 
 
The Gardasil™ vaccination is now available in the United Kingdom for all girls 
between the age of 12-13 years. This new vaccine is more comprehensive than 
Cervarix™ (previously dispensed in the UK) and protects against both low- and high-
risk subtypes (6,11,16,18).  
 
Several randomised controlled trials have shown evidence to suggest that either 
vaccine can decrease the incidence of long term genital HPV16 and HPV18 infections 
and subsequent progression to uterine cervical intra-epithelial neoplasia. This 
protection also extends to other genital regions such as the vagina, vulva, anus and 
penis (Nyitray et al., 2011). As yet, the impact of these vaccines on the incidence of 
persistent oropharyngeal HPV infection has not been studied (Pickard, 2012).   
 
In 2012, a study from the USA recommended that vaccine trials in men could enhance 
our knowledge of the efficacy of HPV vaccination, especially considering the higher 
rates of HPV-positive OPSCC in males compared to females (Gillison et al., 2012). 
HPV vaccination in males would not only raise the potential of protection against 
 57 
OPSCC, but also other HPV related cancers of the anogenital region (Masterson and 
Lechner, 2016). The problem with the herd immunity model (regarding female only 
HPV vaccination) is that it completely excludes men who have sex with men (MSM), 
a group that are more likely to be infected with HPV than heterosexual men and have 
an incidence rate of anal cancer equivalent to that of cervical cancer in an unscreened 
population. 
 
It has been argued that the increasing frequency of male HPV-associated disease, is 
now comparable to that in women, and this is reason enough to vaccinate men and 
stop relying on herd immunity to protect a large proportion of our population (Stanley, 
2012b, Masterson et al., 2016b). Recent data would suggest that if we started 
vaccinating boys today, it may be 30-35 years before the benefits are apparent for 
protection against HPV associated HNSCC (Schache et al., 2011). 
 
As previously stated, patients with established viral infection do not benefit from 
vaccination with L1 capsid proteins. HPV vaccines that focus on antigen-specific T 
cell mediated immunity against E6 and E7 are now in development, which may confer 

















1.3 Epstein-Barr Virus 
 
 
1.3.1 The virus 
 
Epstein-Barr Virus (EBV) is a member of the herpesvirus family and is also referred 
to as human herpesvirus-4 (Serraino et al., 2005). The virus was first identified in the 
1960s by the Epstein laboratory group in a cell line derived from Burkitt's 
lymphoma. Serological studies indicate that most adults worldwide (>90%) are 
infected with EBV (Williams and Crawford, 2006). In developed countries, EBV 
manifests in ~25–75% of cases as infectious mononucleosis (a self-limiting disease 
characterised by lethargy, sore throat, fever and lymphadenopathy).  
 
The primary infection is transmitted by saliva and mainly gains access to epithelial 
cells in the tonsil and tongue base region (Waldeyer’s ring) (Evans, 1971). After 
infection of the host cell, which may only require a single virion, the linear genome 
persist as episomal DNA after binding. The virus is usually asymptomatic or mild in 
children. Most patients become long-term carriers of EBV, without experiencing 
disease. The virus persists in two ways: in epithelial cells of the oropharynx / salivary 
glands / urogenital tract or more commonly in circulating infected immune B cells 
(Borza and Hutt-Fletcher, 2002). In some patients, the latent virus can cause 
malignant tumours such as B- and T-cell lymphomas or nasopharyngeal carcinoma 




1.3.2 Structure and Life Cycle of EBV 
 
The virus primarily proliferates via a non-lytic mechanism (Williams and Crawford, 
2006). During this non-lytic latent process, latent membrane proteins (LMPs) and 
virus-derived nuclear proteins (EBNAs) are expressed by infected host cells (Young 
and Rickinson, 2004). 
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A developing aspect of research into EBV is focused on how viral proteins may play a 
role in lymphoproliferative disease. Although EBV infections commonly lead to mild 
symptoms, attempts at treatments with antivirals have generally been unsuccessful 
(Prabhu and Wilson, 2016). It is particularly difficult to control spread between hosts, 
as symptom-free carriers continue to transmit the virus years after initial infection. 
 
EBV has a linear, double-stranded DNA genome of approximately 184 kb that is 
sheltered within a protein capsid (Fuentes-González et al., 2013).  The virus encodes 
85 genes and open reading frames (ORFs) are divided up into distinct lytic and latent 
sections that interact with a wide variety of cytokines, signal transducers and anti-
apoptotic molecules (Serraino et al., 2005). These products and events promote EBV 
infection, immortalization and transformation (Young and Rickinson, 2004). 
 
In the latent phase of infection, characterised by no production of EBV virus, the EBV 
genome exists in a circular form localised in the host cell nucleus (Young and 
Rickinson, 2004). A minority of genes are expressed which lead to immortalization of 
the host B cell (Fuentes-González et al., 2013). The expression of the full repertoire 
of viral latent genes is referred to as Latency III (Figure 10).  
 
EBV's success as a pathogen relies on its ability to avoid the host immune system, due 
to a network of signaling pathways that prevent intracellular and extracellular 










Figure 10: Genomic organisation of latent Epstein-Barr Virus. Location and 
transcription of the EBV latent genes on the viral DNA episome. The arrows at the 
bottom are coding exons for each of the latent proteins; the latent proteins include 
three latent membrane proteins (LMPs 1, 2A, 2B) and the six nuclear antigens 
(EBNAs 1, 2, 3A, 3Band 3C, and EBNA-LP). EBNAs are transcribed from either the 
Wp or Cp promoter. The top two arrows represent the highly transcribed RNAs 
EBER1 and EBER2 (non-polyadenylated); their activation is a reliable feature of 















1.3.3 EBV–Host Interactions 
 
EBV requires a host cell in which to replicate. Penetration and attachment to this host 
cell are critical events in viral infection. The lytic phase of the virus is characterised 
by production of replication of the virus with production of structural proteins, 
envelope glycoproteins and transactivating proteins. 
 
Like human papillomavirus, cell-mediated immunity (CD8+ / CD4+ T-cell response) 
plays a significant role in regulating both the primary EBV infection and chronic 
latent EBV infection (Prabhu and Wilson, 2016).  
 
EBV infection commonly results in the production of antibodies to four separate 
antigen complexes: EBV-induced early antigen, EBV-induced nuclear antigen 
(EBNA); EBV-induced membrane antigen; and viral capsid antigen. Antibodies to 
membrane and early antigens are produced <3-4 weeks, antibodies to EBNA develop 
late and can persist throughout life (Williams and Crawford, 2006). 
 
EBV types 1 and 2 are the major subgroups identified. EBV type 1 is more common 
in developed countries and type 2 is more common in homosexual males and sub-
Saharan Africa (Young and Rickinson, 2004).  
 
 
1.3.4 Carcinogenesis of nasopharyngeal carcinoma 
 
EBV is classified as a group 1 carcinogen by the International Agency for Research 
on Cancer (IARC) (Prabhu and Wilson, 2016).  In EBV immortalized B cells, multiple 
gene products are expressed during tumour initiation; most are associated with 
inducing genomic instability, cell proliferation and blockage of apoptosis (Williams 
and Crawford, 2006). This is turn contributes to cell growth and continued tumour 
maintenance. 
 
Nasopharyngeal carcinoma (NPC) commonly arises in epithelial cells at the fossa of 
Rosenmϋller, a region of the nasopharynx rich in lymphoreticular tissue, but it can 
also arise from the roof of the nasopharynx (Young and Rickinson, 2004). 
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NPC has a remarkable geographic and racial distribution with the highest incidence 
seen in the South Chinese and Taiwanese populations (Chien et al., 2001). NPC is 
caused by an interplay of viral, environmental and genetic risk factors. Well-
established risk factors for NPC include salt-preserved fish and elevated antibody 
titres against EBV. Specific human leukocyte antigen class I genotypes are also 
associated with this disease (Chang and Adami, 2006). 
 
EBV is commonly detected in nasopharyngeal carcinomas. Serological investigations 
have demonstrated elevated levels of IgA and IgG antibodies against EBV early 
antigen, viral capsid antigen and nuclear antigens in patients with nasopharyngeal 
carcinoma (Chang and Adami, 2006). EBV DNA analysis suggests a clonal type (a 
single EBV infected cell leading to cellular growth,) indicating an early, possibly 
aetiological, event in the development of nasopharyngeal carcinoma (Pathmanathan et 
al., 1995).   
 
Presenting symptoms for NPC can include unilateral or bilateral nasal obstruction, 
blood tinged nasal discharge or severe epistaxis, unilateral conductive hearing loss 
due to Eustachian tube blockage, cranial nerve palsies (particularly III, IV, V, VI, IX 
and X). However, the most common presentation is a persistent enlarged cervical 
node. In addition to undifferentiated NPC (most common), the three main subtypes 
are well, moderately or poorly differentiated keratinizing squamous cell carcinoma 
(Young and Rickinson, 2004). 
 
The proximity of the nasopharyngeal subsite to the eustachian tube orifice provides 
the potential for migration of NPC through to the middle ear cavity. Given the 
established link between NPC and EBV, we also investigated the latter in patients 











What is the principle research aim? 
 
We aim to test the hypothesis that dysplastic epithelial changes preceding the 
development of HPV-associated OPSCC can be identified by specific molecular and 
genetic abnormalities. If proven to be the case, this may suggest a role for screening, 
similar to the uterine cervix model of disease. 
 
 
What are the secondary research aims? 
 
1.  To evaluate the prognostic / therapeutic value of molecular and genetic markers in 
HPV-associated pre-malignancy / malignancy. 
 
2. To investigate immunological response to treatment in HPV16 positive OPSCC. 
 
3. Do certain HNSCC in less usual sites have a different virological profile? As a 
specific test of this, SCC within the temporal bone will be investigated for evidence of 











































2.1 Sample collection 
 
Table 4 Solutions and reagents 
 
Materials Supplier/Constituents Catalogue 
number/Source 
1x TAE running 
buffer 
4.8 g/L Tris, 1.1 ml/L glacial acetic 
acid, 2 ml/L 0.5 M EDTA, pH 8.0 
 
6x DNA sample 
buffer 
0.5% Orange G, 30% glycerol OR 0.25% 
bromophenol blue, 0.25% xylene cyanol, 
30% glycerol 
 





Ethidium bromide Sigma-Aldrich E1510 
DNA transfer buffer 
(20x SSC) 
88.23 g/L Tri-sodium citrate, 175.32 g/L 
NaCl, pH 7-8 
 
DNase-free RNaseA Roche Applied Science 11119915001 
Lysis buffer 10 mM Tris-Cl (pH 8), 10 mM EDTA (pH 
8), 150 mM NaCl, 0.4% SDS 
 
Neutralisation buffer NaCl, 87.66 g/L, Tris base 60.5 g/L, pH 
7.5 
 
Phenol [pH 8 
equilibrated] 
USB Corporation 75829 
Proteinase K 
recombinant 
Roche Applied Science 03115879001 









TE buffer, pH 8 10 mM Tris-Cl (pH 8), 1 mM EDTA 
(pH 8) 
 
TRIzol reagent Invitrogen 15596-018 





autoclaved, 0.2 μm 
filtered 
Ambion 9937 






2.1.1  Patient samples 
 
Clinical samples were obtained from patients attending the Department of Ear, Nose 
& Throat, Cambridge University Hospitals NHS Trust, UK. All patients gave written 
informed consent for this study and ethical approval was obtained from the National 
Research Ethics Service Committee of East of England (12 ⁄EE⁄ 44). All experiments 
were performed in the Department of Pathology at the University of Cambridge. 
 
In patients with oropharyngeal carcinoma, prospective paired fresh samples (normal 
tissue paired with adjacent malignant tissue after histopathological review) were 
frozen in liquid nitrogen until RNA / DNA extraction. In addition, prospective blood 
samples were obtained for a further cohort of OPSCC patients before and after 
curative treatment (radiotherapy +/- chemotherapy) to allow evaluation of cell 
mediated immune response to HPV16 E2, E6 & E7. A retrospective cohort of patients 




2.1.2  Patient outcomes 
 
The main outcome for this research was DFS (disease free survival) which equates to 
time after treatment until first malignant disease recurrence or death. Overall mortality 
was also investigated. The average prospective follow up period for patients with 
OPSCC was 43.7 months. The average retrospective follow up period for patients 
with SCC of the temporal bone ranged from 5-30 years. In chapter three 
(Investigating HPV and cellular changes in benign, pre-malignant and malignant 
oropharyngeal disease), the main secondary outcomes included analysis of survival 
stratified by HPV16 and SYCP2. In chapter four (Investigation of CD4+ & CD8+ cell 
response to HPV E2, E6 and E7 in patients with OPSCC), the main secondary 
outcomes included cell-mediated immune responses to HPV16 E2, E6 and E7 in 
peripheral blood using IFN-γ enzyme-linked immunosorbent spot assay (ELISPOT). 
In Chapter five (Investigating the role of human papillomavirus and Epstein Barr 
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virus in squamous cell carcinoma of the temporal bone) the main secondary outcome 
included analysis of HPV16, EBV and TP53 status. 
 
2.1.3  DNA extraction 
 
Oropharyngeal carcinoma samples (fresh frozen) 
 
As per our unit protocol (Winder et al., 2009), ~25mg minced tissue samples were 
placed into a lysis tube containing 250μl digestion mix (10mM Tris, pH 7.5; 10mM 
EDTA; 0.5% SDS; 200μg/ml Proteinase K) and disrupted on a bench vortex for 20 
minutes and then incubated overnight at 37°C.  Proteinase K inactivation involved 
incubation at 56°C for 10 minutes, then the lysate was subjected to a choloroform / 
phenol extraction: equal volumes (250μl) of chloroform and phenol were added, the 
mixture was allowed to stand for 10 minutes and then centrifuged for 15 minutes 
(13,000 rpm, 4°C); the top aqueous, transparent layer was collected and the remaining 
contents discarded. DNA was precipitated with 1ml 100% cold ethanol overnight at    
-20oC. The DNA pellet was obtained by centrifugation for 15 minutes (8,000 rpm, 
4°C), and the supernatant discarded. The pellet was air dried and re-suspended in 200  
μl PBS. RNase digestion and total genomic DNA isolation (column extraction) were 
then performed using the DNeasy Blood and Tissue Kit (QIAGEN Ltd, UK), 
according to the manufacturer's instructions. DNA was eluted with 50μl milliQ H2O 
(deionised double-distilled) and stored at -20°C until quantification. DNA 
concentration and purity was ascertained by use of a Nanodrop™ 1000 
spectrophotometer (LabTech International) and associated software. All samples had 
a 260/280 nm absorbance ratio between 1.8 and 2.2 and were diluted in milliQ H2O to 
~2.5ng/μl prior to PCR. 
 
 
Temporal bone carcinoma samples (FFPE) 
 
Samples underwent a de-calcification process (Department of Histopathology, 
Cambridge University Hospital NHS Trust, UK) with trichloroacetic acid (Callis and 
Sterchi, 1998) and were stored at -70°C for a variable period. A consultant 
histopathologist with expertise in head and neck pathology reviewed each tissue block 
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to ensure adequate tumour sampling. Total genomic DNA was extracted from FFPE 
samples (9 x 3.5 μm sections) using the QIAamp tissue kit, (QIAGEN Ltd, UK) 
according to the manufacturer instructions. DNA was eluted in purified H2O 
(autoclaved + nuclease free) and stored at -20°C until further evaluation. Purity and 
concentration of DNA was ascertained by use of spectrophotometry. All samples had 
a 260/280 nm absorbance ratio in the range 1.7-2.2 and were diluted in H2O to a 
concentration of 1-27 ng/μl prior to PCR. 
 
 
Oropharyngeal carcinoma samples (FFPE) 
 
Genomic DNA was extracted from 9 x 3.5 μm sections using a QIAamp tissue kit in 
accordance with manufacturer’s guidelines (Qiagen). DNA was eluted in autoclaved 
and nuclease-free H2O and stored at -20°C. Concentration and purity of DNA was 
assessed by spectrophotometry. Samples with an absorbance ratio (260 ⁄ 280 nm) in 




2.1.4  RNA extraction 
 
Oropharyngeal carcinoma samples (fresh frozen) 
 
RNA was extracted from fresh tissue using TRIzol reagent (Invitrogen) according to 
the manufacturer’s instructions. 1 ml of TRIzol reagent was used to lyse cells isolated 
from ~25mg fresh tissue (in a bullet blender at speed 7 for 5 minutes). The lysate was 
then transferred to an RNase-free 1.5ml microcentrifuge tube, and stored for 5 
minutes at room temperature to permit the dissociation of nucleoprotein complexes. 
Chloroform (200μl) was added to the TRIzol reagent (1ml) and the tube vigorously 
shaken for 15 seconds. Following a 3-minute room temperature incubation, the tube 
was centrifuged at 13,000 rpm for 15 minutes in a chilled (4ºC) centrifuge. The upper 
aqueous phase, containing the RNA, was then transferred to a microcentrifuge tube 
(1.5ml), on ice, and 0.5ml isopropanol per 1 ml of TRIzol reagent used added. The 
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RNA was precipitated for 3 hours at -20ºC before being pelleted for 15 minutes at 
13,000 rpm in a chilled, 4ºC, centrifuge. The RNA pellet washed in 1 ml 75% ethanol 
per 1ml of TRIzol reagent used. The supernatant was carefully removed and the pellet 
air-dried for 5-10 minutes, avoiding excessive drying which would reduce solubility. 
The RNA was then re-suspended in ~75-100μl nuclease-free dH2O. The 
concentration was determined by a spectrophotometer and then stored at -80ºC. 
 
 
Oropharyngeal carcinoma samples (FFPE) 
 
Using a protocol adapted for use with Laser Capture Microdissection (Meitner, 2011), 
tissues samples from normal, dysplastic and invasive malignancy were collected into 
0.2ml PCR tube with 20μl lysis buffer from an Invitrogen Purelink FFPE RNA kit 
(18.5μl melting buffer solution + 1.5μl proteinase K,) and stored immediately on dry 
ice. A further 130μl melting buffer and 8.5μl proteinase K was added to the mixture 
and incubated at 60°C for 60-180 minutes until the lysis was complete. After transfer 
to a clean RNase-free Eppendorf tube, the sample was immediately centrifuged at 
maximum speed (13,000 rpm) for 1 minute and the lysate transferred to a new RNase-
free Eppendorf tube (1.7ml).  
 
The binding step from the Purelink FFPE RNA kit involved addition of 200μl 
Binding Buffer and 400μl 100% ethanol; 800μl of the sample was then transferred to 
a spin cartridge in a collection tube and centrifuged at 13,000 RPM for 1 minute. The 
washing step involved addition of 250μl Purelink FFPE RNA kit Wash Buffer to the 
cartridge and centrifugation at 13,000 rpm for a further 1 minute with discard of the 
supernatant. This step was repeated twice. The elution step involved preheating an 
aliquot of the RNase-free Water to 65ºC (~250μl). The spin cartridge was placed in a 
clean 1.7 ml recovery tube. 50μl of RNase-free water was added to the centre of the 
cartridge and incubated for 3 minutes, before centrifugation at 13,000 rpm for 1 






2.1.5  cDNA synthesis 
 
To further investigate HPV16 E6/E7 physical state and LCM extracted tissue, 
complementary DNA (cDNA) was synthesized from RNA for use in real time 
quantitative PCR (see section 2.5.4) using a Quantitect reverse transcription kit 
(QIAGEN) according to the manufacturer’s instructions. 
 
To eliminate any contaminating genomic DNA present following RNA extraction 
(section 2.1.3), reactions were prepared in an RNase-free 1.5 ml microcentrifuge tube 
(7x Genomic DNA wipeout buffer 2μl; Template RNA up to1μg; RNase free water 
14μl final volume) and incubated at 42ºC for 2 minutes before being placed on ice 
(Figure 11). 
 
The reverse transcription reaction consisted of 1μl Quantiscript reverse transcriptase, 
including RNase inhibitor, 4μl 5x Quantiscript RT buffer, including Mg2+ and dNTPs, 
1μl RT primer mix (a blend of oligo-dT and random primers), 14μl Genomic DNA 
elimination reaction (as above) and was incubated at 42ºC for 15-30 minutes. The 
reaction was then terminated by incubating at 95ºC for 3 minutes. Additional 
reactions, where no reverse transcriptase enzyme was added (RT negative), were also 
made and acted as negative controls in downstream applications. Following reverse 














Figure 11: cDNA synthesis check digest 
 
RT positive lanes (1,2,3,4) show expected PCR product of 287 base pairs. RT 
negative lanes (5,6,7,8) show no amplification product which implies no genomic 





















2.2.1  Polymerase Chain Reaction (PCR) 
 
Polymerase chain reaction (PCR) is a technique used to amplify a segment of DNA to 
create millions of copies. It is practical and cheap to perform and the concept has 
multiple applications across a range of biomedical sciences. 
 
Most PCR methods utilise thermal cycling, which involves exposure of reactants to 
cycles of repeated heating and cooling, DNA melting and enzyme driven DNA 
replication which proceed rapidly many times in sequence. Selective and repeated 
amplification is enabled by short DNA fragments (primers) containing sequences that 
complement the target region, along with DNA polymerase (normally Taq 
polymerase, which is a heat-stable DNA polymerase enzyme originally isolated from 
the bacterium Thermus aquaticus). 
 
As PCR progresses, the DNA generated is itself used as a template for replication, 
causing a chain reaction and exponential amplification. DNA polymerase helps to 
assemble a new DNA strand from free nucleotides, by using single-stranded DNA as 
a template short primer sequence (as mentioned above) to initiate DNA synthesis. 
DNA polymerase can only add a nucleotide to the 3'-OH group. 
 
In the first step, DNA melting, the two strands of the DNA double helix are physically 
separated at a high temperature. The second step is performed at a lower temperature 
with the two DNA strands becoming template sequences for the DNA polymerase to 
selectively amplify the target DNA. The precision of PCR results from the use of 
primers that are complementary to sequence around the DNA region targeted for 





2.2.2  PGMY PCR Analysis 
 
A PCR assay utilizing the PGMY09/11 L1 consensus primer set (Table 5) was 
undertaken. Each sample was amplified with PGMY09/11 primers (final 
concentration of each oligonucleotide in the primer set was 10 pmol) and β-globin 
primers (final concentration of each oligonucleotide in the primer set was 2.5 pmol), 
in the presence of 10x buffer, 4mM magnesium chloride, 25 μm of dNTPs, 1 unit of 
Platinum Taq DNA polymerase (Invitrogen, USA) per reaction and 4ul DNA sample 
(Gravitt et al., 2000).  
 
The PCR cycling conditions included a denaturing step for 5 mins at 95°C, followed 
by 40 cycles of 95°C for 1 min, 55°C for 1 min and 72°C for 1 min. This was 
followed by a final extension for 10 min at 72°C. A 0.8-1.5% agarose gel was then 
used to confirm the presence of bands specific for both β-globin and HPV. 
 
Electrophoresis grade agarose gels were made by dissolving agarose powder in 1x 
TAE buffer. The gel solution was then cooled and ethidium bromide added to a final 
concentration of 0.5μg/ml. The resulting solution was then poured into a tray, using a 
comb appropriate for the volume and number of samples to be analysed. The gel tray 
was then placed in a gel tank and submerged in 1x TAE buffer. A 6x sample buffer 
was added to nucleic acid samples before loading into the wells.  In addition, a 
molecular weight marker (1 kb ladder, Invitrogen) was run to enable the size of the 
bands to be determined. Electrophoresis was performed at 80-95V for ~60 minutes. 




2.2.3  Nested PCR 
 
PCR using the GP5+/GP6+ primers (Table 5) was performed as previously described 
(Winder et al., 2009). The amplification cycle was performed in a reaction volume of 
50μl containing 10x PCR buffer, 4mM magnesium chloride, 25μm of dNTPs, 1 unit 
of Platinum Taq DNA polymerase (Invitrogen, USA), 50 pmol of each primer of the 
GP5+/GP6+ primer set and 2μl PGMY DNA PCR product. PCR thermal cycling 
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programme was as follows: denaturing step at 95°C for 5 min, followed by 30 cycles 
of 95°C for 1 min, 40°C for 2 min and 72°C for 1.5 min. This was followed by a final 
extension for 10 min at 72°C. The expected amplicon size was 150 bp.  
 
Positive bands on a gel were excised, the DNA was subsequently purified using 
QIAquick® gel extraction columns (QIAGEN Ltd, UK) according to manufacturer 
instructions. DNA purity and concentration were ascertained using 
spectrophotometry. Samples were then sequenced directly using forward and reverse 
GP5+/GP6+ primers (Source BioScience, UK). The sequences were then aligned with 
known HPV types (Basic Local Alignment Search Tool, National Center for 




2.2.4    E6/E7 DNA / cDNA PCR analysis 
 
Primers specific for HPV16 E6/E7 PCR assay were utilised as described previously 
(Sotlar et al., 2004). The PCR cycling conditions were as follows; 94 °C for 5 min 
denaturing step, followed by 94 °C for 1 min, 60 °C for 45 s and 72 °C for 1 min (x 
40 cycles). This was followed by a final extension period of 10 min at 72 °C. 
 
cDNA generated from extracted OPSCC mRNA was subjected to E6/E7 PCR 
analysis using the same primers and conditions as used for DNA samples (above). 
Expected amplicon sizes were as follows; unspliced E6-E7 mRNA, 406 bp: E6*I, 
224 bp: E6*II, 107 bp. A PCR for GAPDH was performed (amplicon size 122 bp), to 
confirm that the RNA was suitable for amplification, using primers as described 
previously (Eagle et al., 2006). The thermal cycling conditions were as follows; 95 °C 
for 5 min denaturing step, followed by 95 °C for 1 min, 60 °C for 1 min and 72 °C for 







Table 5: PGMY, GP5+/GP6+, HPV16 E6/E7 and GAPDH primer sequences 
 
PGMY09/11 set comprises five forward (11A-E) and thirteen reverse (09F-HMB01) 
primers (including PC04 and GH20 β-globin as internal controls). The GP5+/GP6+ 
set consists of a single forward and reverse primer sequence and is a subset of the 
PGMY amplified region.  
 
 
Primer set Primer name 5’-3’ sequence 
PGMY09/11 PGMY11-A GCA CAG GGA CAT AAC AAT GG 
 PGMY11-B GCG CAG GGC CAC AAT AAT GG 
 PGMY11-C GCA CAG GGA CAT AAT AAT GG 
 PGMY11-D GCC CAG GGC CAC AAC AAT GG 
 PGMY11-E GCT CAG GGT TTA AAC AAT GG 
 PGMY09-F CGT CCC AAA GGA AAC TGA TC 
 PGMY09-G CGA CCT AAA GGA AAC TGA TC 
 PGMY09-H CGT CCA AAA GGA AAC TGA TC 
 PGMY09-I G CCA AGG GGA AAC TGA TC 
 PGMY09-J CGT CCC AAA GGA TAC TGA TC 
 PGMY09-K CGT CCA AGG GGA TAC TGA TC 
 PGMY09-L CGA CCT AAA GGG AAT TGA TC 
 PGMY09-M CGA CCT AGT GGA AAT TGA TC 
 PGMY09-N CGA CCA AGG GGA TAT TGA TC 
 PGMY09-P G CCC AAC GGA AAC TGA TC 
 PGMY09-Q CGA CCC AAG GGA AAC TGG TC 
 PGMY09-R CGT CCT AAA GGA AAC TGG TC 
 HMB01 GCG ACC CAA TGC AAA TTG GT 
 PCO4 CAA CTT CAT CCA CGT TCA CC 
 GH2O GAA GAG CCA AGG ACA GGT AC 
GP5+/GP6+ GP5+ TTT GTT ACT GTG GTA GAT ACT AC 
 GP6+ GAA AAA TAA ACT GTA AAT CAT ATT C 
HPV16  E6/E7 (F) GGG CGT AAC CGA AAT CGG T 
     E6/E7 (R) TCC TCC TCC TCT GAG CTG TC 
GAPDH (F) CCA CCA TGG AGA AGG CTG GGG CTC A 









2.2.5  Taqman qPCR 
 
Primers and probes utilized in this study were manufactured by Sigma-Aldrich. All 
reactions were in triplicate and targeted the HPV E6 gene of HPV 16 as well as two 
internal controls: β-globin and human glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (de Boer et al., 2007, Coleman et al., 2008). Details of the primers and 
probes used are summarised in Table 6. Probes were further purified by HPLC. All 
primers and probe sets were validated using BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and sequence alignment with their target gene 
was conducted using BLAST Align (http://blast.ncbi.nlm.nih.gov/bl2seq/wblast2.cgi). 
 
All qPCR reactions were performed in 20µl containing 1x PCR buffer (Qiagen), 
4.5mM MgCl2 (Qiagen), 375µM dNTPs (Roche), 100nM primer pairs and probe, 0.5 
units (u) Hotstart Platinum Taq (Qiagen) and 4µl template DNA.  Standard curves 
were constructed using purified placental human DNA (Sigma, UK) and purified 
plasmid containing the HPV16. Serial dilutions of 1 in 5 (105 to 6.4pg/μL for DNA or 
20,000 to 6.4 copies/μL for HPV 16) were constructed in a triplex. Figure 12 shows 
standard curves for all probes. 
 
qPCR amplification was performed using Rotor-Gene 3000 (Corbett Life Sciences). 
Cycling conditions were as follows: An initial Taq activation and template 
denaturation step at 95°C for 15 minutes, and 40 cycles of 95°C for 15 seconds and 












Equation 1: Data was analysed using the Rotor-Gene analysis software (version 6.1) 
and further analysis was performed using Microsoft Office Excel 2014. The 
quantification of HPV DNA viral load in samples was accomplished using a standard 
curve incorporated into each experiment. The quantities of internal control genes were 
estimated as ‘ng/μl’ and HPV types were estimated as ‘copies/μl’. The number of 
virus copies within a single cell was calculated using the equation below, the DNA 
content of a single cell is approximately 7pg DNA (Leyva and Kelley, 1974). 
 
 
         
 
 
Table 6: Primers and probe sets used in qPCR assay of viral load 
 
These were used in the detection of HPV and Human DNA in samples taken from 
fresh oropharyngeal samples. Primers and probes were used at a concentration of 
100nM. Primer/probe sequences are represented in a 5’ - 3’ direction. The 5’-
fluorescent labels were attached to each probe (6FAM - 6-carboxyfluorescin, Cy5 – 
cyanine or TET - tetrachloro-6-carboxyfluorescein). Black Hole Quencher 1 (BHQ1) 












































Figure 12: Graphs showing standard curves for all channels 
 
The first dilution of the standard curve was 100ng human placental DNA (a+b) and 
100,000 copies HPV 16 plasmid (c). Serial 1 in 5 dilutions were made until the last 
dilution with 6.4pg DNA and 6.4 copies of HPV 16. The last point on the standard 
curve was water with no DNA or HPV 16 copies. 
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2.2.6  EBV PCR 
 
A PCR assay using ~10ng extracted DNA with the EP5/EM3 primer set (Table 7) was 
performed as described previously (Markoulatos et al., 2001). The PCR cycling 
conditions were as follows: denaturing step of 94°C for 2 min, followed by 40 cycles 
of 94°C for 30 seconds, 57°C for 30 seconds and 72°C for 30 seconds. This was 
followed by a final extension period of 10 min at 72°C.  
 
 
2.2.7  TP53 PCR 
 
A 1.84 kB TP53 gene segment, incorporating exons 5–9, was amplified from purified 
tumor DNA by PCR using primers TP53(F) and TP53(R) (Table 7) and sequenced 
directly (Kusser et al., 1993). This region was chosen because somatic mutations 
outside this DNA-binding region are rare in human malignancies (Oliver et al., 2002). 
The positive control for TP53 mutation consisted of extracted DNA from the human 
immortalised cell line K562 (chronic myeloid leukaemia). A negative (Wild Type) 
control was derived from the CaSki cell line (cervical carcinoma).  The PCR cycling 
conditions were as follows: denaturing step of 95°C for 5 min, followed by 22 cycles 
of 94°C for 20 seconds, 53°C for 40 seconds and 72°C for 20 seconds. This was 












Table 7: Primer sequences for EBV and TP53 PCR. 
 
Primer Sequence (5’-3’) Virus 
Genome region 
amplified 




















n/a Exon 4/5 terminal 
protein RNA 
12,985- 14,806 1841 

















2.3 In situ hybridisation 
 
 
In this technique, a labelled strand of DNA or RNA that complements a target DNA 
or RNA sequence is used to detect the presence of the target sequence in tissue. The 
probe can be labelled using immunohistochemistry, fluorescence or autoradiography 
(Jin et al., 1997). For this project, digoxigenin (DIG), a steroid, was joined to 
deoxynucleoside triphosphates and then these labelled nucleosides were incorporated 
into complementary DNA / RNA sequences. The probes were allowed to conjugate 
with their target sequences and then excess probe was washed away. To detect probe 
within tissue, first an antibody (attached to alkaline phosphatase) against DIG was 
applied. Finally, a solution of nitro-blue tetrazolium and 5-bromo-4-chloro-3’-
indolyphosphate (NBT/BCIP) was applied. When NBT/BCIP is combined with 
alkaline phosphatase, an intense, insoluble black-purple precipitate is formed. An 




















Figure 13: HPV16 DNA in situ hybridization performed on FFPE tissue 
 
The discrete, dot-like nuclear integrative pattern is more often in groups of epithelial 

















2.3.1 DNA probes 
 
Escherichia coli bacteria (strain DH1) containing plasmid pBR322 with inserted 
HPV16 genome was obtained from the Sterling laboratory and grown on 2xTY agar 
plus ampicillin plates overnight at 37°C while shaking at 220 revolutions per minute 
(rpm). 50μL of the starter culture was then plated out onto 50mL of 2xTY medium 
with 50μg/mL ampicillin and allowed to grow overnight (37°C, 220rpm). A single 
colony was then taken from the plate for midi prep culture (according to the protocol 
of the Qiagen Plasmid Midi Kit). 
 
Plasmid DNA was linearized by restriction enzyme digest and HPV DNA isolated 
from plasmid DNA by extraction from gel after electrophoresis. Bam H1 (Roche) 
produced bands of sizes 7904 and 4361 base pairs (Figure 14). 8μg plasmid DNA 
was digested with 20u of enzyme in 1x buffer B in a total reaction volume of 50μL 
overnight at 37°C (each enzyme unit [u] is stated to cleave ~1-2 μg of plasmid DNA 
in 1 hour using these conditions). Digested plasmids were electrophoresed on a 0.8% 
agarose gel for 70 minutes at 80V (Figure 15). The HPV DNA (larger band) was then 
excised from the gel and purified using QIAquick® gel extraction columns (Qiagen 
Ltd, UK) according to the manufacturer’s instructions. 
 
The linearized DNA was then used to make DIG-labelled probes using the 
manufacturer’s protocol of the DIG DNA Labelling and Detection Kit (Roche), which 
uses random primer labelling. Finally, probe-labelling efficiency was estimated 
following the manufacturer’s protocol (Roche). In this technique, serial dilutions of 
probes were made and aliquots placed on a nitrocellulose filter. After cross-linking 
samples to the filter, a colour change reaction was carried out according to the 
manufacturer’s instructions. Probes labelled as efficiently as the provided control 








Figure 14: Map of HPV16 in plasmid pBR322 
 
The BamHI sites are indicated at which cutting removes the plasmid backbone from 






























Figure 15: Agarose gel electrophoresis of Bam HI-digested HPV 16-pBR plasmid 
 
Plasmid pBR322 containing HPV16 was cut via a restriction enzyme digest to 
separate the HPV genome (7.9Kb band) from the plasmid (4.3Kb band). This gel 









Figure 16: Serial dilutions of HPV 16 DIG‐labelled probes  
 
Each serial dilution was spotted onto a nitrocellulose filter. Labelled controls that 
were either labelled simultaneously with HPV probes or labelled previously and 
included in the DIG Labelling and Efficiency Kit (Roche) were also diluted and put 

















2.3.2 RNA probes 
 
Five probe sequences (HPV type 16 E4, E6, E7, L1 & L2) that had already been 
ligated into the expression vectors pGEM3Z or pGEM4Z and transformed into 
bacteria were obtained from the Sterling Laboratory. 
 
Plasmid digests to check for the correct size of the HPV insert were performed for 
each probe construct using 20u EcoR1 and 20u BamHI in 1x buffer B (Roche) in a 
total reaction volume of 20μL. Samples were incubated at 37°C for 80 minutes. 
Samples were run on a 1% agarose gel at 90V for 60 minutes (Figure 17). 
 
 
Figure 17: Plasmid digests for EcoR1 and BamH1 
 
Cut enzyme lanes [C] reveal a large vector (~2700 bp) and small insert fragment 
which is specific for each probe sequence (Expected HPV fragment sizes after 
Bam/Eco digestion: E4 = 278bp; E7 = 317bp; E6 = 497bp; L1 = 367bp; L2 = 385bp). 






As the check digest revealed fragments of the expected size (Figure 17), a subsequent 
gel extraction was performed. Each sample was diluted to a concentration of 15μg in 
50 μL (see below) with the addition of 3μL enzyme (BamHI or EcoR1), according to 
the plasmid construct and 5μL 1 x buffer B (Roche).  
 
Samples were incubated at 37°C for 80 minutes. Samples were run on a 1% agarose 
gel at 80V for 60 minutes. Bands were excised from the gel (~2700bp) and DNA 
purified using the Qiaquick Gel Extraction Kit according to the manufacturer’s 
protocol. 
 
All five probes were labelled according to manufacturer’s instructions using the DIG 
RNA Labelling Kit (SP6/T7) (Roche) and efficiency checked by comparison with 
control probes (Figure 18). The DIG RNA labelling kit labels RNA probes using 






















Figure 18: Labelling efficiency for RNA probes.  
 
Serial dilutions of HPV16 E4, E6, E7, L1, L2 DIG-labelled probes were made and 
spotted onto a nitrocellulose filter. Labelled controls for the T7 and SP6 promoter 



















FFPE sections were first de-waxed in xylene and rehydrated through an ethanol series 
before hybridisation with DIG-labelled probes. After rehydration, slides were soaked 
in 0.02M HCl for 10 minutes, PBS for 5 minutes, 0.01% Triton-X 100 (VWR 
International) in PBS for 3 minutes, and fresh PBS for another 5 minutes. Slides were 
then soaked in Proteinase K buffer (5mM EDTA and 50mM Tris, pH 7.5) that had 
been pre-warmed to 37°C for 10 minutes. Proteinase K was added to the Proteinase K 
buffer at a concentration of 2.5mg/mL and warmed to 37°C. The resulting solution 
was added to each slide to completely cover the available tissue, and slides were 
incubated in a humidified box at 37°C for 10 minutes. Slides were subsequently 
washed twice with 2mg/mL glycine in PBS for five minutes each. Slides were rinsed 
in 20% acetic acid in water (4°C) for ~15 seconds. Slides were then soaked in PBS for 
10 minutes twice, 4% paraformaldehyde in PBS for 5 minutes, and twice more in PBS 
for 5 minutes each. Slides were then dehydrated through a series of ethanol dilutions 
before air drying prior to addition of the probe. DIG-labelled probes were diluted 1:10 
in hybridisation buffer (2x SSC, 5% dextran sulphate, 50% deionized formamide, 
0.2% Marvel,) and boiled for 1 minute. Probes were then applied to sections and 
occluded with coverslips. Slides were incubated for 10 minutes in a pre-warmed metal 
tray at 80°C in order to denature the DNA, and then transferred to a humidified box to 




Slides were soaked for up to 10 minutes in 2x SSC to gently dislodge coverslips. 
Slides were then soaked for 10 minutes in pre-warmed 2x SSC at 50°C (within a 
polystyrene box to reduce temperature fluctuations). For the washing steps, solutions 
were placed on a stirrer at 10 minute intervals. Slides were washed in 0.2x SSC at 
room temperature, pre-warmed 0.2x SSC at 42°C, and then 0.1x SSC at room 
temperature. Slides were then soaked for 15-30 minutes in Buffer 2 (0.5% blocking 
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reagent (Roche) in Buffer 1 (0.1M NaCl, 0.1M Tris pH 7.5, 2mM MgCl2, and 0.05% 
Triton X-100)). Slides were then rinsed briefly in Buffer 1. Anti-digoxigenin-alkaline 
phosphatase labelled antibody was diluted (1:5000) in Buffer 2. Each sample was then 
incubated at 30 minutes at room temperature in a humidified box with enough 
antibody solution to completely cover each tissue section. Slides were subsequently 
washed in Buffer 1 twice for 15 minutes each. Slides were soaked for 30 minutes in 
Buffer 3 (0.1M Tris pH 9.5, 50mM MgCl2, 0.1M NaCl) at room temperature. Next, 
the NBT/BCIP stock solution was diluted 1:50 as per manufacturer instructions 
(Roche) in Buffer 3. Slides were incubated for 15-30 minutes in the dark with the 
diluted NBT/BCIP solution. Reactions were stopped by soaking in TE, pH 8.0 (1mM 
EDTA, 10mM Tris) for 5 minutes. Slides were rinsed in PBS twice, dH20 once, 
counterstained in weak, aqueous eosin, and rinsed in dH20 again. VectaMount AQ 
was applied to sections and coverslips placed. Pictures were taken with an Olympus 
BX41 microscope and a QImaging Micropublisher 3.3 RTV camera. Images were 
captured using Qcapture Pro 5.0 software. 
 




Slides were dewaxed in xylene and rehydrated through a series of alcohols before 
soaking in PBS for 5 minutes and then fixed in 4% paraformaldehyde for 5 minutes. 
Slides were washed in PBS 4 times for 2 minutes each and then incubated in pre-
warmed Proteinase K buffer (2mM CaCl2, 20mM Tris, pH 7.4,) for 3 minutes at 37°C. 
Slides were then incubated in a pre-warmed Proteinase K solution (Proteinase K 
enzyme (25μg/mL) added to Proteinase K buffer) for exactly 10 minutes at 37°C 
before soaking 4 times in PBS for 2 minutes each prior to soaking in an acetic 
anhydride (0.25%) / triethanolamine solution (100mM) for 10 minutes. Slides were 
soaked in PBS 4 times for 2 minutes each. Slides were dehydrated back through an 
alcohol series and air dried prior to the application of the hybridisation solution.  
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A DIG-labelled probe was diluted 1:10 in hybridisation buffer (50% deionized 
formamide, 1x hybridisation buffer (10x SSC, 500mM Tris pH 7.6, 50mM Na2HPO4, 
50mM NaH2PO4, 0.1% Ficoll, 0.1% polyvinyl pyrolidone), 500μg/mL salmon sperm 
DNA, 250μg/mL tRNA, 2mM DTT, 10 mg/ml). The slides were incubated overnight 





2x SSC (0.1% sodium dodecyl solution (SDS)) was pre-warmed to 55°C to allow 
gentle removal of slide coverslips. Slides were then washed for 10 minutes in the 
same solution for 10 minutes at 55°C. RNase (diluted 2μg/mL in 5x SSC) was added 
to each section and slides were incubated for 15 minutes at 37°C. Slides were washed 
in pre-warmed 0.1x SSC, 0.04% SDS twice at 65°C for 20 minutes. Next, slides were 
soaked in Buffer 2 (as described in the DNA ISH post-hybridisation section) for 30 
minutes. Anti-digoxigenin-alkaline phosphatase labelled antibody was diluted 1:5000 
in Buffer 2. Slides were incubated for 30 minutes at room temperature with the 
diluted antibody applied to each section. Slides were washed twice in Buffer 1 for 15 
minutes each. Slides were soaked in Buffer 3 (0.1M NaCl, 0.1M Tris-HCl pH 9.5, 
50mM MgCl2) for 30 minutes. NBT/BCIP stock solution was diluted in Buffer 3 
(1:50) and applied to each section and slides were then incubated room at temperature 
in a humidified box in the dark overnight. The next day, the reaction was stopped by 
soaking for 5 minutes in 1x TE, pH 8.0 (1mM EDTA, 10mM Tris). Slides were rinsed 
in PBS twice, dH20 twice, and counterstained with aqueous eosin prior to mounting 
with VectaMount AQ (Vector Laboratories). Pictures were obtained as per the DNA 











Immunohistochemistry (IHC) utilises the detection of antigens using antibodies. 
Visualizing an antibody-antigen interaction can be achieved in various ways. The 
most popular method involves an antibody conjugated to an enzyme (such as 
peroxidase) that can promote a colour-change reaction. Alternatively, the antibody 
can also be tagged to a fluorophore, such as fluorescein, to promote an 
immunofluorescent reaction. 
 
Antibodies against p16 were used in this study. P16 is a cyclin-dependent kinase 
inhibitor that slows the cell cycle by inactivating phosphorylation of retinoblastoma 
protein (Rb) by cyclin-dependent kinases. High risk HPV E7 expression causes the 
upregulation of p16. Specifically, HPV E7 inactivation of Rb can enhance expression 
of p16, thus allowing this biomarker to act as a good proxy measure for HPV16 E7 
oncogene activity (Robinson et al., 2012). 
 
Antibodies against the proliferative markers minichromosome maintenance protein 
(MCM) 7 and Ki-67 and were also used in this study. MCM proteins contribute 
towards a pre-replicative cycle that is important for instigating DNA replication. 
Quiescent cells or well-differentiated cells tend to down-regulate MCM7. Dysplastic 
and malignant tissue express MCM7 to a variable extent in epithelial cell layers 
(Blow, 2005). Ki-67 is also a useful biomarker for assessment of proliferation of cells. 
However, there are some studies which suggest that Ki-67 is not mandatory for 
successful replication. Also, systemic factors such as nutritional or immune status can 
alter Ki-67 expression (Schrader et al., 2005).  
 
Epstein-Barr virus (EBV) is firmly associated with nasopharyngeal carcinoma (NPC) 
as derived by the presence of EBV DNA within the malignant cells for a majority of 
cases (Zheng et al., 2015). Latent Membrane Protein 1 (LMP1) is thought to be 
among the most likely EBV proteins involved with oncogenesis and tumour 




2.4.1 IHC protocol 
 
Slides were dewaxed in xylene and rehydrated via graded alcohol solutions, then 
soaked in PBS and dH20 for five minutes each. Antigen-retrieval was instigated by 
microwaving slides for 20 minutes on full power in a solution of citric acid (1.8mM) 
and sodium citrate (8.2mM). After full cooling, slides were placed in PBS for 10 
minutes x2. Slides were then placed in 0.3% H202 for exactly 20 minutes before being 
washed twice in PBS for 10 minutes each. The tissue samples were blocked by 
incubating with 1% serum (Vector Laboratories) in PBS for 30 minutes at room 
temperature. The specific serum was derived from the animal in which the 
biotinylated antibody was normalised. In this case, horse serum was used. Primary 
antibodies were used at the following concentrations in PBS: p16 1:20 (BD 
Pharmingen), MCM7 1:200 (Abcam), Ki-67 1:150 and LMP1 1:150 (Dako, Glostrup, 
Denmark).  
 
Slides were incubated with the primary antibody overnight in a humidified box at 
4°C. The samples were then washed twice in PBS for 10 minutes before application 
of the secondary biotinylated antibody (Vector Laboratories) in a solution of PBS 
(1:200). Slides were washed twice in PBS for 10 minutes before application of the 
ABC reagent (Vector Laboratories) at room temperature for 30 minutes.  
 
Slides were subsequently soaked in PBS for 2x 10 minutes. A further colour chain 
reagent (3,3’-Diaminobenzidine (DAB)) was applied for approximately 25 minutes – 
2 hours depending on the primary antibody. The reaction was stopped after a five 
minute soak in PBS. Slides were counterstained with haematoxylin (Vector 
Laboratories) and dehydrated through graded alcohol solutions prior to mounting with 
Vectamount (Vector Laboratories). Pictures were obtained as per the DNA post-







2.5 Whole transcriptome analysis  
 
The detection and quantification of RNA in a biological sample can be accomplished 
through whole transcriptome sequencing (WTS), also known as RNA-Seq (RNA 
sequencing) utilising next generation sequencing platforms. 
 
In defining the continuously shifting cellular transcriptome, WTS provides 
information on mutations/SNPs, alterations in gene expression, abnormal splicing, 
gene fusion and modifications after transcription. A whole host of RNA data can be 
elicited by WTS such as mRNA transcripts, total RNA, tRNA, miRNA and ribosomal 
profiling. Furthermore, WTS can delineate exon/intron boundaries following 
verification and/or amendment of 5’ and 3’ gene boundaries. 
 
Microarrays, which are founded on hybridisation techniques, were previously used for 
gene expression analysis before the advent of WTS. WTS has overcome the 
disadvantage of artefacts that arose in microarrays due to cross-hybridisation and the 
inability to fully quantify low and high expressed genes, which therefore required 
prior knowledge of the sequence. 
 
Oropharyngeal carcinoma patients in this study were categorised into HPV- or HPV+ 
using the techniques described earlier in this chapter. In twenty-four patients, multiple 
fresh frozen biopsy samples were obtained at the time of diagnostic or therapeutic 
surgery. All biopsies were selected for downstream applications based on their RNA 









2.5.1 Investigation of RNA integrity  
 
RNA extracted from tumour samples (see 2.1.3) was assessed for purity using RNA 
6000 Nano Chips and the Agilent 2100 Bio-analyzer (Agilent Technologies, CA, 
USA) according to the manufacturer’s instructions. This system, which has now 
superseded agarose gel electrophoresis in the assessment of RNA integrity, utilizes 
miniature glass chips that contain interconnected reservoirs. The channels between 
reservoirs are filled with a gel matrix, RNA samples, and a dye concentrate. Sample 
components are separated by electrophoresis, the fluorescence detected and translated 
into electropherograms and gel-like images (bands). Only samples which 






















Figure 19: Electropherogram of non-degraded RNA (RIN=7.6) by the Agilent 2100 
Bio-analyzer. Tall peaks represent 18S and 28S rRNA (arrowed) which is 





Figure 20: Electropherogram of degraded RNA (RIN=2.8) produced by the Agilent 
2100 Bio-analyzer. Note the lack of tall 18S and 28S rRNA peaks. FU, ladder 








Figure 21: Gel-like images showing prominent bands at 1.8kbp [18S] and 3.9kbp 




















2.5.2 Illumina bead microarray 
 
This study utilised the Illumina Next Generation Sequencing (NGS) platform to 
provide high-quality gene expression and transcriptome analysis data from a broad 
range of sample types. This technique can quantify and profile any active gene or 
transcript, including novel transcripts. In addition, expression microarray technology 
measures the relative activity of known, predefined genes and transcripts. 
 
All WTS samples were processed by the Cambridge Genomic Service, Department of 
Pathology, University of Cambridge. In brief, messenger RNA-seq complementary 
DNA (cDNA) libraries were prepared from ~400 ng of total RNA. Messenger RNA 
was isolated using poly dT oligonucleotides connected to magnetic beads, fragmented 
using elevated temperature and divalent cations and converted to cDNA using reverse 
transcriptase. DNA polymerase I and random primers were then utilized to convert 
single stranded cDNA into double stranded cDNA. This was blunt end repaired with 
Klenow DNA polymerase and T4 before adenylation of the 3’ end of the fragment. A 
final purification step utilized gel electrophoresis, with fragments cut out in the range 
200 – 300 bp. These fragments were amplified by PCR and sequenced using the 
Illumina Cluster Station and Genome Analyser (Illumina, Inc, San Diego, CA). 
Paired-end sequence analysis (51 cycles per end) was conducted with primers specific 
to the ends of the bridge-amplified cDNA fragments to obtain 51 nucleotides of 
sequence from each end of all cDNA fragments (Laborde et al., 2012). 
 
Each array on the HumanHT-12 version 4 Expression BeadChip (GPL10558) targets 
more than 31,000 annotated genes with more than 47,323 oligonucleotide probes 
derived from the National Centre for Biotechnology Information Reference Sequence 
(NCBI) Release 38 and other sources. Raw reads from normal epithelium (control) 
and tumor samples were processed using the Geospiza GeneSifter Analysis Edition 
pipeline. Expression values for annotated genes were calculated from the aligned data, 
by adding the number of reads linked to all exons and splicing events for a given gene 
and dividing that parameter value normalised by the total number of mapped reads in 
a sample. Two-way analysis of variance identified target sequences with significant 
differential expression between normal and tumor tissue and further stratified by HPV 
status (Tusher et al., 2001). The final choice of target transcripts in the study were 
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based on gene ontology data supplied by the KEGG (Kanehisa et al., 2014) oncology 
pathway network.  
 
2.5.3 Laser Capture Microdissection  
 
The technique of Laser Capture Microdissection (LCM) has been successfully applied 
for the isolation of single cells (involving the capture of one cell from tissue samples 
(Meitner, 2011). LCM has been used to study HPV infection in HNSCC (Malhotra et 
al., 2004) and uterine cervical intraepithelial neoplasia tissue (Callegari et al., 2014) 
from fresh and FFPE samples. The accuracy of estimated RNA within the sampled 
region is expected to be greater when using LCM to dissect smaller areas of tissue 
(Kalantari et al., 2009) (Figure 22). 
 
To validate findings from the prospective WTS samples (see section 2.5), 
retrospective FFPE oropharyngeal tissue were mounted on PEN (polyethylene 
naphthalate) membrane slides by the Tissue Bank, Department of Histopathology, 
Cambridge University Hospitals NHS Trust, UK. An additional section of tissue was 
sliced onto Biobond-coated Superfrost slides (VWR International, UK) and stained 
with H&E by the Tissue Bank to exemplify tissue morphology. 
 
Before LCM, PEN membrane slide-mounted tissue sections were dewaxed and 
rehydrated (1 minute in 95%, 70% ethanol and milliQ H2O) through an ethanol series 
before staining very briefly with 0.4% cresyl violet solution. The slides were 
immediately washed with distilled water to remove any residual staining medium. 
Sections were allowed to dry prior to transportation on ice. 
 
LCM of fixed tissue sections was performed using Leica LMD7000 Laser 
Microdissection System (Leica Microsystems Ltd., UK) in the Multi-Imaging Centre, 
Department of Physiology, Development and Neuroscience, University of Cambridge, 
UK. A 0.5μm laser beam was used to dissect selected areas of tissue from inverted 
PEN slides. Dissected tissue was allowed to fall into an underlying collecting tube, 
containing 40μl PBS (Figure 23). The collection tube was stored on ice until RNA 
extraction (see section 2.1.3). Dissections were performed in triplicate.  
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Figure 22: Laser capture microdissection  
 
Regions of the oropharyngeal biopsy that represent normal tissue, dysplastic and 
malignant lesions were identified (A). Using the technique of laser microdissection, a 
near-IR laser (B) cut around selected areas and liberated the cells away from the tissue 



















Figure 23:  Cell harvest with laser capture microdissection 
 
The Leica microdissection system allows to selectively analyse regions of interest 
(down to single cells) to obtain results that are specific and reproducible. Proteins and 
nuclei acid isolated from the dissected specimens can be directed to molecular 
analyses such as: genotyping, sequencing, PCR and real-time PCR (Picture courtesy 













2.5.4 Real-Time qPCR  
 
As RNA cannot serve as a template for PCR, the first requirement in an RT-qPCR 
assay is the reverse transcription of the RNA template into cDNA (section 2.1.3), 
followed by its amplification by PCR. The basic principle of relative gene 
quantification is to compare the gene of interest (e.g. SYCP2) with that of the internal 
loading control / reference gene (e.g. β-actin). 
 
Validation of expression data by reverse transcription qPCR analysis utilised the 
SYBR green method with an Applied Biosystems ViiA 7 Fast Real-time PCR 
system. Primers (Eurofins MWG Operon) were optimized with β-actin as a control 
gene and then with the transcript region of interest (Tables 8 & 9). When the optimal 
primer concentration produced a linear response to input cDNA concentration (range 
<1–150 ng), samples were analysed in triplicate for each tested transcript. 
 
For this project, the technique of RT-qPCR had previously been utilised within the 
Goodfellow laboratory (Division of Virology, Department of Pathology, University of 
Cambridge). Ideally, the expression of the control gene should remain stable 
regardless of different experimental conditions. To achieve this, several variables 
need to be controlled i.e. enzymatic efficiencies, the amount of starting material, and 
differences between tissues in overall transcriptional activity. Multiple strategies have 












Table 8: Primers and probe sets used in RT-qPCR assay of WTS selected transcripts 
from fresh and FFPE oropharyngeal samples. Primers and probes were used at a 
concentration of 100nM. Primer/probe sequences are represented in a 5’ – 3’ 
direction. Primer selection to start <400bp from the 3’ end. Amplicon size <200bp. 















Figure T1: Primers and probe sets used in RT-qPCR assay of WTS selected transcripts [fresh and FFPE oropharyngeal samples]. Primers and 
probes were used at a concentration of 100nM. Primer/probe sequences are represented in a 5’ - 3’ direction. Primer selection to start <400bp 
from the 3’ end. Amplicon size <200bp. This may optimize amplification of targets with degraded RNA e.g. Laser Capture Micro-dissection. 
 
 
Gene ID Illumina ID1 NCBI Forward Reverse Probe Exon 
Spanning 




AG GCTCCTGTGTGGCCACCGAC Yes 




AGA TGGCTTGTCCTGCATGGCCA No 


















CA AGGCTGGTGGCAAGTGCACG No 




GG AAATCACATCGGGGTCAGGG No 




GAA GCACTCACGCCCTAAGCGCA No 






















Table 9: Primers and probe sets used in RT-qPCR assay of WTS selected transcripts 
from fresh and FFPE oropharyngeal samples. Primers and probes were used at a 
concentration of 100nM. Primer/probe sequences are represented in a 5’ – 3’ 
direction. Primers were designed to produce an amplicon of approximately 250bp, the 
site of amplification was within the transcript, but not specifically designed to be at 












Figure T2: Primers and probe sets used in RT-qPCR assay of WTS selected transcripts [fresh and FFPE oropharyngeal samples]. Primers and 
probes were used at a concentration of 100nM. Primer/probe sequences are represented in a 5’ - 3’ direction. Primer selection anywhere within 




Gene ID Illumina ID1 NCBI Forward Reverse Probe Exon 
Spanning 




GC GACCACGCTGGTGACGGTGG Yes 




AA GCTCACCCGAGGGGAGCTGA Yes 




TGG ACTGGAGCCCAGAGCCTGCT Yes 




G GCCCAATGCCACCGAAGCCT Yes 




GC TGCTGGAGTCAAGCCTGCGC Yes 




CG GGAGCTCCGCGATGTCCTCT Yes 




AGG TCGCAAGCTGGCTGGCTCAC Yes 









TGGC GATCCGCCGCCCGTCCAC Yes 




TC CGTCGTGGAGTCCACTGGCG Yes 
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The gene quantification method used in this study utilises real-time PCR by 
comparing the number of cycles required for the fluorescence of a sample to reach a 
pre-determined level (Pfaffl, 2001). The pre-determined level is known as the cycle 
threshold (Ct). In this project, the fluorescence threshold was established at a level 
between the exponential phase and above non-specific background (0.005 relative 
fluorescence units). Ct values were used to determine relative gene expression as 
described below: - 
 
 
Equation 2: Eref is the real-time PCR efficiency of a reference gene transcript; 
Etarget is the real-time PCR efficiency of target gene transcript; ΔCPref = is the 
crossing point (CP) deviation of control – sample of reference gene transcript; 
ΔCPtarget is the CP deviation of control – sample of the target gene transcript 
(Figure 23). 
 
ratio =    (Etarget) ΔCPtarget (control – sample) 
                        




Equation 3: The Pfaffl method of gene quantification requires the calculation of 
reaction efficiencies. For each gene, a PCR reaction from a normal sample was 
performed, having made 2-fold serial dilutions covering the range equivalent to 1 – 
150ng of cDNA. The Applied Biosystems ViiA 7 Fast Real-time PCR system 
automatically produced a standard curve, and calculated the reaction efficiency using 
the equation. Where M is the slope of the standard curve which itself is the change in 
Ct divided the change in log input: -  
 




Figure 24: Serial dilution real-time PCR curves 
 
These curves are an example of the data produced by RT-qPCR. In this example, the 
reference curves (green) represent the fluorescence for the reference gene (β-actin) 
and the target curves (blue) represent the gene of interest (CDKN2A). From the 
curves it is evident that the average CP for the reference gene (green) are lower than 





















Figure 25: Calculation of standard curves 
 
qPCR data curves for a target gene following repeated serial dilutions allows an 
automated standard curve calculation. In this example, R2 = 0.998, M = -3.3399, Y-













Standard PCR reactions (total volume 20μl) were performed using 10μl MESA BLUE 
MasterMix Plus for SYBR® Assay (a combination of Hotstart Meteor Taq together 
with an inert Blue dye), 0.2μl primer mix (concentration 100nM), 7.8μl dH2O, cDNA 
2μl (concentration 70-80ng/μl). The Applied Biosystems ViiA 7 Fast Real-time 
PCR cycle was performed as follows: - 
 
• Hold stage = 50°C for 2 min followed by 95°C for 10 min;  
• PCR stage = 95°C x 15s; 60°C x 1 min (x40 cycles);  
• Melt curve stage 95°C x 15s then 60°C for 1 min then 95°C for 15 sec 
(continuous cycle until end of run) 
• Length of run = 1 hour 50 minutes 
• Optical emission filters (both PCR & melt curve) = 520nm +/-15; 558nm +/-






















2.6  Enzyme-Linked ImmunoSpot (ELISPOT)  
 
 
Table 10: Solutions and reagents 
 










PI solution 50 μg/ml propidium 
iodide, 100 μg/ml RNase 
A 
n/a 
Foetal calf serum Bioclear Batch 122- 
38507 
Penicillin (100 U/ml), 
streptomycin (0.1 mg/ml), 
100x, liquid, sterile-
filtered, cell culture tested 
Sigma-Aldrich P0781 
Freezing medium 90% FCS, 10% DMSO  
Phosphate buffered saline 
(PBS) 
NaCl (8 g/L), KCl (0.2 
g/L), Na2HPO4 (1.15 g/L), 
K2H2PO4 (0.2 g/L), 
autoclaved to sterilise 
 















The ELISPOT assay is widely used in human cells and is a mainstay in the diagnosis 
of tuberculosis and the monitoring of rejection in organ transplantation. In a 
population of peripheral blood mononuclear cells (PBMCs), the ELISPOT technique 
can detect infrequent antigen-specific T cell (and B cell) cytokine activity with great 
accuracy and sensitivity, making it ideal for monitoring cell-mediated immunity. 
 
Furthermore, the IFN-γ (Interferon-gamma) ELISPOT assay can identify and quantify 
cytokine-producing cells. An individual spot in the assay denotes a single reactive 
cell. This allows the derivation of quantitative (i.e. frequency of responding cells 
within the target population) and qualitative (i.e. the specific cytokine or other 
secreted immune molecule) from the ELISPOT assay. 
 
Requirements for the assay include a 96-well PVDF-membrane microtiter plate within 
which surfaces are coated with capture antibody binding to the epitope of the 
specified cytokine.  Following seeding during the cell stimulation and incubation 
phase, a single layer of PBMCs develops along with the target antigen on the surface 
of the membrane. This antibody-antigen complex will stimulate the T-cell (or B-cell) 
to release a cytokine(s) which remains on the surface membrane, directly surrounding 
the secreting cell prior to degradation by proteases, drifting into culture media, or 
attaching to bystander cells. The retained cytokine can be visualised as an 
ImmunoSpot i.e. a specific footprint of the activated cell (Figure 26 & 27) following 
further steps. 
 
The advantage of the ELISPOT method over Conventional ELISA assays is its ability 
to enumerate rare antigen-specific cells by capturing the secreting cytokine which 
makes it more sensitive and accurate. ELISPOT has theoretical detection limit of 1 in 
1,000,000 cells because of the ability to isolate a single antigen positive cell within a 
population of one million cells. This is an advantage when at a minimum, 100,000 to 
500,000 PBMCs is typically used per well for an assay and can go up to one million 






2.6.1 Blood sample collection for ELISPOT assay 
 
A blood sample (40ml) was drawn at baseline after diagnosis and 3 months post 
treatment. To examine the specificity of the IFN-γ ELISPOT, healthy patients were 
recruited to the study, each of whom underwent tonsillectomy for a benign condition. 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation using Ficoll-Paque (GE Healthcare, Sweden) and washed with 
phosphate buffered saline (PBS). The extracted PBMCs were then mixed with fetal 
calf serum (FCS) supplemented with 10% dimethyl sulfoxide (DMSO; Sigma) before 
storage in liquid nitrogen.  
 
Pre- and post-therapy samples for each patient were tested in the same experiment. 
After thawing and washing in cold sterile P10 (PBS + 10% FCS), PBMCs underwent 
positive depletion of CD56+, CD8+ and CD25+ cells using magnetic microbeads 
(Miltenyi Biotec, Surrey, UK) according to the manufacturer’s instructions. Purity of 
the mononuclear cell selection (CD4+/CD8+/CD56+) was verified by fluorescence 
activated cell sorter analysis (see below). 0.5-1.5 x 106 CD4+, CD8+ or CD56+ cells 
were each added to a 15ml conical tube and washed with culture medium (RPMI 1640 
supplemented with 10% FCS, 2 mM glutamine, 100 IU/mL penicillin, and 100 μg/mL 
















2.6.2 IFN-γ ELISPOT 
 
To measure IFN-γ release, flat-bottomed 96-well polyvinylidene difluoride (PVDF) 
membrane backed plates (Millipore, Bedford, UK) were first washed with sterile PBS 
before coating with 50μl of mouse IgG1 anti-human IFN-γ monoclonal antibody (1-
D1K, 15μg/ml in 0.1M NaHCO3 buffer; pH 9.5, Mabtech, Sweden) and incubation at 
4°C overnight.  
 
The next day, coated wells were washed x6 with PBS before blocking with 50μl of 
culture medium (CM) for 3 hours at 37°C. Aliquots of CD4+ / CD8+ / CD56+ cells in 
CM (100μl ~1 x105) were added to each well. Stimulatory mAbs to CD28 and CD49d 
(Pharmingen, Oxford, UK) both at 0.5 μg/ml, were then added for CD4+ T-cell assays 
(Waldrop et al., 1998). Only stimulatory mAbs to CD28 were added for CD8+ T-cell 
assays (Goon et al., 2002).  
 
To induce non-specific cytokine production (required for CD4+ or CD8+ cells), 2μl of 
phorbol myristate acetate (5ug/mL; Sigma-Aldrich, UK) and 10μl of ionomycin 
(100μM concentration; Sigma-Aldrich, UK) were added to each positive control well. 
Peptide libraries spanning the entire length of HPV16 E2, E6 and E7 proteins 
(Mimotopes, Victoria, Australia) were grouped in pools, and added to the CD4+ / 
CD8+ cell culture medium to achieve a final concentration of 1 μM for each peptide, 
prior to incubation for 18 hours at 37°C in 5% CO2. 
 
The cells were then discarded and the plate washed x6 with PBS/0.05% Tween-20. 
Each well was then coated with 50μl (4μg/ml) of biotinylated anti-human IFN- 
antibody (7-B6-1-biotin, Mabtech, Sweden) and the plates incubated for 2 hours at 
37°C. A further x6 wash with PBS/0.05% Tween-20 preceded the addition of a 
streptavidin–alkaline phosphatase conjugate for 1 hour (prepared according to the 
manufacturer’s instructions and added at a volume of 100 μl/well; Biorad, UK). The 
reaction was terminated by washing with tap water and allowed to air-dry. The 
number of spots in each well were subsequently counted with digital image software 




Figure 26: Schematic diagram outlining the methodology behind an IFN-γ ELISpot 



































2.6.3 Fluorescent activated cell sorting (FACS) analysis 
 
Sub-populations of live or fixed cells can be separated according to fluorescent 
labeling with this technique. Cells stained with fluorophore-conjugated antibodies can 
be separated from one another depending on which fluorophore they have been 
assigned (or alternatively size, shape or granularity of the cell) using forward and side 
scatter lasers. The fluorophores used in this study included phycoerythrin (PE), 
Fluorescein isothiocyanate (FITC) and Allophycocyanin (APC). A cell expressing one 
cell marker is separated using an PE-conjugated antibody that recognizes the marker, 
and another cell type expressing a different marker is separated using a FITC-
conjugated antibody specific for that marker.  
 
Cell for analysis were harvested and pelleted as previously described (see above). The 
pellet was re-suspended in 1 ml of PBS. A 15 ml Falcon tube was prepared containing 
2.5 ml of 100% ethanol. The tube was gently vortexed and the cell suspension added 
dropwise. The cells were re-centrifuged before being re-suspended in 500μl PI 
solution (to highlight dead cells; further elucidated later by tryphan blue dye). The 
tube was then incubated on ice for 15 minutes before being transferred to allow the 
cells to be fixed at -20ºC overnight or until they were ready to be analysed. The fixed 
cells were pelleted for 5 minutes at 1000 rpm, the supernatant removed and the pellet 
washed with 5 ml PBS. Following a 40-minute incubation at 37ºC, 3 ml of PBS was 
added and the cells centrifuged as above. The supernatant was removed and the cells 
re-suspended in 500μl PBS, 5% BSA before being passed through a 70μm cell 
strainer into a 5ml polystyrene round-bottom test tube. The cells were then analysed 












Investigating HPV and 

















OPSCC carcinogenesis may involve progressive transformation from normal 
epithelium to pre-malignant tissue (dysplasia / carcinoma in situ) to invasive cancer 
(Miller and Johnstone, 2001, Jayaprakash et al., 2011, Leemans et al., 2011, van 
Zeeburg et al., 2012, Mooren et al., 2014). While the presence of HPV subtypes 
within invasive oropharyngeal SCC has been evaluated in large epidemiological 
studies (Mehanna et al., 2012, Nasman et al., 2015) there is limited data on this 
subject in regions of confirmed dysplasia / carcinoma in situ (Mooren et al., 2014).  
 
In a meta-analysis of 269 articles, Mehanna et al. (2012) demonstrated that the 
proportion of HPV+ oropharyngeal carcinoma in North America and Europe has 
increased over the past ~20 years to ~70%. Nasman et al. (2015) found evidence for 
high risk HPV types in 186/252 OPSCC cases (74%), they also demonstrated a rise in 
prevalence by comparing samples registered from 2000-2006 to those registered from 
2007-2012. 
 
Prior studies in areas of confirmed dysplasia / carcinoma in situ have reported 
markedly variable HPV prevalence rates due to limitations of size and variable assay 
techniques (Miller and Johnstone, 2001, Chaudhary et al., 2009). Jayaprakash et al. 
(2011) published a meta-analysis of 22 relevant articles, suggesting HPV16 to be 
present in ~25% of all dysplastic lesions within the oropharyngeal subsite – the same 
author concluded this to be a conservative estimate due to the inclusion of oral cavity 
SCC lesions in some of the studies (traditionally a subsite with low HPV16 
prevalence). 
 
The majority (~75%) of patients with HPV-positive OPSCC present at an advanced 
stage (III/IV) with cystic nodal disease (Licitra et al., 2006, Ang et al., 2010). In view 
of this, investigation of pre-malignant molecular pathways represents an important 
research priority, with the ultimate aim to produce a non-invasive screening tool 
(Psyrri et al., 2012) or better evaluation of the risk of pre-invasive disease. 
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High risk human papillomaviruses (HPV16, 18, 31, 33, 34, 35, 39, 45, 51, 56, 58 and 
59) are associated with nearly all cases of uterine cervix carcinoma and ~20% to 30% 
of HNSCC. As HNSCC also arise in HPV-negative patients (associated with tobacco 
and alcohol exposure), this type of cancer provides unique opportunities to define 
similarities and differences based on a viral aetiology. Although HPV16 is thought to 
be responsible for >95% of viral associated OPSCC, further work is required to 
investigate the effect of different HPV types on disease outcomes (Chaturvedi et al., 
2013). 
 
At present, there is a relative paucity of data regarding factors that influence 
progression of disease from normal epithelium to in situ carcinoma to invasive 
malignancy.  In normal individuals, mucosal HPV carriage in the head and neck 
varies between 2% - 8% (Duray et al., 2011, Gillison et al., 2012). HPV16 prevalence 
in the oral cavity is ~1% in the US population (Gillison et al., 2012). Age (peak 
prevalence 30-34 and 60-64 years), sex (males >females), smoking, and multiple 
sexual partners were independently associated with oral HPV infection in 
multivariable models. The duration / persistence of oral HPV16 is most likely 
influenced by local and systemic immune status of an individual (discussed further in 
chapter 4). Initial studies suggest that most oral HPV infections are likely to be 
cleared within a year (Chung et al., 2014). In OPSCC, Thavaraj et al. (2014) indicate 
that virus-induced field cancerisation and/or multifocal oncogenic HPV infection is 
uncommon outside of the palatine or lingual tonsil region. 
 
Our methodology reflects previous studies on patients with HPV-associated uterine 
cervix / anogenital carcinoma. Microarray analysis on fresh frozen tissue samples 
representing invasive malignancy and normal epithelium may determine novel 
transcripts - the most clincially relevant of which are then validated using a quantitive 
analysis e.g. RT-qPCR.  
 
The Illumina platform for whole transcriptome analsyis was chosen primarily due to 
an existing association with the University of Cambridge (Department of Pathology). 
Each DNA microarray contains ~50,000 oligonucleotide probes and compares 
favourably with other market competitors in terms of cost and fidelity of data. 
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The results described in the chapter have been published in Masterson et al. (2015), 
and some passages have been quoted verbatim from this publication. 
 
 
3.1.1 Aims of the investigation 
 
This study was designed to identify significant differences in gene expression profiles 
of HPV-positive (HPV+) and HPV-negative (HPV-) OPSCC and to better understand 
the functional effects of HPV infection in the pre-malignant pathway.  
 
Twenty-four consecutive patients with locally advanced primary OPSCC were 
included in a prospective clinical trial. Fresh tissue samples (tumour versus matched 
normal epithelium) were subjected to whole transcriptome analysis and the results 
validated on the same cohort with reverse transcription–quantitative real-time PCR 
(RT-qPCR). In a separate retrospective cohort of twenty-seven OPSCC patients, laser 
capture microdissection of FFPE tissue allowed RNA extraction from adjacent 















3.2 Materials and Methods 
 
3.2.1 Study population 
 
After informed consent, twenty-four consecutive patients with OPSCC donated 
multiple fresh biopsy samples (from regions of macroscopically normal and invasive 
tumour material) at Cambridge University Hospitals NHS Foundation Trust between 
June 2011 and July 2013 (Table 11). A further twenty-seven OPSCC patients were 
included from a retrospective cohort and assessed for evidence of carcinoma in situ / 
dysplastic change surrounding invasive carcinoma (Table 12). Disease stage was 
classified using the AJCC / UICC TNM classification of malignant tumours (Edge et 
al., 2010). Data from this study were deposited in the NIH Gene Expression Omnibus 
database under accession code GSE56142.  
 
In all prospective fresh biopsy samples, tumour and the adjacent normal tissue were 
processed to allow DNA and RNA extraction (2.1.2 & 2.1.3). A consultant 
histopathologist with expertise in head and neck pathology reviewed each specimen to 
ensure representative sampling (minimum of 75% cancer cells for malignant tissue).  
 
The retrospective FFPE tissue cohort was subjected to laser capture microdissection. 
This allowed precise RNA extraction from areas of invasive cancer, carcinoma in situ 




3.2.2 HPV stratification 
 
HPV stratification methods included consensus PGMY PCR (Gravitt et al., 2000); 
type-specific HPV16 DNA PCR and E6/E7 mRNA PCR; DNA sequencing; p16INK4A 
IHC; and HPV DNA in situ hybridisation.  
 
Prospective cohort: Oropharyngeal fresh tissue samples from normal and invasive 
malignant regions (max. 25 mg) were DNA extracted using a protocol published from 
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this unit (section 2.1.2) (Winder et al., 2009). As previously described (section 2.2.2 
& 2.2.3), L1 DNA PCR analysis of tumor DNA (50-100 ng) involved the 
PGMY09/11 primer set with all negative samples subjected to further amplification 
using GP5+/GP6+ primers (de Roda Husman et al., 1995, Gravitt et al., 2000). DNA 
bands identified after agarose gel electrophoresis were excised, purified using 
QiaQuick Gel Extraction columns (QIAGEN Ltd, UK) and sequenced directly 
(section 2.2.4; Source Bioscience, Cambridge, UK). E6/E7 DNA and cDNA PCR 
analysis involved primers specific for HPV16 E6/E7 (Sotlar et al., 2004). For all fresh 
tissue biopsies, parallel FFPE samples enabled p16INK4a immunohistochemistry (see 
below).  
 
Retrospective cohort: p16INK4a immunohistochemistry was performed on FFPE 
tissue using a mouse monoclonal antibody (BD Biosciences, USA) (Masterson et al., 
2013). DNA in situ hybridisation consisted of a probe directed against high risk HPV 
subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66 (Ventana INFORM HPVIII, 
Tucson, Arizona) (Grogan et al., 2006). DNA extraction from FFPE tissue is 





3.2.3 RNA Sequencing 
 
The 24 OPSCC patient samples provided multiple fresh biopsy samples at the time of 
diagnostic or therapeutic surgery. Template RNA samples (up to 1μg in 1μL) were 
extracted as previously described (section 2.1.3). Whole transcriptome analysis 
utilized the Illumina GAIIx machine (HumanHT-12 v4 BeadChip) and the results 
were validated with RT-qPCR (Applied Biosystems ViiA 7) (section 2.5.2). All 






3.2.4 Real-Time qPCR 
 




3.2.5 Statistical analysis 
 
Statistical calculations were performed using SPSS Version 21 (Chicago, IL, USA). 
To identify 80% of clinically relevant genes from the Illumina analysis, we based our 
power calculation on data supplied from Laborde et al (Laborde et al., 2012). A 
minimal sample size of 10 subjects in each group were required if FDR (False 
Discovery Rate) was set at 0.5% and the desired mean log2 fold change >1 (x10 
change from baseline) (Li et al., 2013). A Pearson’s regression coefficient was 
utilized to investigate any correlation between the Illumina and RT-qPCR analysis 
(Sabo et al., 2008). RT-qPCR data were analyzed by the 2-ΔΔCT technique as described 
previously (Slebos et al., 2006). In summary, the average Ct was derived for the three 
replicate analyses of the reference gene (β-actin), and this was subtracted from the 
average Ct value from the three replicate analyses for the genes of interest. Expression 
differences between the HPV+ and HPV- tumors were compared using these 
normalised ΔCt values and the observed differences subjected to a Student’s t test. 
Rates of disease free survival were estimated by means of the Kaplan–Meier method 
and were compared by the log-rank test. A multivariate model was developed using 
Cox regression to investigate the effect of clinical factors on disease outcome 
(HPV16, SYCP2, p16INK4a, SFRP1, T stage, N stage, sex, physiological performance 
status, oropharyngeal subsite, histology grade, smoking, concurrent chemotherapy and 
age). The main outcome for this study was DFS (disease free survival) which equates 
to time from completion of treatment until first malignant disease recurrence or death. 
Overall mortality was also investigated. The whole transcriptome analysis informed 
which biomarkers may be of relevance. Other secondary outcomes are highlighted in  







3.3.1 HPV stratification 
  
In total, 18/24 of the fresh biopsy samples (prospective cohort) and 23/27 of the FFPE 
samples (retrospective cohort) were classified as HPV positive - defined by evidence 
of HPV16 L1/E6/E7 DNA, HPV16 E6/E7 mRNA or HPV DNA ISH episomal / 
integrative staining pattern. Immunohistochemical analysis for expression of p16INK4a 
was demonstrated for all HPV positive OPSCC samples but also present for 3 out of 
10 OPSCC samples categorised as HPV negative (Table 11 / Table 12).  
 
 
3.3.2 DNA & RNA extraction 
 
DNA and RNA extraction from fresh frozen and FFPE specimens is described in 
section 2.1.2 & 2.1.3. RNA extraction from fresh tissue required x3 biopsy specimens 
from areas of malignant change versus adjacent normal mucosa. One previous study 
suggests that stability of HPV16 E6/E7 mRNA improves when the virus is integrated 
as opposed to episomal (Jeon and Lambert, 1995).  The RNA Integrity Number 
(R.I.N) varied from 1.5 – 8.5 (see section 2.5.1). Of 144 samples collected, 97 
displayed an R.I.N of >6 and were deemed suitable for downstream applications 
(Illumina array / RT-qPCR). RNA extracted from FFPE tissue was of poorer quality 
in comparison to fresh samples. R.I.N values ranged from 0.4 – 5.2 (R.I.N cut-off 
value 2) and <40% were deemed suitable for downstream applications (RT-qPCR). 
 
 
3.3.3 Gene expression differences with HPV status in OPSCC 
 
Among the 47,323 oligonucleotide probes on the DNA microarray, 223 differentially 
expressed genes were statistically significant in classifying normal versus invasive 
tissue with further stratification by HPV status  (p<0.01; FDR of 0.5%; Figure 28A+B 
(p134-35) and Appendix 1). As expected, one of the most significantly expressed 
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genes in HPV+ tumour tissue was cyclin dependent kinase inhibitor 2A (CDKN2A; 
Log2 fold change 1.7 +/- 0.3 SE), which encodes for p16INK4A. This cellular protein 
may be up-regulated as a result of oncogenic HPV E7 inhibiting activity of 
retinoblastoma (pRb) (Syrjanen, 2004). Other genes noted to have significant 
differential expression in the HPV+ group and potential relevance in malignant 





A subset of differentially expressed genes from the Illumina platform analysis was 
confirmed by RT-qPCR (selected based on clinical relevance in malignant disease). 
The six target transcripts were: CDKN2A, SYCP2, SFRP1, DLG2, CRNN and CRCT1. 
A high level of agreement existed between the Illumina and RT-qPCR analysis 
(Pearson correlation coefficient r = 0.905; p-value = 0.013; Kolmogorov-Smirnov test 
of normality p>0.10; Figure 28C). 
 
In the prospective fresh tissue cohort (Appendix 2), in HPV+ OPSCC, RNA 
expression levels of CDKN2A and SYCP2 were increased with an average log2 fold 
change of 1.7 (p<0.01; 95% CI 1.0-3.2), and 1.8 (p<0.01; 95% CI 1.35-3.35), 
respectively. Significantly decreased expression was found for CRCT1 (log2 = -3.0; 
p<0.001; 95% CI 2.2-4.4), SFRP1 (log2 = -2.3; p<0.01; 95% CI 1.7-2.8), CRNN (log2 
= -2.2; p<0.01; 95% CI 1.7-2.9) and DLG2 (log2 = -1.5; p<0.01; 95% CI 1.4-2.2) 
when compared to normal tissue.  
 
Laser Capture Microdissection (LCM) from the retrospective FFPE cohort allowed 
analysis of log2 fold change in adjacent regions of normal epithelium, invasive 
malignancy and carcinoma in situ (Figure 30A; Appendix 3 & 4). The results largely 
reflect the analysis from fresh frozen samples for the HPV+ cohort; SYCP2 (log2 fold 
change = 3.1; p<0.01; 95% CI, 1.8-4.4) and SFRP1 (log2 fold change = -0.97; 95% 
CI, -0.57-1.61) demonstrated the largest differential expression from normal 
epithelium to pre-malignant (carcinoma in situ) tissue. In the same cohort, 70% of 
patients displayed significantly elevated expression of CDKN2A in the pre-malignant 
region (log2 fold change >1.5). Figure 30B shows comparative data for both fresh 
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and FFPE tissue designated within the HPV+ category.  
 
3.3.5 Clinical outcomes 
 
The average DFS for all patients was 43.7 months (+/-SE 2.5). For the HPV16+ 
cohort the DFS period increased to 47.3 months (+/-SE 2.3). Significant expression of 
SYCP2 (log2 fold change >1.5) and SFRP1 (log2 fold change <1.5) cohorts 
demonstrated an average DFS period of 49.6 months (+/-SE 2.2) and 40.1 months (+/-
SE 3.8) respectively. A multivariate proportional hazards model using Cox regression 
analysis revealed HPV16, SYCP2, smoking and physiological performance status to 
have significant influence on DFS (Figure 31 & Appendix 5).  
 
To evaluate prognostic accuracy of SYCP2 expression in regions of HPV+ in situ 
carcinoma, we constructed a Receiver Operating Characteristic (ROC) curve 
(Appendix 6). Area Under Curve (AUC) ROC was found to be 0.86 (SE +/- 0.08; 
95% confidence interval 0.71–0.99), indicating a good discriminating power when 
compared to control subjects. Sensitivity and specificity estimates over a range of cut-
off points suggest optimal results were obtained for the log2 fold range 1.5-3.0 
(Sensitivity 70%; Specificity 95%). Similar testing of SFRP1 expression revealed the 
AUC ROC to be 0.64 (SE+/-0.11; 95% confidence interval 0.42–0.86), indicating a 
















In this prospective observational study, we describe the use of mRNA massive 
parallel sequencing technology to investigate HPV+/- OPSCC tumors versus matched 
normal tissue. The data obtained were then validated by RT-qPCR and the results 
utilized on retrospective FFPE tissue to investigate pre-malignant change surrounding 
areas of invasive carcinoma.  
 
In all patients, the majority displayed evidence of high risk HPV16 positivity 
(prospective cohort 75%; retrospective cohort 85%). Predictable fold changes of RNA 
expression in HPV-associated disease included multiple transcripts within the p53 
oncogenic pathway (e.g. CDKN2A / CCND1). Other candidate transcripts found to 
have altered levels of expression in this study have not previously been established 
(SFRP1, CRCT1, DLG2, SYCP2 and CRNN).  
 
SYCP2 showed the most consistent fold change from baseline in pre-malignant tissue 
and aberrant expression of this protein may contribute to genetic instability during 
HPV-associated cancer development. If further corroborated, this data may contribute 
to the development of a non-invasive screening tool.  
 
To date, comparatively few studies have investigated expression profiles in HPV-
associated OPSCC (Slebos et al., 2006, Martinez et al., 2007, Pyeon et al., 2007, 
Walter et al., 2013) and even fewer have focused on pre-cancer pathways (Mooren et 
al., 2014).  
 
Slebos et al. (2006) looked at gene expression profiles of HPV+ and HPV in 36 fresh 
frozen HNSCC tumour samples (mainly oral cavity). Microarray statistical analysis 
based on positive HPV16 status (22% of patients) resulted in a list of 91genes that 
were differentially expressed. Highly expressed genes in HPV16+ samples included 
those involved with transcription (RFC4, TAF7L, RPA2, and TFDP2), cell cycle 
regulators (CDC7, p18 and p16INK4A) and meiosis / nuclear structure (SYCP2). 
 
Martinez et al. (2007) compared the cellular gene expression profiles of 11 HPV-
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positive and HPV-negative oropharyngeal carcinomas with those of the normal oral 
epithelium (all fresh frozen tissue). Using Affymetrix Human U133A GeneChip, they 
showed that 397 genes were differentially expressed in HPV-positive HNSCC 
compared to normal oral epithelium. The up-regulated genes included those involved 
in cell cycle regulation (CDKN2A), DNA repair (RAD51AP1) and cell differentiation 
(SFRP4), while down-regulated genes include those involved in proteolysis (PRSS3). 
59 differentially expressed genes in HPV-positive HNSCC as compared to both HPV-
negative HNSCC and normal oral tissues. Up-regulated genes included those involved 
in meiosis and nuclear structure (SYCP2), transcription regulation (ZNF238) and 
DNA repair (RFC5). Genes involved in signal transduction (CRABP2) and 
proteolysis (KLK8) were found to be down-regulated in HPV-positive HNSCC. 
GeneChip experiments were validated by quantitative real-time RT-PCR analysis for 
representative genes.  
 
Pyeon et al. (2007) looked at whole genome expression profiles for 42 fresh frozen 
HNSCC (60% oral cavity, 40% oropharynx), uterine cervix cancers, and site-matched 
normal epithelial samples. The analysis revealed that HPV positive HNSCC and 
cervical cancers had different patterns of gene expression yet shared many changes 
when compared to HPV-negative HNSCC. Some of these were predicted, but many 
others were not. Notably, HPV-positive cancers over-expressed testis-specific genes 
that are normally expressed only in meiotic cells (SYCP2 and TCAM1). HPV-
positive cancers also demonstrated up-regulation of a larger subset of DNA 
replication and cell cycle genes than that observed in HPV-negative HNSCC e.g. 
PC4/SFRS1-interacting protein 1 (PSIP1), V-myb (MYB), synaptogyrin 3 
(SYNGR3), SWI/SNF-related, matrix-associated, actin-dependent regulator of 
chromatin (SMARCA2) and p16 (CDKN2A). Expression was decreased for genes 
involved in in epidermal development and hormone activity e.g. cortactin (CTTN), 
kallikreins (KLK8, KLK10), cyclin D1 (CCND1) and caveolin 1 (CAV1).  
 
Walter et al. (2013) used an integrated genomic analysis and validation methodology 
for 138 HNSCC fresh frozen samples (mainly oral cavity / oropharynx) and identified 
differential utilization of the lineage markers TP63 and SOX2, deregulation of the 
NFE2L2 / KEAP1 oxidative stress pathway, and preference for the oncogenes 
PIK3CA and EGFR. These molecular signatures could have clinical utility by 
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complementing classification by HPV infection status as well as the high-risk marker 
CCND1.  
 
Mooren et al. (2014) performed p16INK4A immunohistochemistry on FFPE sections 
for 162 oropharyngeal squamous cell carcinomas (OPSCC), 14 tonsil and 23 
laryngeal dysplasias, and 20 tonsil and 27 laryngeal papillomas. Enzyme-
immunoassay, FISH and PCR analysis were used to ascertain HPV-presence and type. 
Of the 14 tonsillar dysplasias and 162 OPSCC, 10 (71%) and 51 (31%) were 
HPV16+, respectively. p16INK4A immunohistochemistry showed strong nuclear and 
cytoplasmic staining in 50 out of 51 HPV16+ and 5 out of 111 HPV-negative OPSCC 
(p < 0.0001) and in all HPV16-positive tonsillar dysplasias. In contrast to this, highly 
variable p16INK4A staining patterns were detected in the papillomas and laryngeal 
dysplasias, irrespective of HPV-status.  
 
Further characterization of a pre-malignant state in the development of HPV-
associated OPSCC would be of clinical value as it infers the potential for a screening 
test (similar to the uterine cervix carcinoma model). In addition, it may also be of use 
as a prognostic factor if a biopsy of an abnormal area showed benign hyperplasia or in 
situ / dysplastic change. In HNSCC surgical excisions, dysplastic epithelium is often 
found adjacent to the cancer (van Zeeburg et al., 2012), but the exact nature of the 
disease in these regions is poorly defined (Miller and Johnstone, 2001, Jayaprakash et 
al., 2011). 
 
Within our retrospective Laser Capture Microdissection (LCM) cohort, 70% of 
patients displayed significantly increased expression of CDKN2A (a proxy marker for 
HPV infection) in regions of carcinoma in situ relative to normal epithelium. This is 
higher than the HPV16 estimate (~25% of 458 oral cavity and oropharyngeal 
dysplasia samples) provided by Jayaprakash et al (Jayaprakash et al., 2011) and may 
be consistent with the hypothesis that HPV plays a significant role in the early phase 
of oropharyngeal carcinogenesis. Of course, high risk HPV infection can be a 
transient phenomenon and detection alone may not be sufficient to provide a causal 
association. Many studies have previously demonstrated the presence of HPV types 
even in normal oral cavity tissue (Kreimer et al., 2010, Kreimer et al., 2013, Beachler 
et al., 2015). Gillison et al. (2012) performed the largest epidemiological study on this 
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topic (~6000 subjects), and estimated the prevalence for high-risk HPV types to be 
6.9%, of which ~1% can be attributed to HPV16. 
 
It should still be noted that high-risk HPV types (e.g. 16 and 18) in normal oral cavity 
samples have significantly lower prevalence than the estimates reported by 
Jayaprakash et al. (2011). The available literature also suggests a higher prevalence of 
HPV16 within areas of in situ malignant change when stratified by the male sex 
(twice that of females) and between areas of transformation from normal through to 
dysplastic epithelium (three times higher prevalence in dysplastic tissue) (Jayaprakash 
et al., 2011).  
 
In our prospective cohort of 24 OPSCC patients, RNA massive parallel sequencing 
data provided a statistically significant association for 223 target transcripts stratified 
by tumor and HPV status. Gene ontology data revealed most transcripts to have 
limited clinical relevance but a focused analysis of oncological pathways produced 
several possible transcript candidates e.g. SYCP2, SFRP1, DLG2, CRNN and CRCT1. 
Of these, SYCP2 demonstrated the most significant change from baseline in pre-
malignant retrospective FFPE tissue, surpassing the performance of CDKN2A 
(encoding for p16INK2A).  
 
The elevated expression of synaptonemal complex protein 2 (SYCP2) in HPV-
associated tumor tissue has previously been noted in three expression analysis studies 
(Slebos et al., 2006, Martinez et al., 2007, Pyeon et al., 2007) with elevated log2 fold 
change values of 2.7, 3.7 and 2.9 respectively. SYCP2 is a testis-specific human gene 
and aberrant expression in HPV+ cancers may contribute to the genomic instability 
induced by high-risk HPVs and subsequent oncogenic change (Pannone et al., 2011), 
alternatively, elevated expression may simply be a result of this instability and de-
differentiation of epithelial cells. A hypothetical model applied to HPV+ 
oropharyngeal carcinoma is provided in Figure 32 At present, the Wisconsin Alumni 
Group Foundation has included SYCP2 as one of three target biomarkers in 
development for HPV associated OPSCC (Lambert et al., 2015). To date, no other 
study has demonstrated elevated expression in pre-malignant tissue. The use of 
SYCP2 as a prognostic indicator is also of interest given our disease free survival 
data, however, further research will be required to discern if this is truly independent 
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of HPV16 expression. 
 
The p16INK4a protein is an inhibitor of cyclin dependent kinase and has increased 
expression with elevated levels of HPV E7, however, many units have reported a 
concern regarding false positive results (Schache et al., 2011). Within our HPV16 
negative cohort (10/51), three patients had elevated expression of p16INK4a, which may 
concur with this analysis. At present, stratification of OPSCC tumors by p16INK4a 
alone is still the preferred approach by most oncology centres as it is cheap, 
dependable and routinely performed in most analytical laboratories. In an era of 
OPSCC de-escalation treatments, which are based on a viral etiology, this may incur a 
risk of undertreating a small proportion of patients falsely considered as HPV-positive 
(Masterson et al., 2014). The use of stepwise algorithms, which combine different 
HPV assays may compensate for the limitations of individual tests and should now be 
considered in clinical settings (Robinson et al., 2012). 
 
In this study, positive smoking status proved to have significant adverse effect on 
disease free survival regardless of HPV category (multi-variable analysis p<0.03). 
The negative impact of smoking in HPV+ OPSCC has previously been highlighted by 
several randomized trials with post-hoc analysis of HPV status (Rischin and Young, 
2010, Gillison et al., 2012, Posner et al., 2011). All studies indicated that the degree 
of tobacco exposure at diagnosis and during treatment directly correlates with the risk 
of disease progression and death from malignancy. This may indicate that smoking 
confers additional tumor mutations in the HPV+ cohort, leading to more aggressive 
disease and inferior responses to available curative-intent therapies.  
 
However, important questions remain about how to quantify smoking risk to enable 
comparison between studies. All the major de-escalation trials have largely adopted 
the arbitrary cut-off point proposed by O’Sullivan et al. (O'Sullivan et al., 2012) in 
which ‘smokers’ are defined as having >10 pack year history. Perhaps more reliable 
information can be obtained from Laborde et al. (2012) who recently published 
transcription profile data in OPSCC patients stratified by both HPV and smoking 
status. This indicated that two genes involved in the p53 DNA damage-repair 
pathway, ATR and CHEK2, display patterns of increased expression associated with 
HPV-negative OPSCC smokers only. Our study did not confirm any significant 
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association with ATR or CHEK2. 
 
This study is limited by focusing exclusively on whole transcriptome analysis (a 
single approach), we recognize the need to integrate DNA sequence analysis in future 
projects (Leemans CR et al., 2011). DNA analysis will demonstrate changes that have 
occurred to the DNA sequence, whereas mRNA sequence analysis clarifies the effect 
of those changes. This critically important process therefore identifies which 
mutations and rearrangements could be the best diagnostic and prognostic indicators. 
Many current studies display the importance of DNA sequencing in establishing 
mutations associated with cancer development. The final choice of the six target 
transcripts in this study may also be open to debate as it is primarily based on gene 
ontology data supplied through the KEGG (Kanehisa et al., 2014) pathway network.  
 
In conclusion, developments in whole-genome sequencing and mRNA analysis are 
rapidly creating an opportunity to provide personalized information on genetic and 
functional aspects of malignant tumors. Regarding HPV+ OPSCC, the investigation 
of differentially expressed genes in normal, pre-malignant and malignant tissue may 
reveal unique pathways that can explain their different natural history and biological 
properties. The data from this study reveal SYCP2 as a potentially important 
biomarker; if corroborated on a larger scale this may contribute to the development of 
a non-invasive screening tool e.g. mouthwash or brush biopsy. Current 
epidemiological data would suggest it is not sufficient to simply screen for OPSCC by 
presence of HPV16 alone (due to a ~1% carriage rate in the general adult population). 
Clearly, further well-designed prospective studies are required to confirm this data 











Table 11 Clinical and histopathological data for the prospective cohort (n=24) 
 
HPV-positive status defined as evidence of HPV16 L1/E6/E7 DNA or HPV16 E6/E7 
mRNA +/- p16INK4A expression (>70% tumor cell staining); BoT, Base of Tongue; 
Well, well differentiated SCC; Mod, moderately differentiated SCC; Poor, poorly 
differentiated SCC; PS, performance status (Eastern Co-operative Oncology Group, 
ECOG); CRT, chemoradiotherapy; RT, radiotherapy; #, locoregional recurrence; †, 































Table 12: Clinical and histopathological data for the retrospective cohort (n=27) 
 
HPV-positive status defined as evidence of HPV16 L1/E6/E7 DNA or episomal / 
integrative pattern on HPV DNA ISH +/- p16 expression. Concordant regions of 
normal, in situ and invasive carcinoma were subjected to further analysis to discern 
mRNA expression of the six target biomarkers (CDKN2A, SYCP2, SFRP1, DLG2, 
CRNN and CRCT1). BoT, Base of Tongue; Well, well differentiated SCC; Mod, 
moderately differentiated SCC; Poor, poorly differentiated SCC; PS, performance 
status (Eastern Co-operative Oncology Group, ECOG); CRT, chemoradiotherapy; 
RT, radiotherapy; #, locoregional recurrence; †, non-malignant cause of death; ††, 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 28A Two-way analysis of variance identified target sequences with significant 
differential expression between normal and tumor tissue and further stratified by HPV 
status. The volcano plot x-axis is the log2 fold-change value (tumor versus normal 
epithelium) and the y-axis is –log10 odds value (HPV-positive versus negative 
cohort). The horizontal line represents a log odds value, p<0.01 (FDR of 0.5%), as the 
threshold cutoff. Samples highlighted in red have significantly increased expression 
within tumour tissue compared to normal controls. Samples highlighted in green have 






Figure 28B Hierarchical clustered heatmap of 223 genes displaying significant 
differential expression. As expected, CDKN2A, ranked highly on full transcriptome 
analysis. Five other genes that may have clinical relevance in HPV+ malignant 
disease are SYCP2, SFRP1, CRCT1, CRNN and DLG2.  
 
 
                            HPV positive              HPV negative 
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Figure 28C Validation graph for expression analysis (Illumina versus RT-qPCR; Pearson 
correlation coefficient r = 0.905; p-value = 0.013; Kolmogorov-Smirnov test of normality 
p>0.10) (Masterson et al., 2015). Standard Error Mean (SEM) bars calculated by Log2 fold 















Description (novel transcript in HPV+ OPSCC) 
CRNN  
(-3.6 +/- SE 
0.5) 
169 CRNN [cornulin) is a recently identified gene encoding a protein with an S100 EF-
hand calcium-binding motif, and its expression is known to be down-regulated in 
esophageal squamous cell carcinoma. CRNN overexpression in oral squamous 
carcinoma negatively regulates cell proliferation by the induction of G1 arrest.   
CRCT1 
(-3.5 +/- SE 
0.3) 
223 CRCT1 (cysteine-rich C-terminal 1) is a protein-coding gene, and has been validated 
by a similar gene expression profiling study for cervical carcinoma. Down 
regulation of CRCT1 [also known as NICE1] may predispose to oncogenic change. 
SFRP1 
(-1.2 +/- SE 
0.2) 
35 This gene encodes a member of the Secreted Frizzled Related Protein (SFRP) family 
that contains a cysteine-rich domain homologous to the putative Wnt-binding site 
of Frizzled proteins. Members of this family act as soluble modulators of Wnt 
signaling; epigenetic silencing of SFRP genes leads to deregulated activation of the 
Wnt-pathway, which is associated with cancer.  The role of SFRP1 as a tumour 
suppressor has been proposed in many cancers based on its loss in patient tumors.  
DLG2 
(-0.7 +/- SE 
0.1) 
218 This PDZ domain gene has not been investigated previously but DLG1 and DLG4 
have demonstrated a significant interaction with HPV16 E6 in cervical carcinoma. 
This gene encodes a member of the membrane-associated guanylate kinase 
(MAGUK) family. The encoded protein forms a heterodimer with a related family 
member that may interact at postsynaptic sites to form a multimeric scaffold for 
the clustering of receptors, ion channels, and associated signaling proteins.  
SYCP2 
(1.5 +/- SE 0.2) 
16 SYCP2 (synaptonemal complex protein 2) is a protein-coding gene.  SYCP2, an 
SYCP1 homologue, is a component of the meiotic synaptonemal complex like 
structure. Increased expression of these meisosis specific proteins in testicular 








Description (established transcript in HPV+ OPSCC) 
CDKN2A 
(1.7 +/- SE 0.3) 
32 Cyclin-dependent kinase inhibitor 2A (CDKN2A) is also known as P16INK4A. It is a 
tumor suppressor protein that is encoded by the CDKN2A gene. CDKN2A / P16INK4A 
plays an important role in regulating the cell cycle and is significantly over-
expressed in response to HPV E7. 
CCND1 
(-1.2 +/- SE 
0.1) 
136 The CCND1 gene encodes for the protein Cyclin D1. Cyclins function as regulators 
of CDKs (Cyclin-dependent kinases). This cyclin forms a complex with and functions 
as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle 
G1/S transition. Cyclin D1 has been shown to interact with Retinoblastoma (Rb), 
which is a tumor suppressor protein. Cyclin D1 expression should be down 
regulated in HPV-positive head and neck squamous cell carcinoma because of pRb 
suppression.  
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Figure 29A The initial analysis focused on the P53 oncogenic pathway in HPV positive 
disease, where we found predictable and significant fold changes for both p16 and Cyclin 


















Figure 29B Our search then expanded to explore other known cancer pathways which may 
or may not contribute to this condition. All the gene transcripts highlighted in red font are 
represented on the Illumina array and differentially expressed in our samples according to 
invasive versus normal tissue with further stratification by HPV status. P53 oncogenic 












Figure 30A H&E staining showing the junction between normal epithelium and severe 
dysplasia in HPV+ tonsil SCC (top left) (Masterson et al., 2015). MCM7 (top right) and 
Ki67 (bottom left) positive stains are present in >2/3rd of the abnormal epithelium but 
restricted to the basal layers in normal epithelium. In situ hybridisation reveals an elevated 
level of HPV 16 DNA (bottom right) in the dysplastic epithelium when compared to the 







































Figure 30B RT-qPCR analysis for all HPV+ sample types showing significant differential 
expression of SYCP2 (elevated log2 fold change = 3.1 [95% CI 1.8-4.4]; p<0.01) in pre-
malignant (in situ) compared to normal tissue (Masterson et al., 2015). Standard Error  
Mean (SEM) bars calculated by Log2 fold change difference between normal and invasive 





Figure 31 Disease free survival calculations from Kaplan-Meier survival analysis (SYCP2 
p<0.02 / HPV16 p<0.02). Cox regression to investigate the effect of clinical multiple 
parameters on disease free survival retained HPV16 and SYCP2 in the final model (see Figure 






Figure 32 Hypothetical model for SYCP2 (synaptonemal complex protein 2) regarding 
HPV+ OPSCC. SYCP2 is a protein that is involved in the linkage of chromosomes via the 
synaptonemal complex, binding DNA at the scaffold attachment regions and driving the 
prophase of meiosis. Alterations in the gene expression of SYCP2 have been associated with 
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Infection with human papillomavirus can be of variable duration and may or may not be 
associated with overt clinical symptoms. Cutaneous HPV lesions generally manifest as warts 
and will often resolve over a period of months to years. Anogenital infections may remain 
asymptomatic or hidden for some time e.g. CIN and AIN pre-malignant stages. 
 
DNA amplification-based tests demonstrate that anogenital infections are quite frequent and 
often self-limiting (Garland et al., 2016). Impaired cell mediated immunity may result in 
failure to clear or control infection, and in the case of the high risk (oncogenic) HPV, an 
increased likelihood of developing invasive carcinoma. Viral evasion of innate immunity, 
which in turn delays activation of the adaptive immunity, seems to be correlated to duration 
of HPV associated disease  (Stanley, 2012a). 
 
Animal models show that specific antibodies formed against the virus coat protein L1 are 
protective, which suggests that this may be an effective prophylactic vaccine strategy (Frazer, 
2009). Virus like particle (VLP) vaccines circumvent epithelial immune evasion strategies by 
undergoing intramuscular delivery to the body. VLPs are reported to generate significant 
levels of B cell memory, as indicated by persistence of the antibody and robust recall 
responses (Stanley, 2008).  
 
HPV16 and 18 are responsible for ~70% of uterine cervix cancers, although multiple other 
oncogenic types increase the HPV positivity rate to ~99% (Garland et al., 2016). High risk 
HPV infections are now also accepted as major aetiological agents in squamous cell 
carcinoma of the anus, vulva, vagina, penis and more recently the oropharynx. HPV is 
considered to be a causal agent in ~5% of human cancers with HPV16 by far the most 
common type (de Martel et al., 2012). 
 
The results described in the chapter have been published in Masterson et al. (2016a), and 
some passages have been quoted verbatim from this publication. 
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4.1.1 Immune response to HPV associated anogenital disease 
 
Regarding anogenital HPV disease, significant effort has been directed towards 
understanding the natural history of the host's immune response. Evidence gained from the 
study of immune compromised patients (e.g. HIV and renal transplant recipients) 
demonstrate the importance of cell-mediated immunity (CMI) in control of HPV infection; 
often documenting a higher prevalence of disease in this cohort. Such individuals show 
increased frequency of anogenital HPV infection and increased HPV persistence in the body 
(Palefsky, 2008). Infection with multiple oncogenic HPV types are also more common 
(Hernandez et al., 2014).  
 
Investigation of CMI responses to HPV has been hampered by multiple factors. First, HPV 
infection is specifically located to squamous epithelial sites, with little systemic 
manifestation. Second, gene transcription patterns of the HPV life cycle are intricately related 
to the stages of differentiation of keratinocytes. Only in recent years have successful models 






Epithelial cells, once viewed principally as a physical barrier, are now regarded as having 
much more complex immunological roles. Cervical keratinocytes secrete low levels of a 
variety of pro-inflammatory cytokines, chemokines and growth factors, and can be induced 
by various stimuli (Van den Bergh and Guerti, 2014). 
 
Innate immunity in the anogenital model is now understood to heavily involve tumour 
necrosis factor (TNF), transforming growth factor β (TGF-β), and the type I interferons (IFN-
α and IFN-β), which are produced by epithelial and other cell types (Stanley, 2012a, Songock 
et al., 2017). 
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Investigation of the role of Natural Killer (NK) cells in the aetiology of HPV associated 
anogenital disease suggests a protective function. HPV16+ infected keratinocytes in subjects 
with carcinomas have been correlated to decreased NK cell lysis (Brestovac et al., 2013, 
Malejczyk et al., 1993). NK cells can destroy virally infected tumour cells via killer 
immunoglobulin-like receptors (KIR) that recognise ameliorated MHC class I expression. 
Decreased sensitivity of PBMCs to immunostimulatory cytokines such as IL-2 and IFN-α (as 
seen in chronic infection or increased PD1 expression) may lead to a reduced immune 






Adaptive cell mediated immunity involves the recognition and effector phases of epithelial 
immune responses demonstrated in both cutaneous and mucosal HPV-infected tissues 
(Frazer, 2009). These include clonally expanded T cells that have returned to infected 
epithelial tissues via mechanisms involving adhesion molecules and chemokines; Langerhans 
cells, which capture antigens for transfer to regional lymph nodes and presentation to naive T 





Depleted immune surveillance may be due to reduction in Langerhans cells because of 
normal egress or other unidentified mechanisms. Prolonged infection and  oncogenic change 
has been linked to the depletion of Langerhans cells in HPV infected epithelial cells, along 
with other local immune deficiencies (Doorbar et al., 2015).  
  
Once Langerhans cells have captured antigen, the recognition phase continues with their 
transfer to locoregional lymph nodes. Cytokines which are principally derived from HPV 
infected keratinocytes are important mediators of this process. These include TNF and IL-1α 
(primarily from keratinocytes) and IL-1β (primarily from Langerhans cells). IL-10, which 
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acts as an inhibitor of Langerhans cell migration, is produced by keratinocytes. The initiation 
of Langerhans cell maturation into dendritic cells is promoted by granulocyte-macrophage 
colony-stimulating factor, also produced by keratinocytes (Moerman-Herzog et al., 2015). 
 
 Effector phase 
 
Proliferation and related studies of T-cell responsiveness to HPV  
 
T-cell proliferative responses and IL-2 release help to determine the role of helper T 
lymphocytes (CD4+) in providing protection against the development of HPV-associated 
lesions (Doorbar et al., 2015, Stanley, 2012a). 
 
Studies to date have analysed helper T-lymphocyte responses to HPV-16 antigens, as HPV-
16 is the commonest oncogenic HPV type (Bosch et al., 2006). Due to the roles of the E6 and 
E7 in cell transformation, immune responses to HPV16 E6 and E7 proteins and peptides have 
been widely studied (Stanley, 2012a). Subjects with normal cytology have been proven to 
display a more frequent response to these antigens in comparison to those who have 
developed pre-malignant or invasive uterine cervix SCC (Steele et al., 2005). 
 
A study by Woo et al. (2010) investigated T-cell response to the gene products of HPV-16 
E2, E6 or E7 using a longitudinal design. This demonstrated that subjects were more likely to 
have cleared their HPV infection and less likely to develop pre-malignant change if positive 
responses to either E2 or E6 peptides were demonstrated. de Jong and van Poelgeest (2004) 
also observed that baseline HPV16 specific CD4+ helper T-cell response is either absent or 









Studies of CTL-mediated killing 
 
Major histocompatibility complex (MHC) class I-restricted CTLs which are CD8+, are 
known to be responsible for the recognition and killing of virus-infected host cells and virus-
induced tumours (Frazer, 2009). 
 
Analysis of uterine cervix pre-malignant and malignant specimens has displayed the presence 
of activated CTL in lesions using immunohistochemical staining (Origoni et al., 2013). 
Sirianni et al. (2004) revealed that CD8+ T cells reactive to wild-type p53 (more usually 





HPV immune evasion strategies 
 
Observational studies demonstrate that HPV can effectively evade recognition by the immune 
system for many months (Pett et al., 2006). The HPV infectious cycle itself may be 
responsible for this as very low levels of viral protein are expressed - resulting in no or 
limited viraemia. Virus replication and assembly only occur in cells already destined for 
“programmed death”, with limited resultant inflammation and no excitatory signal to engage 
the immune system (Stanley, 2012a).  
 
High risk HPV E6 and E7 proteins actively suppress the activation of interferon response 
genes; interferon being a key antiviral defence mechanism (Kanodia et al., 2007). Further to 
this, the E7 proteins have been demonstrated to downregulate Toll Like Receptor 9 which 
effectively evades the innate immune response delaying the activation of adaptive immunity 






4.1.2 Immune response to HPV-associated oropharyngeal carcinoma 
 
In head and neck squamous cell cancer, immunodeficiency has been shown to correlate with 
a poor prognosis (Ferris, 2015).  However, few studies have addressed the specific role of 
cell mediated immunity in HPV-associated OPSCC (Wansom et al., 2010, Ramos et al., 
2013). Within this context, specific questions to be addressed include susceptibility / 
persistence of HPV infection and progression to malignancy. 
 
Spanos et al. (2009) showed that a functional immune response was critical to achieving 
adequate tumour clearance with chemoradiation in a murine model. Hoffmann et al. (2010) 
investigated CD8+ T cells reactive to HPV16 E7 in a small cohort of patients with OPSCC, 
this specific T-cell response (HPV16 E7) was commonly detected in subjects with a positive 
HPV16 status but the study lacked survival analysis as a clinical outcome measure. 
 
Most of the studies above focus on immune response at the point of diagnosis and prior to 
curative therapy. At present, it is unclear whether conventional treatment protocols for 
OPSCC (Mirghani et al., 2015) inhibit or promote tumour immune response mechanisms 
(Freiser et al., 2013). Distel and Buttner (2012) investigated intra-tumoral immune profiles 
before and after primary chemoradiation and concluded that post-therapy cytotoxic T 
lymphocytes (CTL) were depleted to a lesser extent than immunosuppressive T regulatory 
cells. This contrasts with the findings of Al-Taei et al. (2013) who found decreased systemic 
HPV specific T cell responses and accumulation of immunosuppressive influences in 
oropharyngeal cancer patients following radical therapy 
 
Similar to anogenital disease, natural regulatory T cells (Treg) are important 
immunosuppressive cells and have been correlated with a poor prognosis in HNSCC (Karimi 
et al., 2015). They have an important role in homeostasis and can be characterised by high 
co-expression of CD4+ and CD25+(Smigiel et al., 2014). Treg inhibit T cell activity by 
induction of ATP hydrolysis and apoptosis via the Fas / FasL pathway (Motz et al., 2014). 
An increasing body of evidence would suggest they are responsible for ameliorating tumour-
specific immune responses (Nishikawa et al., 2005), and as such are a potential barrier to 
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immunotherapy (Hoffmann et al., 2010, Lindau et al., 2013). Although some 




4.1.3 Aims of the investigation 
 
Immunological response to human papillomavirus in the development and progression of 
HPV16+ OPSCC (accounting for most viral associated cases) is largely unknown and may 
provide important insights for new therapeutic strategies e.g. adjuvant immunotherapeutic 
approaches that target viral antigens E6/E7 may act systemically to reduce microscopic foci 
of malignant disease.  
 
In this prospective clinical trial (UKCRN11945), specific cell-mediated immune responses to 
HPV16 E2, E6 and E7 in peripheral blood using IFN-γ enzyme-linked immunosorbent spot 
assay (ELISPOT) were examined before and after radical treatment. CD56+, CD4+, CD8+ and 














4.2 Materials and Methods 
 
 
4.2.1 Study population 
 
The study comprised fifty-one patients with primary oropharyngeal squamous cell carcinoma 
and eleven control subjects with benign disease. All patients were treated with curative intent 
by radiotherapy +/- chemotherapy. Disease specific survival was investigated by multivariate 
analysis. Disease stage was classified using the AJCC / UICC TNM classification of 
malignant tumours (Edge et al., 2010). 
 
 
A baseline sample of the tumour was taken for histological analysis and the remainder 
processed for DNA +/- RNA extraction. A consultant histopathologist with expertise in head 
and neck pathology reviewed each tissue block to ensure adequate tumour sampling. Clinical 
data for all subjects are shown in Table 14A+B. The outcomes observed for this study were 
DFS (Disease Free Survival) stratified by CD4+ / CD8+ response to HPV16 E2, E6 & E7 
epitope (see section 2.1.2). The average follow up length was 43.7 months. 
 
 
4.2.2 Lymphocyte cell preparation 
 
In each patient, a blood sample (40ml) was drawn at baseline after diagnosis and 3 months 
post treatment. To examine the specificity of the IFN-γ ELISPOT, healthy patients were 
recruited to the study, each of whom underwent tonsillectomy for a benign condition. 
 
 
4.2.3 Blood sample collection for ELISPOT assay. 
 
See section 2.6.1  
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4.2.4 ELISPOT assays for IFN-γ   
 
See section 2.6.2  
 
 
4.2.5 Flow cytometry 
 
See section 2.6.3 (Fluorescent activated cell sorting (FACS) analysis). 
 
 
4.2.6 HPV stratification 
 
See section 2.2 (Detection of HPV in clinical samples). 
 
 
4.2.7 Statistical analysis 
 
Statistical calculations were performed using SPSS Version 21 (Chicago, IL, USA).  Rates of 
disease free survival were estimated by means of the Kaplan–Meier method and were 













4.3.1. HPV-specific T cell responses correlate with tumour HPV status 
 
In total, 41/51 of tumour samples were classified as HPV positive - defined by evidence of 
HPV16 L1/E6/E7 DNA or HPV16 E6/E7 mRNA +/- HPV DNA ISH episomal / integrative 
staining pattern. Immunohistochemical analysis for expression of p16INK4a was demonstrated 
for all HPV+ OPSCC samples but also present for 2 out of the 10 OPSCC samples 
categorised as HPV negative (Table 14A+B).  
 
Data summarising HPV status and T cell response are shown in Appendix 8 & 9. When 
linking HPV16 status with the ELISPOT data, we found that 80% (33/41) of patients who 
had detectable HPV16 DNA in tumours also had CD4+ or CD8+ T cell response to HPV16 
E6/E7. Only one patient with a HPV negative tumour displayed such a response, suggesting a 
correlation is likely between HPV positive status of the tumour and T cell response to HPV 
antigens.  
 
4.3.2 CD4+ and CD8+ T cell response to HPV16 E7 reduce post-treatment for the 
majority of patients 
 
Specific IFN-γ responses to HPV16 E2, E6 & E7 by both CD4+/CD8+ T-cells were 
investigated at initial diagnosis of malignancy and three months after completion of 
chemoradiation for 39/51 patients. Pre-treatment CD4+ response to E2 was detected for eight 
patients (8/30); this frequency decreased slightly after treatment (8/39). One patient 
demonstrated a CD8+ response to E2 prior to treatment only. 
 
Overall, CD8+ T cell responses to HPV16 E6 and E7 peptides were detected pre-treatment in 
60% (18/30) and 70% (21/30) of patients, respectively. Post-treatment evaluation revealed 
there was no significant change in CD8+ response to E6 (39.5%; 15/38; p<0.16) and a 
significant decreased response to E7 peptide (44.7%; 17/38; p<0.02; Figure 32). 
 
 161 
Pre-treatment CD4+ T cell responses to HPV16 E6 and E7 peptides were detected in 60% 
(18/30) and 70% (21/30) of patients, respectively. Post-treatment, there was a significant 
decrease in ELISPOT responses to both E6 (35.9%; 14/39; p<0.02) and E7 peptides (43.6%; 
17/39; p<0.01; Figure 33).  
 
To ascertain sensitivity and specificity of the IFN-γ assay, patients undergoing tonsillectomy 
for benign disease were also subjected to the same analysis at baseline. All displayed no 
positive IFN-γ response for either CD4+ or CD8+ T-cells except for one subject (1/11). The 
same subject displayed evidence for HPV16 L1 DNA on initial HPV stratification. 
 
IFN-γ production by CD56 cells (NK cell population) was utilised to discern non-specific 
(innate) immune response within the clinical subgroups. Appendix 10 shows no significant 
difference was detected for all patients pre- or post-treatment.  
 
 
4.3.3 Decreased CD4:CD8 ratio following radical therapy 
 
The CD4:CD8 ratio pre-treatment was similar to that seen in healthy controls (3.03 vs. 2.87). 
However, CD4+ (0.74 vs. 0.42x109/L) and CD8+ (0.37 vs. 0.33 x109/L) cell numbers were 
reduced post-therapy with a larger proportionate decrease in CD4+ T cells (p<0.04; Figure 
33). Haemoglobin level (13.1 vs. 12.1 g/dl), total lymphocytes (1.4 vs. 1.1 x109/L), 
monocytes (1.6 vs. 1.3 x109 /L) and platelet count (298 vs. 307 x109 /L), all remained stable 
before and after treatment.  
 
 
4.3.4 CD4+CD25+CD127low/- Treg cell frequencies increase in HPV+ OPSCC patients 
after treatment 
 
Frequency of CD4+ cells with high co-expression of CD25+ and low co-expression of CD127 
were examined for most patients (34/51) using gate-settings as previously described (Figure 
35 & Appendix 11) (Baecher-Allan et al., 2001, Ormandy et al., 2005). Although the 
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proportion of CD4+CD25+CD127low/- Treg cells did not differ at baseline between the patient 
groups, there was significant elevation in HPV+ OPSCC patients after treatment (pre-
treatment 6.6% +/-SE 0.9 versus post-treatment 9.5% +/-SE 0.6 p<0.03).  
 
 
4.3.5 Improved disease free survival with elevated CD8+ T cell response to HPV16 E7  
 
The average DFS for all patients was 43.7 months (+/-SE 2.5). For the HPV16+ cohort, the 
DFS period increased to 47.3 months (+/-SE 2.3). In those with an increased CD8+ T cell 
response to E7, the average DFS period was 49.6 months (+/- SE 2.3; Figure 36 & Appendix 
12). A multivariate proportional hazards model using Cox regression analysis revealed 
HPV16 (P<0.02), retained or enhanced CD8+ T cell response to E7 (p<0.03) and smoking 




















Oropharyngeal squamous cell carcinoma is the possible outcome of infection with high-risk 
human papillomavirus (HPV) and is preceded by a phase of persistent HPV infection during 
which the host immune system fails to eliminate the virus. Fortunately, most oral cavity HPV 
infections are cleared before oncogenic conversion (Gillison et al., 2012, Garland et al., 
2016). 
 
In this prospective observational study, we report a systematic analysis of IFN-γ response in 
primary oropharyngeal carcinoma. The significant finding of this dataset would suggest an 
attenuated response by CD4+/CD8+ T-cells to HPV16 peptides after completion of radical 
therapy. Specific factors found to influence disease free survival include HPV16 status, 
smoking and post-treatment CD8+ response to HPV16 E7.  
 
As yet, most HNSCC studies investigating interaction between T-cell response and the 
HPV16 E6 or E7 oncoproteins are small and confined to a non-clinical setting (Sirianni et al., 
2004, Hoffman et al., 2006, Spanos et al., 2009, Wansom et al., 2010, Al-Taei et al., 2013, 
Ramos et al., 2013, Ferris, 2015). This contrasts with the more extensive research evaluating 
specific immune response in uterine cervix cancer (Andersson et al., 2000, de Jong and van 
Poelgeest, 2004, Kaufmann et al., 2007, Roman et al., 2007, Farhat et al., 2009, Stanley, 
2012a).  
 
The improved clinical outcome with retained CD8+ response to HPV16 E7 may contradict 
data from previous studies that show a more prominent immunogenic role for E6 (Farhat et 
al., 2009, Nakagawa et al., 2000). This situation may have arisen due to the more preserved 
status of E7 (compared to E6) in pre-malignant and malignant disease (Andersson et al., 
2000). E7 has also been used as the target epitope for many therapeutic vaccination trials for 
CIN (Roman et al., 2007). 
 
HPV E6 is transcribed from the same transcript as E7 and thus may be be expressed in 
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similar frequencies and quantity. It may be reasonable to assume a similar antiviral T-cell 
response, particularly for E6*1, which is the splice isoform of E6 expressed at high levels 
(along with E7) in tumours. E7 is expressed at the expense of full length E6, therefore a 
spectrum of responses to E7 and E6*1 and not full length E6 in tumours is possible (Tang et 
al., 2006).  
 
CD8+ cytokine response to the HPV16 E7 epitope was more likely in our HPV16 
RNA+/DNA+ group - as such it may simply act as a proxy marker for improved clinical 
outcome regardless of the immune phenotype. However, this specific response could have 
clinical relevance as CD8+ T-cells are the dominant immune killer cells for virus-infected 
cells, intracellular bacteria and cancer cells. Previous studies (Albers et al., 2005, Hoffman et 
al., 2006) also indicate that patients with HPV16+ HNSCC exhibit an increased number of T 
cells specific for peptides derived from the HPV E7 oncoprotein. Also, in contradiction to our 
study findings, HPV-specific T-cell responses (as a marker of HPV infection) would 
presumably lead to generalised correlations with improved survival for most or all CD4+ 
and CD8+ T-cell responses (E2, E6 & E7).  
 
The reduced T cell responses after treatment noted in this study cannot be explained by a 
concurrent decrease in lymphocytes or memory T cells; absolute numbers for both groups 
remained unaffected after radical therapy (Figure 34). Instead, there was a significant 
increase in regulatory T cells (Treg) noted within the HPV16+ cohort before and after 
treatment (11.6% versus 15.4%; p<0.02). These data suggest that immunosuppression (due to 
increased regulatory T cell activity) can influence HPV-specific immune response post-
treatment; in addition, they would support murine models where an immunodeficient host 
failed to clear HPV16 positive tumour cells after exposure to cisplatin (Spanos et al., 2009). 
 
Schuler et al. (2013) have demonstrated a higher Treg frequency and a lower CD8+/Treg ratio 
post CRT with no stratification by HPV status. The study authors suggest that the Treg 
fraction in PBMC is relatively resistant to CRT, unlike the CD4+ and CD8+ T-cells. This 
hypothesis was tested in vitro and demonstrated supportive data. Our study indicates that 
increased frequency of Tregs (post-treatment) is restricted to HPV+ cohort (Figure 35). If 
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confirmed to be the case, important drivers of this association may include pathways related 
to PDZ-domain proteins (E6), pRB, p107, p130, wildtype p53 or E7. 
 
Although disease free survival was not significantly influenced by Treg frequency before and 
after treatment, further functional studies may be beneficial. In particular, investigation of 
PD1 or PDL-1 expression from TILs (Tumour infiltrating lymphocytes) pre- or post-
treatment may be of clinical value (Lyford-Pike et al., 2013). A previous study has 
demonstrated increased PD1 expression from TILs is linked to improved survival in HPV+ 
OPSCC (Badoual et al., 2013). It may be of interest to determine whether changes in (or 
selection for) a PD1-high tumour cell population drives the balance between cytotoxic and 
regulatory T cells (Figure 37).  
 
Our data reveal two patients assigned to the HPV- OPSCC cohort tested positive for 
p16INK4A. Potential reasons for this observation include intra-observer / inter-observer 
variation of the immunohistochemical background stain. In addition, a small but significant 
cohort of the false positive HPV- samples have p16INK4A mutations that may account for 
accumulation of inactive p16INK4A (Romagosa and Simonettis, 2011). These data reinforce 
previous evidence that p16+ status alone is not a safe or justifiable method of assigning HPV 
status to a tumour (Robinson et al., 2012, Masterson et al., 2014, Mirghani et al., 2015). 
 
Limitations of this research are the small sample size and the possible insensitivity of the 
assay due to the localised nature of the infection. The reduced cohort size may result in less 
power to detect associations with E6 or E7. Problems with detection of Cell Mediated 
Immunity (CMI) response in peripheral blood are not surprising since HPV16 is a specific 
oropharyngeal subsite infection and consequently the number of circulating memory cells 
would be hypothesized to be small (in addition a decreased systemic immune response may 
be secondary to viral suppression). The E2 antigen may also have a more important role in 
viral control at an earlier stage of infection (Davidson et al., 2003). It would be of interest to 
obtain information regarding sustainability of the IFN-γ ELISPOT response at a more distant 
time-point after primary treatment (>5-10 years). We postulate that this may continue to 
decrease as antigen exposure becomes diminished (with clearance of infection or the cancer). 
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Conversely, a rising CD4+ / CD8+ T cell response may indicate recurrence of disease. 
 
In summary, we have found that the frequency of IFN-γ secreting CD4+ / CD8+ T-cells 
specific for HPV16 E6 and E7 peptides were decreased in most patients 3 months after 
radical therapy. Further to this, we observe a significantly improved disease free survival 
outcome in the small subset of patients who retain or enhance their CD8+ E7 response. 
HPV16 and smoking status were also found to correlate with survival.  Increased 
immunosuppressive influences after treatment (for the HPV16 cohort) are supported by a 
concomitant rise in Treg frequencies. Although the E6 and E7 epitopes are apparently 
immunogenic in patients with HPV-associated oropharyngeal carcinoma, it is unclear why 
specific T-cells are unable to eliminate or prevent oncogenic change at an earlier stage. 
Further studies are required to explain this resistance of tumour targets to cytotoxic T cells 
and to find potential strategies that will increase the chances of developing HPV-based 



















Table 14A: Clinical and histopathological data (HPV positive) 
OPSCC patients had a mean age of 58 years and the male-female ratio was 4:1. The majority had local 
advanced disease (stage IVA ~70%). No patient had distant metastases (stage IVC). Treatment involved 
chemotherapy (cisplatin 100 mg/m2, days 1, 22, 43) given concurrently with radiation therapy (65 Gy in 35 
fractions to both primary and nodal sites). In two subjects with significant renal or cardiac disease, 
cetuximab 400 mg/m2 IV loading dose 1 week before the start of radiation therapy, then 250 mg/m2 
weekly. For patients with limited nodal disease (usually >3cm), a selective or modified radical neck 
dissection was performed before the start of chemoradiation. The multi-disciplinary team assessed clinical 
response based primarily on surface measurements at direct laryngoscopy, supplemented by radiographic 
imaging (18F-fluoro-2-deoxyglucose positron emission tomography / computed tomography [FDG 
PET/CT]). Disease free survival and overall survival were determined after a median period of 43 months. 
BoT, Base of Tongue; Well, well differentiated SCC; Mod, moderately differentiated SCC; Poor, poorly 
differentiated SCC; PS, Eastern Co-Operative Group (ECOG) physiological performance status; CRT, 
chemoradiotherapy; RT, radiotherapy. Clinical outcome: #, locoregional recurrence; †, non-malignant 
cause of death; ††, malignant cause of death; n/a, not available. 
 
Study 























1 T3N3M0 IVB M Tonsil 61 0 Poor Current + 16 + + + - CRT + 43
2 T1N1M0 III M BoT 48 0 Poor Never + nil + - - + CRT + 47
3 T3N2bM0 IVA M Tonsil 72 1 Mod Former + 16 - + + + RT - 11 ††		
4 T1N2bM0 IVA M BoT 59 0 Well Current + 16 - + + - CRT + 43
5 T3N3M0 IVB F BoT 68 3 n/a Never + 16 + + + - RT - 14 †	
6 T1N2bM0 IVA F BoT 49 0 Poor Never + 16 + + + + CRT + 51
7 T3N2cM0 IVA M BoT 33 0 Mod Never + 18 + + + + CRT - 4
8 T1N1M0 III F Tonsil 67 1 Poor Never + 16 - + + + RT + 40
9 T2N2bM0 IVA M BoT 57 0 Poor Current + 16 + + + + RT - 44
10 T1N2bM0 IVA M BoT 65 0 Poor Never + nil + + + + CRT + 43
11 T1N2bM0 IVA F Tonsil 61 0 Mod Current + 16 + + + -  CRT + 48
12 T1N0M0 I M BoT 77 1 n/a Former + 16 + + + - RT - 7 †	
13 T3N2cM0 IVA M Tonsil 51 0 Poor Current + 16 + + + + CRT - 12 ††		
14 T2N1M0 IVA M Tonsil 49 1 Poor Never + 16 + - + - RT - 4 †	
15 T2N2cM0 IVA M BoT 57 1 n/a Never + 16 + + + - CRT - 40
16 T2N2bM0 IVA M BoT 64 0 Mod Former + 16 + + + + CRT + 47
17 T1N2bM0 IVA M BoT 75 1 Mod Former + 16 + + + + RT + 39
18 T2N1M0 IVA M Tonsil 47 0 Poor Never + 16 + + + - CRT + 39
19 T1N1M0 III F Tonsil 60 0 Mod Former + 16 + + + + RT - 39
20 T1N2aM0 IVA F Tonsil 62 0 Poor Never + 16 + + + + RT + 42
21 T4aN0M0 IVA M Tonsil 82 1 Poor Never + 16 + + + - RT - 4 †	
22 T2N2bM0 IVA M BoT 52 0 Poor Never + 16 + - + + CRT + 43
23 T2N2bM0 IVA M Tonsil 58 0 Well Current + 16 + + + + CRT + 30
24 T2N1M0 III M BoT 51 0 Mod Never + 16 + + + + CRT - 53
25 T2N2cM0 IVA M BoT 40 0 Mod Never + 16 - - + + CRT - 13 ††		
26 T3N2aM0 IVA M Tonsil 56 2 Poor Never + 33 + + + + CRT + 37
27 T1N2aM0 IVA M Tonsil 46 0 Poor Current + 16 - + + + RT + 38
28 T1N1M0 III M BoT 53 0 n/a Never - 16 + + + - CRT - 37
29 T1N2bM0 IVA M BoT 78 1 Poor Former + 16 + - + - RT + 37
30 T2N2aM0 IVA M Tonsil 58 0 Mod Never + 16 + + + + CRT + 39
31 T1N2aM0 IVA M Tonsil 55 0 Mod Current + nil + + + + CRT + 35
32 T1N2bM0 IVA M BoT 81 1 Poor Former + 16 + + + + RT - 12 ††		
33 T1N2aM0 IVA M Tonsil 59 0 n/a Former + 16 - + + - RT + 36
34 T1N2bM0 IVA M Tonsil 61 0 Poor Current + 16 - - + + RT + 41
35 T2N2cM0 IVA F BoT 51 0 Poor n/a + 16 + + + + CRT + 44
36 T2N1M0 III M Tonsil 53 1 n/a Former + 16 + + + - CRT - 41 # 10 mths
37 T1N1M0 III F Tonsil 40 0 Poor Current + 33 + + + + RT - 40
38 T1N0M0 I M Tonsil 67 0 n/a Former + 16 - - + - RT - 51
39 T2N2aM0 IVA M Tonsil 52 0 Poor Current + 16 + + + + CRT + 44
40 T1N2bM0 IVA F Tonsil 63 1 Poor Never + 16 + + + + CRT  + 44






Table 14B: Clinical and histopathological data (HPV negative) 
Study 























42 T1N2aM0 IVA M Soft pal. 61 2 Poor Current - nil - - - - RT + 34 # 16 mths
43 T2N2aM0 IVA F Tonsil 56 0 Mod Current - nil - - - - CRT + 48
44 T1N1M0 III M BoT 60 0 Poor n/a - n/a n/a n/a n/a - CRT + 37
45 T3N1M0 III M BoT 71 0 Mod Current - n/a n/a n/a n/a - CRT - 35 # 11 mths
46 T3N0M0 III M BoT 56 1 Mod Current - n/a - - - - CRT - 15 #	15	mths
47 T2N2bM0 IVA M Tonsil 53 0 Poor Never + n/a - - - - CRT - 40
48 T1N1M0 IVA M Tonsil 42 0 n/a Former + n/a - - - - CRT - 41
49 T3N1M0 III M Tonsil 43 1 Mod Current - n/a - - - - CRT - 13 ††	
50 T1N2bM0 IVA M Tonsil 77 1 n/a Former - n/a - - - - RT + 37






Figure 33: HPV16 E2, E6 & E7 response detection by IFN-γ ELISPOT pre and post radical 
therapy (Masterson et al., 2016a). 
 
A response was considered positive if the average number of spot forming cells (SFC) in HPV antigen 
well was 2 standard deviations (SD) above the average of negative control. The frequency of cytokine 
secreting CD4+ / CD8+ / CD56+ cells were then derived by the formula: number of spots/number of cells 
per well. For this study, we assume that increased staining of CD4+ equates to CD4+ T cells; we assume 














































































Figure 34: Mean haematological parameters (+/- SD) in OPSCC patients (n=51) before and 
after radical therapy (Masterson et al., 2016a). The graph shows changes in A) CD4 & CD8 
%  B) haemoglobin C) lymphocytes D) monocytes and E) platelets. The CD4:CD8 ratios 
were calculated using the frequencies of CD4+ and CD8+ population. All other subgroups 





Figure 35A: Gating strategy to isolate CD4+CD127low/−CD25+ T-cells (T-regulatory cells)  
 
Flow Activated Cell Sorting (FACS) was undertaken using the FacsCalibur flow cytometer 
(BD Biosciences) and analysed with Flowjo software (Treestar, USA). Tregs (T-regulatory 
cells) were isolated from peripheral blood and the lymphocyte population was gated based on 
forward and side scatter (left upper plot), followed by gating all CD4+ T-cells (right upper 
plot [CD4=FITC]). The cell populations were then sorted based on CD127low/− and CD25+ 
expression (left lower plot, CD4+CD127low/− T-cell gated population [CD127= APC]; right 








Figure 35B: Pre- and post-treatment analysis of Treg population (stratified by HPV status). 

















Figure 36: Disease Free Survival (DFS) stratified by a) HPV16 status and b) Post-treatment 
CD8 response to HPV16 E7 (Masterson et al., 2016a). 
 
A multivariate model was developed using Cox regression to investigate the effect of clinical 
factors on disease free survival (HPV16, ΔCD4+ T-cell response to E6/E7 (pre-treatment 
versus post-treatment change in IFN-γ production), ΔCD8+ T-cell response to E6/E7 (pre-
treatment versus post-treatment change in  IFN-γ production), p16INK4a, Treg frequency (%), 
T stage, N stage, sex, physiological performance status, oropharyngeal subsite, histology 
grade, smoking, concurrent chemotherapy, age and CD8+ / Treg ratio (pre / post / Δ ratio). 
 
 











Figure 37: Hypothetical role for PD-1 (Programmed death protein 1) in HPV associated 
OPSCC (Masterson et al., 2016a). 
 
PD-1 is an inhibitory receptor expressed on various immune cells, including activated T-cells 
and Treg cells. By blocking the interaction between PD-1 and its primary ligand, PD-L1 (red 
circle), T-cell effector functions are enhanced by increasing proliferation and cytokine 
activity (IFN-γ). Data from this study would suggest further work is required to discern the 





MHC complex PD-L1 T-cell receptor 








Figure 38: Therapeutic HPV vaccines (Masterson et al., 2014). 
 
Immunotherapeutic approaches that target viral antigens can act systemically to target 
microscopic foci of malignant disease (local or distant) following chemoradiotherapy or 
tumour-ablative surgery. This may be of clinical benefit as the overall toxicity of tumour 
vaccines and other immune-based treatments are potentially less than that of 
chemoradiotherapy (with notable rare exceptions such as severe pneumonitis secondary to 
mTOR inhibitors e.g. Temserolimus [CCI 779]). Pre-clinical studies have utilized bacterial or 
DNA based vectors (e.g. Listeria Monocytogenes ADXS11-001, pNGVL-4a-CRT or GPI-
0100) to deliver HPV16 E6/E7/L1 to Antigen Presenting Cells (APC) to augment T-cell-
mediated immune response (Jones, 2012, Califano, 2011, Peng et al., 2015). The most 
prevalent approach utilises ADXS11-001 as an immunotherapy based on live 
attenuated Listeria monocytogenes that secretes fusion protein Lm-LLO-E7 targeting HPV-
associated tumours. An attenuated version of the bacteria lacks PrfA, a transcription factor 
essential for the expression of virulence factors. This ensures the bacterium is unable to 
function as an intracellular parasite.  The Lm-LLO-E7 protein is processed by the endogenous 
antigen-processing pathway, facilitating the presentation of epitopes in the context of MHC 
class I molecules (Cory and Chu, 2014). An alternative approach involves targeting the 
cellular protein p16INK4a (mixed with MONTANIDE ISA-51 VG), however this may have 
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Squamous cell carcinoma within the temporal bone region is a rare and destructive type of 
malignancy with a poor prognosis. The reported annual incidence is 1-6 cases per million, 
which accounts for 0.3% of all tumors of the head and neck (Gidley et al., 2010). Regional 
lymph node metastases can occur in 10-20% of patients but distant spread is rare (Sasaki, 
2001, Moffat et al., 2005). 
 
The site of origin of the invading tumour may not be obvious at presentation as the tumour 
progresses by direct incursion into the temporal bone and adjacent structures (parotid, 
temporomandibular joint, dura, brain). Multiple factors (Sasaki, 2001, Gidley et al., 2010) 
influence the development of SCC within the epithelium adjacent to the temporal bone. 
Exposure to ultraviolet light has been implicated in the development of SCC which originates 
in the pinna or external auditory canal (EAC) (Gidley et al., 2010). Chronic suppurative otitis 
media (CSOM) and radiotherapy have been widely reported to have an association (Moffat et 
al., 2005). SCC arising in the nasopharynx may also invade the temporal bone, by extension 
via the eustachian tube. One theory, which may connect the various sites and their 
predisposing factors, is the establishment of a chronic inflammatory process leading to 
metaplastic or neoplastic change (Lim et al., 2000). 
 
Within the head and neck region, the association of HPV with SCC affecting the oropharynx, 
hypopharynx and nasopharynx has been clearly established. A recent meta-analysis of the 
world literature demonstrated that the proportion of oropharyngeal SCC caused by HPV has 
increased to 72.2% (Mehanna et al., 2012). New clinical trials are currently in progress to 
evaluate management based on this viral aetiology (Psyrri et al., 2012). 
 
Epstein Barr Virus is also associated with various forms of cancer, particularly Hodgkin's 
lymphoma, nasopharyngeal carcinoma and Burkitt's lymphoma. The global burden of EBV 
associated cancer is lower than HPV with a prevalence ~2% versus ~5% respectively (Khan 
and Hashim, 2014, Forman et al., 2012). The potential contribution of viral infection to SCCs 
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of the whole intra-temporal region has not previously been investigated. This is surprising 
given the high morbidity and mortality associated with this disease and the established link to 
chronic inflammation.  Case reports and small retrospective studies have indicated that HPV 
may play a role.   
 
Jin et al. (1997) utilized PCR with consensus primers for the detection of HPV types 6, 11, 
16, 18, 31, 33, 52b, and 58 in a retrospective study on FFPE material. HPV DNA ISH was 
performed, using probes to identify both low and high-risk HPV types. In fourteen cases with 
middle ear SCC of the temporal bone, eleven showed an association with high risk HPV 
activity. 
 
Wang et al. (2009) reported presence of low risk HPV types in the external ear canal for 7 out 
of 10 cases with benign papilloma lesions <1cm in diameter. HPV ISH analysis was 
performed for the hybridisation of DNA probes, including both low-risk and high-risk HPV 
subtypes. The results revealed that seven out of ten cases were positive for low-risk HPV 6 or 
11. No high-risk types (16, 18, 31, 33, 35, 39, 51, 52, 56, 58, and 66) were detected. 
 
Miah et al. (2012) reported one case of malignant transformation of benign ear canal 
papillomatosis to SCC of the temporal bone. The study strongly encouraged further genetic 
analysis of benign lesions to assess their susceptibility for malignant transformation. 
 
Marioni et al. (2003) analysed two patients with Schneiderian-type papilloma involving the 
temporal bone. Both samples had evidence of human papillomavirus using polymerase chain 
reaction with consensus primers. 
 
If a viral aetiology for temporal bone SCC can be established beyond doubt, this would have 
important diagnostic, therapeutic and prognostic implications.  
 
A review of the literature would suggest a possible association between high risk HPV and 
SCC of the temporal bone. Outstanding questions relate to corroboration of this data and 
assessment of clinical outcomes based on this viral aetiology.  
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This study will be based on a retrospective analysis of FFPE samples, such an approach is 
primarily based on the rare incidence of this carcinoma and the existing large number of bio-
banked material already at this teaching hospital location. 
 
One of the major limitations of this study relates to a decalcification technique utilizing 
trichloroacetic acid (TCA). TCA is known to have an adverse effect on the quality / amount 
of extracted DNA and as such this may reduce the sensitivity for high risk HPV subtypes.  
 
The results described in the chapter have been published in Masterson et al. (2013), and some 




















5.2 Materials and Methods 
 
5.2.1 Patients and Specimens 
 
This study received formal approval by the National Research Ethics Service Committee of 
East of England (12/EE/44). Retrospective archival clinical samples were obtained covering 
the period 1983-2008 (Department of Histopathology, Cambridge University Hospital NHS 
Trust, UK). All cases with a diagnosis of SCC affecting the external ear canal or middle ear 
cavity were included. Biopsies were obtained at the time of the surgical procedure. Patient 
data including age, sex, smoking status, clinical presentation and disease stage (obtained from 
hospital and primary care records) were correlated to patient outcome (overall and disease 
specific survival).  
 
 
5.2.2 Extraction of DNA 
 
See section 2.1.2 DNA extraction (Temporal bone carcinoma samples (FFPE)).  
 
 
5.2.3 Polymerase Chain Reaction 
 
HPV PCR analysis 
 
See section 2.2.2 PGMY PCR Analysis & 2.2.3 Nested PCR. 
 
HPV DNA sequence analysis 
 
See section 2.2.4 Direct cycle sequencing. 
 
EBV PCR analysis 
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See section 2.2.6 EBV PCR. 
 
5.2.4 In situ Hybridisation  
 





See section 2.4. Primary antibodies were used at the following concentrations in PBS: p16 
1:20 (BD Pharmingen), MCM7 1:200 (Abcam), Ki-67 1:150 and LMP1 1:150 (Dako, 
Glostrup, Denmark).  
 
 
5.2.6 TP53 Sequencing 
 





Characteristics of the study population were summarised using descriptive statistics. Tumour 
samples were considered positive for HPV if detected by PCR (with DNA sequence analysis) 
or RNA in situ hybridization with corroborative evidence on p16 immunohistochemistry. 
Tumour samples were also considered to have an association with EBV if detected by PCR or 
LMP-1 immunohistochemistry.  
 
Rates of overall and disease specific survival were estimated by means of the Kaplan–Meier 
method and were compared between these groups with the use of the log-rank test. The chi-
squared test was used to analyse all other proportionate data between subgroups. Differences 
with values of p<0.05 were considered significant. All calculations were performed using 





5.3.1 Clinical data 
 
A total of 20 cases of temporal bone SCC involving the EAC or middle ear cavity were 
identified from the hospital records and entered the study (1 sample per patient). Most cases 
(70%) displayed moderately differentiated squamous cell carcinoma, the remaining cases 
were split equally between well and poorly differentiated carcinoma. The age at presentation 
varied from 37 to 79 years, with a median of 62.5 years (SD +/-11.3yrs). Eleven (55%) of the 
patients were men and nine were women. The mean follow-up period was for 34 months 
(range 1-184). Three-year disease specific survival was 40% (SE +/-11%) with no significant 
difference noted when stratified by HPV status, age, sex, smoking or disease stage. The 
clinical and laboratory data are summarised in Table 15 and Figure 39A+B. 
 
 
5.3.2 Detection of HPV by PCR 
 
After three separate assays, most DNA samples (14/20) showed amplification of the β-globin 
268 base pair (bp) product and were therefore deemed suitable for PCR evaluation of HPV.  
In all remaining samples (6/20), no further analyses were attempted.  
 
DNA extracted from an HPV11 positive genital wart sample was used as a positive control 
for both β-globin and HPV PCR. One sample (case 4; Table 15) showed amplification of a 
450bp product with PGMY primers. Nested PCR GP5+/GP6+ primer set showed a positive 
band (150 bp) in 3 patients (cases 2, 4 and 6; Table 15). DNA sequencing of positive samples 
revealed the subtype HPV16 in all cases. Point mutation analysis revealed minor 





5.3.3 Detection of EBV by PCR 
 
One patient sample (Case 19; Table 15) displayed evidence of EBV positivity when analysed 
by the EP5 / EM3 primer set. A control sample using genomic EBV DNA (EBNA–2) revealed 
the 182 bp amplicon. 
 
5.3.4 In situ hybridisation 
 
To determine transcriptional activity within the tumour tissue, samples noted to have β-
globin amplification with PCR were subjected to further analysis by RNA in situ 
hybridisation. Two samples (each HPV+ on PCR / DNA sequence analysis) showed evidence 
of epithelial expression of HPV16 E6 or E7 and L1 mRNA. The control sense probe was 
negative. The positively stained cells were distributed throughout the entire layer of 
superficial neoplastic epithelium (Figure 40A-D). EBER RNA in situ hybridisation was 





All three HPV DNA-positive tumours underwent p16 immunohistochemistry, two of which 
displayed evidence of specific nuclear and cytoplasmic staining (Figure 39B). HPV DNA-
negative controls did not display evidence of p16 activity.  The LMP-1 immunohistochemical 
stain for detection of EBV was negative for all samples (Table 15). 
 
 
5.3.6 TP53 mutation analysis 
 
Sufficient DNA was available for direct sequencing of exons 5–9 of the TP53 gene in the 
majority (13/14) of samples within the study. A functional mutation was discovered in 3/10 
HPV-negative and 0/3 HPV-positive samples (Table 15), however this difference was not 





In addition to the findings of Jin et al (1997), this study suggests an association with high risk 
HPV in a minority of patients with temporal bone SCC. However, the mere presence of HPV 
types (as determined by both molecular and immunohistochemical techniques) does not 
imply causation for this disease. It follows a trend recently encountered in other areas of the 
head and neck (Ang et al., 2010). Three out of 14 patients were found to have detectable 
HPV16 DNA. No significant difference in disease specific survival was detected for the 
HPV-positive group. All study patients were recruited sequentially and demographic details 
are similar to other reported case cohorts (Jin et al., 1997, Sasaki, 2001, Gidley et al., 2010). 
 
Although the 21.5% HPV16 detection rate in this study represents a minority, the clinical 
significance may be apparent if duplicated by other centres and correlated to longer term 
outcomes. The study expands on similar research conducted by Jin et al. (1997), which was 
restricted to the middle ear cavity but nonetheless demonstrated high risk HPV16 in 11/14 
samples. This higher HPV detection rate may reflect ethnic composition – this may be 
inferred based on the wide discrepancy between EBV seroprevalence rates in Taiwan 
(88.5%) when compared to Europe / USA (50-66.5%) (Balfour et al., 2013, Dowd et al., 
2013). The above statistics for EBV may also reflect in the rate of nasopharyngeal carcinoma 
in Taiwan (16.9 / 100,000 person years) when compared to Europe / USA (0.5 -2 / 100,000 
person years) (Chien et al., 2001, Chang and Adami, 2006). A potential limitation of the Jin 
et al. (1997) study is the absence of clinical follow up and DNA sequence analysis to exclude 
contamination of samples. 
 
A significant proportion of oropharyngeal cancers (40-75%) are now thought to have HPV16 
DNA integrated within their genomic DNA, with minor contributions made by other 
oncogenic HPV subtypes (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) (Ang K et al., 
2010). The rise in HPV-associated oropharyngeal carcinoma has been well documented (de 
Martel et al., 2012) and it is noteworthy that all similar cases in the temporal bone region 
were identified in the last decade – this may reflect the quality of samples obtained or 
possibly the growing importance of HPV within the head and neck region.  
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In this cohort, the link with EBV is less evident, with only one patient demonstrating a 
possible association on PCR analysis. This may represent either the true level of background 
infection, inhibitory pathways in vivo / vitro or inadequate detection of a low viral load. The 
premise for investigating this virus stemmed from the proximity of the nasopharyngeal 
mucosa to the temporal region. EBV is associated with the overwhelming majority of 
nasopharyngeal carcinoma (NPC) as evidenced by expression of LMP1 or EBER in tumour 
cells (Young and Rickinson, 2004). 
 
At present the definitive treatment for SCC of the temporal bone is with major surgery and 
free flap reconstruction with limited scope for primary medical therapy (Moffat et al., 2005). 
Previous studies will not have accounted for a potential viral aetiology which may confound 
clinical outcomes (Ang K et al., 2010). Although this malignancy is comparatively rare, the 
morbidity associated with current treatment would provide a strong argument for change. In 
common with other published datasets (Jin et al., 1997, Sasaki, 2001, Gidley et al., 2010), 
most cases in this study present with advanced stage IV disease. A practical application of 
this research may therefore involve targeted screening to ensure earlier diagnosis. 
 
It is tempting to conclude from the survival analysis (Figure 39A) that HPV-associated 
patients showed a trend towards improved survival but small numbers prevent this from 
proving statistically significant. If this limited data can be confirmed on a larger scale this 
may support studies which observe that repression of E6 and E7 (in HPV-positive SCC) will 
lead to activation of the p53 and pRb pathways, decreased cellular proliferation and cellular 
growth arrest (Major et al., 2005). This situation is quite different from conventional disease 
(HPV-negative SCC), where an irreversible p53 mutation may be present (Oliver et al., 
2002). It is of interest to note that all such mutations found in this study were restricted to the 
HPV-negative cohort, however, no clear divide is evident. 
 
HPV is primarily transmitted through close skin or mucosal contact during vaginal, oral or 
anal sex (Cason and Mant, 2005). Research conducted recently in the United States indicates 
that, at any single time point, 42% of females may have an anogenital HPV infection, in 
comparison with <7% in the oral cavity region (Gillison et al., 2012). Genital-finger 
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transmission may be possible but has yet to be conclusively proven (Gottschling et al., 2009).  
One observational study recently investigated the presence HPV DNA on hand samples in 
patients with a prior diagnosis of penile HPV. Seventy percent of specimens were positive, 
the majority of which were of the same HPV type (Bosch et al., 2006). 
 
Non-genital routes of HPV infection have yet to be fully elucidated but it is generally 
accepted that haematogenous spread is unlikely (Gottschling et al., 2009). It is also 
contentious as to whether HPV may undergo fomite transmission from person to person (e.g. 
towels, sheets, medical instruments) (Syrjänen and Puranen, 2000).  Major et al. suggest that 
spread from mother to child (vertical or perinatal transmission) of HPV6 or HPV11 may 
rarely lead to juvenile onset recurrent respiratory papillomatosis (Major et al., 2005). 
However, Fredericks et al. (1993) suggest that HPV genotypes detected in exfoliated 
maternal cells can be traced in oropharyngeal mucosa of infants in up to 70% of cases. Smith 
et al. (1991) demonstrated the presence HPV DNA in ~3% of buccal mucosa samples in a 
cohort of 2 out 72 newborn infants. Cason et al. (1995) revealed HPV vertical transmission 
rates of ~73% at 24 hour after birth and demonstrated this persisted in ~80% of cases at 6 
months. 
  
So which method could potentially predispose to HPV infection within the temporal bone? 
The two obvious routes of ingress for the virus would include direct spread from the oral 
cavity through the eustachian tube or topical spread through the external ear canal. The 
presence of a tympanic membrane or mastoid cavity perforation will potentially influence 
either route.  
 
Two of the three HPV-positive patients in this study had a pre-existing tympanic membrane 
defect; this was also a common finding in HPV-negative disease and prevents accurate 
localization of the primary to the external or middle ear cavity. Figure 39B suggests an 
association with viral positivity and extended length of otological symptoms that may support 
a link with chronic inflammation. 
 
The exact prevalence of HPV16 at different sites within the head and neck region is at 
present undetermined. The best proxy marker comes from a systematic review by Gillison et 
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al. (2012), which demonstrated a 1% (95% CI 0.7-1.3) prevalence rate for oral HPV16 in the 
general adult population. A comparison with the SCC temporal bone group may suggest a 
significant difference (1% versus 21% p<0.01), however, this needs to be interpreted with 
caution due to the obvious baseline differences. The rate of oral cavity HPV persistence may 
also be higher than currently observed at the anogenital site, facilitating the potential for 
malignant change (Cason and Mant, 2005). 
 
The discovery of human papillomavirus DNA from this cohort of samples is insufficient 
evidence to lead to the conclusion that HPV is involved in the causation of the disease. HPV 
is common on all skin or mucosal surfaces and the detection of HPV DNA may just be 
contamination. We therefore chose to investigate HPV transcriptional activity within the 
tumour site by RNA in situ hybridisation (Figure 40A-D). The detection of HPV16 E6 or E7 
mRNA may indicate transcriptional carcinogenic activity and is considered the current 
standard for confirmation of HPV-associated disease (Schache et al., 2011). 
 
Since HPV DNA in head and neck cancer is frequently integrated into the genome of host 
cells, it is of interest to detect HPV16 L1 mRNA in one of the patients. This may reflect 
capsid expression and active replication of HPV16; features more in keeping with an 
episomal status of the HPV genome. However, we note that L1 expression has also been 
detected in HPV-associated HPV HNSCCs affecting the oropharynx (Winder et al., 2009) 
and anogenital regions (Koncar et al., 2017). 
 
The limitations of this study are disparate methods of sample collection, variable storage 
length and a decalcification technique utilising trichloroacetic acid (TCA). This study is 
restricted to the UK and may not reflect other countries with different age / ethnicity profiles. 
Finally, the sample size is limited due to the rare nature of this disease and therefore may not 
be applicable to the wider population. 
 
This study outlines early clinical data that relate high risk HPV16 to SCC temporal bone and 
as such may have a direct impact on patient care. A theoretical cause for malignant 
transformation may be transmission of the virus through the eustachian tube or external ear 
canal in combination with longstanding inflammation. The data collected suggests the need 
 187 
for further investigation, preferably in the form of a prospective setting. This will have the 
































Table 15: Summary of clinical and laboratory analyses 
Most DNA samples (14/20) showed adequate amplification of the β-globin 268 base pair 
product and were therefore deemed suitable for further analyses. All HPV-positive cases 
demonstrated wild type (WT) p53, in contrast, the three p53 mutations found were confined 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 39: Temporal bone carcinoma survival analysis (Masterson et al., 2013) 
A, Disease Specific Survival stratified by HPV status (Log Rank p=0.211). B, HPV PCR 
positive sample clinical dataset.  
Figure 1 Temporal bone carcinoma survival analysis. A, Disease Specific Survival 
stratified by HPV status (Log Rank p=0.211). B, HPV PCR positive sample clinical 







O N Number of patients at risk HPV 
6 11 4 3 1 -ve 
0 2 1 0 0 +ve 





















2 Otorrhea for 18 months. 
Previous radiotherapy to 
ipsilateral temporal lobe 
13 years previously. 
16 - - - - - 
4 Mastoid cavity discharging 
>30 years. Recent otalgia 
>8 months. 
16 + - - + + 
6 Bilateral otitis externa >3 
years. Six month history of 
blood stained discharge  
16 + - + - + 





Figure 40: HPV detection in SCC of temporal bone (Masterson et al., 2013).  
A, HPV16 E7 mRNA sense probe (control) shows no uptake in epithelium. B, HPV16 E7 
mRNA antisense probe shows increased uptake throughout all layers of the epithelium. C, 
HPV16 L1 mRNA sense probe (control). D, HPV16 L1 mRNA antisense probe also shows 
uptake throughout all layers of the epithelium. 
 
A     B 
       
 
C                                    D 







Figure 41: Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) RNA in situ 
hybridisation (linear scale bar 200µM; inset picture magnified x2.5). A, Nasopharyngeal 
carcinoma control reveals strong uptake of probe in comparison to B, RNA negative probe. 
C, EBV PCR positive patient reveals no uptake of probe when compared to D, RNA negative 
probe (Masterson et al., 2013).* 
 A B 
   
 C                                    D 
   
*An RNA Negative Control Probe is a single oligonucleotide, designed from zebra fish DNA. Basic 
Local Alignment Search Tool (BLAST) analysis is utilized to confirm no homology with any human 
sequence. 
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  Chapter 6 































The data presented in this thesis emphasize the significant influence of high risk HPV 
infection on HNSCC (and in particular OPSCC). Further studies are likely to focus on 
developing non-invasive screening tools, therapeutic strategies based on vaccination / 
immune modulation or de-escalation of current treatment protocols.  
 
 
6.1 HPV and cellular changes in benign, pre-malignant and malignant oropharyngeal 
disease  
 
The principle aim of this thesis was to investigate the hypothesis that dysplastic epithelial 
changes preceding the development of HPV-associated OPSCC can be identified by specific 
molecular and/or genetic abnormalities. 
 
As the majority (~75%) of patients with HPV-associated OPSCC present at an advanced 
stage (Licitra et al., 2006, Ang et al., 2010), earlier detection of malignant disease could be of 
immense benefit.   
 
The project focused on examination of OPSCC fresh frozen samples using whole 
transcriptome analysis to identify potential biomarkers of relevance. Verification of results by 
reverse transcription–quantitative PCR confirmed predictable fold changes of RNA 
expression in HPV-associated disease e.g. CDKN2A / CCND1. A testis-specific gene not 
normally expressed in somatic cells, synaptonemal complex protein 2 (SYCP2), showed  
consistently elevated fold change in malignant tissue when compared to normal tissue. In 
addition, secreted frizzled related protein 1 (SFRP1), a modulator of the Wnt signaling 
pathway was found to have significantly reduced expression in malignant tissue. 
 
Laser capture microdissection on FFPE samples enabled specific investigation of regions 
identified as malignant or pre-malignant (if present). These confirmed the findings on fresh 
frozen tissue and in addition showed elevated expression of  SYCP2 in pre-malignant tissue 
when compared to normal tissue. This latter finding indicates the potential for SYCP2 as 





A significant finding of this work relates to increased expression of SYCP2 in HPV 
associated pre-malignant tissue (adjacent to invasive oropharyngeal carcinoma). If replicated 
on a larger basis, this may contribute to a potential non-invasive screening tool for early stage 
(pre-clinical) disease. A literature review would suggest testicular cell adhesion molecule 1 
(TCAM1) and stromal antigen 3 (STAG3) are also potential candidate biomarkers in this 
respect and the possibility exists to combine multiple target transcripts into a single 
quantitative assay (Lambert et al., 2015). Regarding SYCP2, further functional studies using 
animal models are required to elucidate a true causal relationship with HPV associated 
malignant disease. It could simply be the case that elevated expression of SYCP2 reflects 
genomic instability and de-differentiation of epithelial cells.  
 
Prospective randomised controlled clinical trials with a post hoc analysis of pre-treatment 
biopsies have now established that detection of HPV in oropharyngeal tumours (a subgroup 
within the head and neck region) may confer a survival advantage to the patient (Fakhry et 
al., 2008, Ang et al., 2010). This recognition that HPV-positive tumours have a better 
prognosis than traditional tobacco- and alcohol-associated disease has particular importance 
with regards to current treatment protocols (Genden, 2013, Ferris, 2015). It leads to the 
question of whether it may be possible to safely de-escalate the intensive therapies (primarily 
aimed at the type of disease now known to be HPV-negative) that can unnecessarily harm 
this subgroup (Masterson et al., 2014). One large multi-centre study based in the UK 
(PATHOS, 2015) shows promise by investigating the surgical management of patients with 
HPV-associated OPSCC. Adjuvant treatment protocols (ameliorated RT dose or removal of 
chemotherapy versus standard therapy) are then allocated according to TNM stage, smoking 
status or histopathological risk factors e.g. extra-capsular spread / positive surgical margins. 
 
Within the oropharynx, HPV16 constitutes the overwhelming majority (~90-95%) of HPV 
subtypes associated with malignancy (Schache et al., 2011). This contrasts with uterine 
cervix mucosa, where approximately 15 high-risk subtypes cause >99% of disease. These 
findings suggest that the cancer progenitor cell of origin is likely to influence the clinical 
outcome when HPV infection is involved, and that the natural history of HPV life cycle is 
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different according to the site and cell of infection. Indeed, there is some evidence to suggest 
that in OPSCC, the viral genome is episomal and not integrated, as in uterine cervix 
malignancy (Leemans et al., 2011). The majority of studies in the literature, however, support 
the role of HPV integration in OPSCC (Leemans et al., 2018).  
 
So far, the largest single cohort of patients with HNSCC (n=279) subjected to whole genome 
sequence (WGS) analysis with phenotypic correlation is The Cancer Genome Atlas (TCGA, 
2015). Using this example, head and neck clinicians in the UK are embarking on an 
ambitious goal, within the auspices of the 100K Genomes Project (Caulfield et al., 2017), 
that will involve WGS analysis for >500 patients with HNSCC. Recruitment will primarily 
involve new HNSCC patients diagnosed at major oncology units, and in addition, 
appropriately stored samples from existing national clinical trials. The new project is likely to 
identify a broader range of biomarkers that can aid diagnosis, prognosis and facilitate 




6.2: T cell response to HPV E2, E6 and E7 in patients with OPSCC 
 
A further aim of this thesis was to investigate the immunological response to treatment in 
HPV16 positive OPSCC. A subtle immune defect has long been thought to trigger the 
susceptibility of some individuals to persistent HPV infection with either low or high risk 
HPV types (Duray et al., 2010). Such variations in host immune response may also affect the 
likelihood of HPV-related head and neck cancer.  Cell-mediated immune responses to 
HPV16 E2, E6 and E7 were examined in peripheral blood using IFN-γ enzyme-linked 
immunosorbent spot assay (ELISPOT) in patients with OPSCC treated by 
chemoradiotherapy.  
 
T cell responses against E6 or E7 peptides correlated with HPV DNA/RNA status. Within the 
HPV16+ OPSCC cohort, enhanced immunoreactivity to antigen E7 was linked to improved 
survival. In addition, an observed increase in regulatory T cell frequencies (in the HPV 
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associated cohort only; see Figure 35 page 168) after treatment would suggest that 





Although the E6 and E7 epitopes are apparently immunogenic in patients with HPV-
associated oropharyngeal carcinoma, it is unclear why specific T-cells are unable to eliminate 
or prevent oncogenic change at an earlier stage. Further studies are required to explain this 
resistance of tumour targets to cytotoxic T cells and to find potential strategies that will 
increase the chances of developing HPV-based therapeutic vaccine in the future. In addition, 
clarification regards the elevated regulatory T cell frequencies observed in HPV associated 
OPSCC requires further prospective research – if confirmed this will also provide a potential 
useful therapeutic target. 
 
The overall toxicity of tumour vaccines and other immune-based treatments are potentially 
much less than that of radiotherapy or chemotherapy (with notable rare exceptions such as 
severe pneumonitis secondary to mTOR inhibitors). Adjuvant immunotherapeutic approaches 
that systemically target viral antigens could have the potential to remove microscopic foci of 
malignant disease.  
 
Research strategies have so far utilized HPV16 E6/E7/L1 as the target antigens for antigen 
presenting cells (APC) to augment T-cell-mediated immune response (Califano J, 2011, 
Jones, 2012, Peng et al., 2015). Dendritic cells are a specific form of APC that can prime T 
cells in vivo to become cytotoxic T lymphocytes (e.g. HPV16 E6/E7 CD8+) or T helper cells 
(e.g. HPV16 E6/E7 CD4+). An alternative approach involves targeting the cellular protein 
p16INK4a, however this may have the potential to be non-specific in ~10% cases (Jäger E, 






6.3 The role of human papillomavirus and Epstein Barr virus in squamous cell 
carcinoma of the temporal bone 
 
 
A final aspect of this study was to determine the role of HPV and EBV in the pathogenesis of 
squamous cell carcinoma within the temporal bone region. This is an uncommon tumour 
which is normally preceded by a history of inflammation within the external auditory canal 
(EAC) or middle ear / mastoid cavities (Gidley et al., 2010). Although HPV has been 
implicated in many head and neck malignancies, its role in SCC of the temporal bone has not 
been established. If a viral aetiology can be found, this may affect treatment strategies (Jin et 
al., 1997). Patients were investigated for presence of high risk HPV types using polymerase 
chain reaction, RNA in situ hybridisation, DNA sequence analysis, and p16 
immunohistochemistry. In addition, all specimens underwent separate investigation for the 
presence of latent and active Epstein-Barr virus infection or mutations within exons 5-9 of 
the TP53 gene. HPV16 DNA was detected in ~20% of the available cases, however, no 
significant difference in disease specific survival was noted for the papillomavirus positive 
group. Epstein-Barr virus was not detected and all TP53 mutations were restricted to the non-
viral group as expected (as HPV+ induced malignancy is associated with reversible inhibition 
of p53 function and not irreversible mutation). This study outlines early clinical data that 
relate high risk HPV16 to SCC temporal bone and as such may have a direct impact on 
patient care.  A theoretical cause for malignant transformation may be transmission of the 





The data collected suggests the need for further investigation, preferably in the form of a 
prospective setting. A twenty percent HPV positivity rate alone does not suggest definite 
association nor causality. A large multi-centre trial involving fresh tissue and sensitive / 
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Full heatmap of 223 transcripts that are differentially expressed between HPV-positive and 






RT-qPCR data for prospective fresh tissue A) HPV16 positive (samples 1-18 peach 
background) and B) HPV16 negative (samples 19-24 blue background) cohorts. When the 
optimal primer concentration produced a linear response to input cDNA, samples were 
analyzed in triplicate for each tested transcript (CDKN2A, CRCT1, SYCP2, SFRP1, CRNN, 
DLG2). Beta-actin (ACTB) was utilized as the housekeeping gene. N, normal tissue; M, 
malignant tissue. Efficiency range 98-103%; Slope range 3.4 - 3.2; LLD, Lower Limit 





RT-qPCR data for retrospective cohort (LCM invasive versus normal tissue; HPV16 
positive samples 1-23 peach background; HPV16 negative samples 24-27 blue background). 
FFPE tissue samples were subjected to laser capture microdissection to enable RNA 





RT-qPCR data for retrospective cohort (LCM carcinoma in situ versus normal tissue; 
HPV16 positive samples 1-10 peach background; HPV16 negative samples 24-25 blue 
background). FFPE tissue samples were subjected to laser capture microdissection to enable 
RNA extraction from representative regions of in situ carcinoma (pre-malignant change) and 







Disease free survival - multivariable and univariable statistical analysis. A multivariable 
proportional hazards model using Cox regression analysis revealed HPV16, SYCP2, smoking 
and physiological performance status to have significant influence on DFS.  
 
 
Appendix 6 & 7 
 
Receiver Operating Characteristic (ROC) curve to evaluate prognostic accuracy of SYCP2 
(Appendix 6) / SFRP1 (Appendix 7) biomarker expression in regions of HPV+ in situ 
carcinoma. All control subjects were patients undergoing tonsillectomy for benign pathology. 




Appendix 8: Data summarising HPV status and T cell response for each subgroup 
FFPE samples: p16INK4a immunohistochemistry was performed on FFPE tissue using a 
mouse monoclonal antibody (BD Biosciences). DNA in situ hybridization consisted of a 
probe directed against high risk HPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 
66 (Ventana INFORM HPVIII, Tucson, Arizona). Genomic DNA was extracted from 9 x 3.5 
μm FFPE sections using a QIAamp tissue kit in accordance with manufacturer’s guidelines 
(QIAGEN Ltd, UK). DNA was eluted in autoclaved and nuclease free H2O and stored at –
20°C. Concentration and purity of DNA was assessed by spectrophotometry. Samples had an 
absorbance ratio (260/280 nm) in the range of 1.8–2.0, and were diluted with H2O to a 
concentration of 1–25 ng/μl prior to PCR. L1 and E6/E7 DNA PCR were performed as for 
fresh tissue samples (below). Fresh frozen samples: Oropharyngeal fresh tissue samples 
(max. 25 mg) were DNA extracted using a protocol published from this unit (Winder et al., 
2009). As previously described, L1 DNA PCR analysis of tumour DNA (50-100 ng) involved 
the PGMY09/11 primer set with all negative samples subjected to further amplification using 
GP5+/GP6+ primers (Gravitt et al., 2000). DNA bands identified after agarose gel 
electrophoresis were excised, purified using QiaQuick Gel Extraction columns (QIAGEN 
Ltd, UK) and sequenced directly (Source Bioscience, Cambridge, UK). E6/E7 DNA and 
cDNA PCR analysis involved primers specific for HPV16 E6/E7 (Sotlar et al., 2004). For all 
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fresh tissue biopsies, parallel FFPE samples enabled p16INK4a immunohistochemistry (as 
above). N/A, not available. 
 
 
Appendix 9: HPV16 E2, E6 & E7 response detection by IFN-γ ELISPOT pre and post 
radical therapy (CD4+ & CD8+) 
 
A response was considered positive if the average number of spot forming cells (SFC) in 
HPV antigen well was 2 standard deviations (SD) above the average of negative control. The 
frequency of cytokine secreting CD4+ / CD8+ / CD56+ cells were then derived by the formula: 
number of spots/number of cells per well. For this study, we assume that increased staining of 
CD4+ equates to CD4+ T cells; we assume that increased staining of CD8+ equates to CD8+ T 
cells; we assume that increased staining of CD56+ equates to NK cells. 
 
 
Appendix 10: IFN-γ production by CD56 cells (NK cell population) was utilised to discern 
non-specific (innate) immune response within the clinical subgroups. No significant 
difference was detected for all patients pre- or post-treatment. SFC, Spot Forming Cells. 
 
 
Appendix 11: Treg analysis for each study participant pre- and post- radical therapy. 
Treg population defined as CD4+CD25+CD127low/-. For HPV+ OPSCC cohort, 16/24 




Appendix 12: Disease free survival - multivariate and univariate statistical analysis 
A proportional hazards model using Cox regression analysis revealed HPV16, CD8+ response 
to HPV16 E7 and smoking to have significant influence on DFS. 
 
 
Appendix 13: 100K Genomes Project (Head & Neck domain) 
Open letter to all major head and neck units in the UK.  
